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MicroRNAs (miRNAs) are small RNAs of ~22 nucleotides in length that regulate 
gene expression post-transcriptionally. MicroRNAs regulate many biological 
processes, and may contribute to cancer initiation and progression. In the normal 
gastrointestinal mucosa, myofibroblasts are involved in wound healing, and in 
tumours, they play a role in cancer progression. The present study aimed to 
determine the miRNA expression profiles in different populations of 
myofibroblasts from gastric and oesophageal tissues, namely, cancer-associated 
myofibroblasts (CAMs), adjacent non-tumour tissue myofibroblasts (ATMs) and 
normal tissue myofibroblasts (NTMs), and to investigate the processes that are 
influenced by differential miRNA abundance in different myofibroblast 
populations. In addition, miRNA profiling of a putative myofibroblast precursor 
cell type, mesenchymal stromal cells (MSCs), was studied.  
Global miRNA expression profiling of a panel of previously characterised gastric 
and oesophageal myofibroblasts was determined using locked nucleic acid (LNA) 
miRNA arrays. The microarray data for hsa-miR-29b, hsa-miR-181d, hsa-miR-
214 and hsa-miR-424 were validated by quantitative RT-PCR. Using 
unsupervised miRNA datasets, principal component analysis (PCA) segregated 
gastric and oesophageal NTMs, and CAMs from gastric and oesophageal 
carcinomas. Analysis of global miRNA expression showed distinct profile of 
MSCs in comparison to gastric and oesophageal NTMs. Hierarchical clustering 
analysis of miRNAs exhibiting significantly different abundance revealed distinct 
clusters between CAMs and ATMs, CAMs and NTMs and between ATMs and 
NTMs.  
In 12 paired samples of gastric CAMs and their corresponding ATMs, 12 
miRNAs were significantly different with hsa-miR-181d being the most up-
regulated miRNA in CAMs. Using already validated targets of 10 of these 
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miRNAs, an analysis using MetaCore
®
 indicated that the regulation of cell cycle 
progression and Wnt signalling were differentially affected. In a comparison of 
each CAM and its corresponding ATM, Wnt signalling was the only process that 
was significantly targeted by miRNAs that were different in abundance, in all 12 
pairs. 
Using previously determined gene expression data, pairwise analysis of 20 
transcripts associated with Wnt signalling showed a significant increase in 
WNT5A and TGFB2 mRNAs in CAMs compared to their ATMs. Additionally, 
Western blot analysis showed increased expression of Wnt-5a in CAMs. The 
results of migration and EdU incorporation assays indicated that Wnt-5a induced 
the migration and proliferation of both CAMs and ATMs. The abundance of hsa-
miR-181d was significantly increased in CAMs by Wnt-5a. Migration of AGS 
(gastric cancer) cells was stimulated by Wnt-5a and was inhibited in the presence 
of TIMP-3, a validated target of the miR-181 family. After hsa-miR-181d 
knockdown, the migration and proliferation of CAMs were significantly 
decreased, and stimulation with Wnt-5a reversed the migratory inhibition of hsa-
miR-181d knockdown CAMs. Conditioned medium from hsa-miR-181d 
knockdown CAMs inhibited the migration of AGS cells.  
The findings suggest that differential miRNA abundance is a feature of normal 
myofibroblasts from the stomach and oesophagus, and myofibroblasts from 
normal and cancer tissues. One consequence is increased Wnt-5a in gastric CAMs 
that is implicated in the regulation of cell migration, in health and disease, at least 
partly through modulation of hsa-miR-181d. 
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The double helix structure of deoxyribose nucleic acid (DNA), which was held 
together by pyrimidine and purine bases through hydrogen bonding, was first 
described by Watson and Crick in 1953 [1]. Not long after, a concept emerged that 
the genetic information was transferring from DNA to messenger ribonucleic acid 
(mRNA), which served as a template for protein synthesis, and this idea became 
known as the “central dogma of molecular biology” [2]. Subsequently, the idea 
has been revised as more complex mechanisms emerged in eukaryotes for 
processing genetic information [3]. For example, the existence of reverse 
transcriptase, which converts mRNA to complementary DNA (cDNA), the 
presence of non-coding sequences in the genome, the mechanisms of epigenetics 
that alter transcriptional activity, and post-transcriptional gene regulation such as 
alternative pre-messenger RNA splicing have all been described [3]. Despite 
many controversies, the central dogma remains relevant today as it provides a 
basic framework for understanding the mechanisms of controlling gene expression 
and protein synthesis [3].  
Recent advances in genomic research have included the human genome project, 
which indicates an approximately 20,000 protein-coding genes account for only 
about 1% of the entire human genome [4]. The remaining transcripts are non-
coding RNAs, some of which are involved in the translational machinery (e.g. 
ribosomal RNAs, transfer RNAs) and some are involved in splicing (e.g. small 
nucleolar RNAs) [5]. A group of small non-coding RNAs called microRNAs 
(miRNAs), which were first discovered in Caenorhabditis elegans in 1993,
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function to regulate gene expression post-transcriptionally either by inducing 
translational repression or by mRNA degradation, or both [6]. Currently, more 
than 2000 human mature miRNA sequences are deposited in the miRBase (release 
19; August 2012). It is predicted that up to 60% of protein-coding genes are 
targets of miRNAs, thus indicating the importance of miRNAs in regulating post-
transcriptional gene activity, and also influencing biological processes [7].  
The present thesis focuses on the regulation of gene expression by miRNAs in 
cancer and in particular, gastric carcinoma, oesophageal squamous cell carcinoma 
and oesophageal adenocarcinoma. According to cancer mortality statistics (2010), 
oesophageal and stomach cancers are in the top ten most common causes of 
cancer death in the United Kingdom. In addition, there is a high incidence of 
gastric and oesophageal adenocarcinomas in other European countries and 
developing countries [8, 9]. So far, studies have largely focused on malignant 
epithelial cells, but recent research suggests the involvement of the tumour 
microenvironment in malignant progression as well as in mediating therapeutic 
resistance [10]. It is known that tumour cell growth, invasion and metastasis can 
be modulated by miRNAs in stromal cells [11] but in general, the latter are poorly 
understood. The present study focuses on miRNAs in cancer-associated 
myofibroblasts (CAMs), which are an abundant cell type in both gastric and 
oesophageal tumour stromata and may provide a novel therapeutic strategy for 
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1.2 The upper gastrointestinal tract 
The upper gastrointestinal tract, which consists of the salivary glands, oesophagus, 
stomach and the small intestine, functions to aid food digestion and nutrient 
absorption [12]. The oesophagus is a tubular organ that transports food and fluids 
to the stomach. The oesophagus also consists of upper and lower oesophageal 
sphincters so as to prevent the reflux of gastric juice [13]. In addition, the stomach 
is an endocrine and exocrine organ that aids food digestion through the secretion 
of gastric juice, which contains hydrochloric acid and digestive enzymes [14]. The 
five regions of the stomach are: a) the cardia, which is near to the 
gastroesophageal junction; b) the fundus, which is the upper portion near to the 
oesophagus; c) the body or the corpus, which is the intermediate region; d) the 
pyloric antrum, which is the lower portion of the stomach, and e) the pyloric 
sphincter, which separates between the stomach and duodenum of the small 
intestine [15].      
 
1.2.1 Pathophysiology of oesophageal mucosa 
The oesophageal mucosa, consisting of non-keratinised squamous epithelium, 
contains submucosal mucous glands that secrete protective factors such as mucin 
and bicarbonate ions so that diffusion of hydrogen ions into the mucosa, and auto-
proteolytic digestion by pepsin are prevented [16]. Gastroesophageal reflux is a 
common condition in which there is recurrent regurgitation of acidic gastric juice 
into the distal oesophagus, resulting in reflux oesophagitis [17]. Subsequent 
genetic mutations of epithelial cells can cause either benign oxyntocardia 
metaplasia or intestinal metaplasia, which may progress to Barrett’s oesophagus 
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[18]. Barrett’s oesophagus is characterised by an acquired metaplastic change 
from squamous epithelium to an intestinal phenotype with goblet cell 
differentiation [19]. In addition to acid, the reflux of bile acids from the duodenum 
through the stomach and into the oesophagus may also contribute to the 
development of Barrett’s oesophagus. This is due to the inhibition of Notch 
signalling (Chapter 1.5.3) and an increased expression of caudal type homeobox 2 
(CDX2), a marker for intestinal epithelial differentiation [20].  
Oesophageal cancers are commonly classified into two histological sub-types: 
squamous cell carcinoma and adenocarcinoma [21]. Cigarette smoking and 
alcohol consumption are risk factors for the development of oesophageal 
squamous cell carcinoma [21] while Barrett’s oesophagus is a risk factor for the 
development of dysplasia and oesophageal adenocarcinoma [19]. 
 
1.2.2 Gastric acid regulation and mucosal defence mechanisms  
Tubular gastric glands in the gastric mucosa consist of mucous neck cells, other 
secreting cells, proliferating cells and enteroendocrine cells [22]. Gastric glands in 
the fundus and corpus regions are populated by histamine-secreting 
enterochromaffin-like (ECL) cells, acid-secreting parietal cells and peptic/chief 
cells that release pepsinogen, whereas glands in the antrum are populated by 
gastrin-secreting G cells [15, 23]. 
The antral hormone, gastrin, was discovered in 1905 by John Edkins and 
subsequently, it has been characterised as a peptide hormone which stimulates 
gastric acid secretion [24]. Other acid secretagogues such as acetylcholine (ACh) 
  Introduction 
6 
 
and histamine are associated with gastric acid secretion too [25]. The regulation of 
gastric acid secretion at the cellular level is shown in Figure 1.1. Gastrin binds to 
cholecystokinin-2 (CCK-2) receptors, previously known as gastrin/CCK-B 
receptors that are expressed by ECL cells, and induces histamine synthesis and 
secretion [26]. When histamine binds to its H2-receptor on the surface of parietal 
cells, there is an increase in cyclic adenosine monophosphate (cAMP) and 
intracellular calcium ions (Ca
2+
) with subsequent activation of protein kinase C 
(PKC) [27]. Protein kinases phosphorylate intracellular proteins, leading to the 




-ATPase) vesicles to the plasma membrane 
of parietal cells, allowing the secretion of a hydrogen ion in exchange for a 





Figure 1.1 A schematic representation of the regulation of gastric acid secretion. Amino 
acids from the gastric lumen and gastrin-releasing peptide (GRP) from the nervous system 
stimulate G cells to release gastrin which binds to CCK-2 receptors on the surface of ECL 
and parietal cells. In ECL cells, there is an increased biosynthesis and secretion of 
histamine. The binding of histamine to its H2-receptor on the surface of a parietal cell 




-ATPase). ACh from the 
nervous system can induce acid secretion in parietal cells. The secretion of somatostatin 
(SST) from antral and corpus D cells inhibits the signalling mechanisms of acid secretion.    
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The role of a mucus bicarbonate barrier is to protect the gastric mucosa against 
hydrochloric acid and luminal pepsin. Pepsin belongs to a family of active 
proteases and is released when pepsinogen from peptic/chief cells is cleaved by 
gastric acid [28]. To maintain a neutral pH microenvironment at the cell surface, 
the secretion of bicarbonate ions from surface gastric epithelial cells inhibits the 
diffusion of hydrogen ions into the mucosa through the process of neutralisation 
[28]. Additionally, mucus from mucous cells serves as a physical barrier against 
the proteolytic activity of pepsin, and to inhibit the diffusion of hydrogen ions 
[28]. Furthermore, the secretion of acid from parietal cells causes bicarbonate ions 
to be released and diffused into the lumen of capillary blood vessels, leading to an 
alkaline tide, and may contribute to acid neutralisation at the epithelial cell surface 
[29].  
Subsequent secretion of gastric acid reduces luminal pH and at pH below 3.5, D 
cells in the gastric antrum secrete somatostatin (SST), which inhibits G cells 
through paracrine signalling [22]. Additionally, when stimulated by neurohumoral 
factors such as noradrenaline, vasoactive intestinal polypeptide, calcitonin gene-
related peptide and cholecystokinin, corpus D cells secrete SST to inhibit the 
functions of parietal and ECL cells [22] 
 
1.2.3 Pathology of gastric epithelium  
Chronic Helicobacter pylori (H. pylori) infection and the use of non-steroidal anti-
inflammatory drugs (NSAIDs) and aspirin are risk factors for the development of 
peptic ulcer disease [30, 31]. Peptic ulcer disease, which is described as mucosal 
defects of at least 0.5 cm in diameter that penetrate through the muscularis 
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mucosa, can be classified into duodenal ulcers or gastric ulcers [32]. Additionally, 
there is a significant increase in peptic ulcers in NSAID users with H. pylori 
infection compared to those NSAID users without H. pylori infection [33].   
Chronic H. pylori infection causes gastritis in which SST concentrations are 
reduced, resulting in increased gastrin secretion [34]. Gastritis can be classified 
into antral-predominant gastritis or corpus atrophic gastritis. Antral gastritis is 
associated with increased gastrin-stimulated acid secretion that results in the 
development of duodenal ulcers [35]. Prolonged gastrin stimulation or 
hypergastrinaemia causes mucosal hyperplasia through increased expression of 
growth factors including regenerating protein-1α (REG1A) and heparin-binding 
EGF-like growth factor (HBEGF) by ECL and parietal cells, respectively [36, 37].  
Conversely, corpus gastritis has been linked to the development of gastric ulcers 
and is associated with impaired acid secretion such as inhibition of parietal cell 
function [38]. A decrease in acid secretion leads to an increased secretion of 
gastrin, which stimulates epithelial cell proliferation [39]. Continuous epithelial 
cell proliferation and inflammation induce gastric gland loss and atrophy in the 
antrum and subsequently, intestinal metaplasia, which is a precursor lesion of 
intestinal-type gastric adenocarcinoma [40, 41]. Atrophy is described as loss of 
glandular tissue due to continuous mucosal injury [38].  
About 3% of H. pylori positive individuals subsequently develop gastric 
carcinoma [42] while the risk for patients with gastric ulcer to develop gastric 
carcinoma is 2-fold increase [43]. The pathogenicity of H. pylori is attributed to 
strains containing cagA (cytotoxin-associated gene A) gene that has been 
associated with the development of gastric cancer [44]. Also, it has been found 
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that H. pylori infection induces spermine oxidase in gastric epithelial cells, 
resulting in cell apoptosis and the production of hydrogen peroxide that causes 
DNA damage [45]. Furthermore, a sub-population of gastric epithelial cells is 
found to exhibit apoptosis resistance and DNA damage, thus increasing the risk 
for malignant transformation of normal epithelial cells [45].                  
In addition, there is evidence suggesting a contribution of chronic H. pylori 
infection to autoimmune atrophic gastritis such as pernicious anaemia [46]. 
Pernicious anaemia causes vitamin B12 deficiency and is characterised by atrophy 





of parietal cells and secreted intrinsic factor [46, 47]. Moreover, population 
studies have indicated an increased risk of gastric carcinoma and gastric carcinoid 
tumours in patients with pernicious anaemia [48]. 
 
1.3 The maintenance of tissue organisation in the upper gastrointestinal tract  
The integrity of the upper gastrointestinal tract epithelium is partly maintained by 
epithelial stem cells that divide asymmetrically to produce two daughter stem 
cells; one of which continues to self-renew while the other generates a population 
of progenitor cells, which proliferates and differentiates into various epithelial 
lineages [49]. Evidence suggests a single gastric stem cell, on average, is located 
in the isthmus region of each gland unit [50]. In addition, oesophageal stem cells 
are thought to reside in the basal compartment of the squamous epithelium while 
stem cells from the small intestine are located at the base of the crypt [51].  
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The stem cell niche, which consists of extracellular matrix (ECM) and 
mesenchymal cells (e.g. subepithelial myofibroblasts), is thought to provide an 
optimal microenvironment to maintain progenitor cell survival, and to regulate 
epithelial cell functions through mesenchymal-epithelial interactions [52]. In 
mucosal injury, myofibroblasts and bone marrow derived mesenchymal stromal 
cells (MSCs) also contribute to wound healing [49]. 
 
1.3.1 Epithelial progenitor cells 
The maintenance of tissue architecture depends on the rates of cell proliferation, 
differentiation and apoptosis. In the gastric glands, there is a bi-directional 
migration of progenitor cells, also known as transit amplifying cells, from the 
isthmus or neck region towards the superficial epithelium to become mucous cells, 
and towards the gland base region to differentiate into parietal and peptic/chief 
cells [53]. As the cells differentiate, they lose their replicative capacity and 
undergo apoptosis eventually with an average turnover period of 3, 54 and 194 
days for gastric pit, parietal and peptic/chief cells, respectively [53]. Furthermore, 
the turnover period in gastric epithelial cells is altered during pathological 
conditions (e.g. chronic H. pylori infection during gastric carcinogenesis) [54].    
Studies have identified gastric progenitor cell markers such as the expression of 
doublecortin-like kinase 1 (DCLK1) in the isthmus region of corpus glands, and 
the expression of villin transgene in some base regions of antral glands [50]. 
Villin-positive cells have been shown to have multi-lineage potential after 
interferon stimulation [55]. Additionally, leucine-rich repeat containing G protein-
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coupled receptor 5 (LGR5), which is a well-known biomarker for intestinal stem 
cells, is expressed in the base region of antral glands [56]. 
In cancer, stem cells or progenitor cells may transform into malignant cells due to 
the acquisition of mutations. This gives rise to cancer stem cells or termed cancer-
propagating cells, which are defined as a population of self-renewal cells within 
the tumour that initiate and sustain malignant growth [57]. Furthermore, recent 
work points to the ability of these cells to seed new tumours and to spawn non-
cancer stem cell populations that lack the tumour-initiating ability [58]. Cancer 
stem cells are generally associated with aggressive tumours and poor prognosis 
[59]. For example, CD44 molecule, which is a transmembrane glycoprotein, is 
shown to be a biomarker for gastric cancer stem cells, and has been associated 
with an increase in resistance to chemotherapy-induced cell death [60].  
 
1.3.2 Mesenchymal stromal cells  
Unlike adult tissue stem cells, MSCs are heterogeneous, non-hematopoietic and 
reside in the niche of perivascular tissues (e.g. bone marrow and adipose tissue) 
[61]. They are described as plastic-adherent fibroblast-like cells that exhibit 
multipotent differentiation capacity in vitro [62]. According to the International 
Society for Cellular Therapy, MSCs are positive for human clusters of 
differentiation (CD) molecules, namely, CD105, CD73 and CD90, and negative 
for CD45, CD34, CD14, CD19 and HLA-DR surface molecules [63].  
The roles of MSCs include the regulation of immune response and maintenance of 
tissue homeostasis. Previous studies have demonstrated the effects of MSCs on 
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suppressing the proliferation of T cells [64], and reducing the proliferation and 
cytotoxicity of natural killer cells [65], thus suggesting immunosuppressive 
properties in MSCs. During wound healing, MSCs migrate to the injury site and 
differentiate into myofibroblasts and endothelial cells [61]. Moreover, MSCs 
exhibit chemotactic activity. For example, MSCs secrete vascular endothelial 
growth factor (VEGF) and macrophage inflammatory protein 1-alpha (MIP1α) to 
recruit endothelial cells and macrophages, respectively [66].  
 
1.3.3 Myofibroblasts 
Myofibroblasts are relatively rare in most normal tissues but in response to injury, 
local fibroblasts transdifferentiate into myofibroblasts, also known as “activated 
fibroblasts”, to facilitate wound healing through deposition of ECM proteins and 
secretion of growth factors and cytokines [67]. During wound healing, 
myofibroblasts may also originate from pericytes and bone marrow MSCs [67]. In 
contrast to other tissues, there is a population of residual myofibroblasts, which 
regulates epithelial cell functions in the gastrointestinal tract [68].  
Myofibroblasts are characterised by positive staining for alpha smooth muscle 
actin (α-SMA) and vimentin, and negative staining for desmin [69]. Moreover, 
fibronectin, which is involved in  cell adhesion and migration, has been detected 
on the myofibroblast surface [69]. In human cultured gastric and colonic 
myofibroblasts, the expression of cyclooxygenase-1 (COX1) and cyclooxygenase-
2 (COX2), involved in prostaglandin synthesis [70, 71], may contribute to the 
maintenance of glandular architecture and mucosal protection [72]. During 
inflammation, gastric myofibroblasts exhibit increased rates of cell migration and 
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 exchanger (NHE) isoforms and that NHE1 plays a 
role in regulating migration and proliferation of gastric myofibroblasts [74].  
Myofibroblasts regulate the migration and proliferation of epithelial cells 
physiologically. In superficial mucosal injury, colonic myofibroblasts secrete 
transforming growth factor-beta 3 (TGF-β3), which induces rapid epithelial cell 
migration across the wound layer in a process called restitution, so as to maintain 
the integrity of the epithelium [75]. Furthermore, TGF-β3 enhances transepithelial 
resistance as a previous study has demonstrated the inhibition of secretagogue-
induced chloride secretion from epithelial cells [76]. In addition, growth factors 
that are secreted by myofibroblasts such as hepatocyte growth factor (HGF) [77] 
and keratinocyte growth factor (KGF) [78] have been associated with increased 
proliferation of the gastrointestinal tract epithelial cells. 
There is also a role for myofibroblasts in mucosal immunology. Intestinal 
myofibroblasts have been associated with innate immune responses through 
regulation and expression of toll-like receptors (TLRs) [79]. When  stimulated 
with bacterial lipopolysaccharide or lipoteichoic acid, the expression of TLR-2, 
TLR-3, TLR-4, TLR-6 and TLR-7 in intestinal myofibroblasts is increased, 
leading to the secretion of pro-inflammatory cytokines and chemotactic factors 
that recruit immune cells to sites of inflammation [79]. Furthermore, the 
expression of class II major histocompatibility complex (MHC) molecules in 
colonic myofibroblasts has been found, suggesting these cells function as antigen-
presenting cells which activate CD4-positive T-cells during activation of adaptive 
immunity [80].   
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1.4 Extracellular matrix homeostasis 
In addition to cytokine secretion, myofibroblasts deposit ECM proteins (e.g. 
collagens, laminins, fibronectin) and secrete ECM-degrading proteases which 
regulate ECM turnover [81]. The ECM helps to maintain tissue architecture and 
homeostasis and normally, it serves as a barrier to tumour growth and metastasis 
[82]. The ECM consists of fibrous proteins (e.g. collagens) embedded in a visco-
elastic gel of glycoproteins (e.g. fibronectin), proteoglycans (e.g. decorin) and 
glycosaminoglycans (i.e. hyaluronan) [83]. The maintenance of ECM homeostasis 
involves regulation by proteases and their inhibitors. These proteases are 
classified into metalloproteinases; mainly the matrix metalloproteinases (MMPs), 
serine proteases such as urokinase-like plasminogen activator (uPA) and tissue-
type plasminogen activator (tPA), and cysteine proteases such as collagen-
degrading cathepsins [84]. 
 
1.4.1 Matrix metalloproteinases 
The MMPs, which belong to a family of zinc-dependent endopeptidases, are 
involved in physiological processes (e.g. embryonic development, wound healing) 
and cancer progression [85]. A total of 28 human MMPs has been identified, and 
they are classified into five main categories according to their substrate 
specificity, primary structures, and cellular localization, namely, the matrilysins 
(e.g. MMP7), collagenases (e.g. MMP1), stromelysins (e.g. MMP3), gelatinases 
(e.g. MMP2), and the membrane-type MMPs (e.g. MMP14) [86]. Other members 
of the metalloproteases include a disintegrin and metalloproteinases (ADAMs), 
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which are transmembrane proteins, and ADAMs with thrombospondin motifs 
(ADAMTS), which are secreted and bound to ECM proteins [84].  
The MMPs are synthesised as inactive zymogens (i.e. pro-MMPs) and mostly they 
become activated after proteolytic cleavage in the extracellular environment [87]. 
The activity of MMPs is low in the normal state, and is induced in response to 
external stimulus. For example, proinflammatory cytokines stimulate the secretion 
of MMP1, MMP2 and MMP3 in colonic myofibroblasts [88, 89]. In intestinal and 
gastric myofibroblasts, the expression of MMP1, MMP2 and MMP3 has also been 
identified, suggesting the importance of these MMPs [73, 90]. Substrates for 
MMP1 such as perlecan and insulin-like growth factor binding protein-3 
(IGFBP3) have been shown to increase the bioavailability of fibroblast growth 
factor (FGF) and insulin-like growth factor (IGF), respectively [91]. Additionally, 
studies have shown the proteolytic activation of transforming growth factor-beta 
(TGF-β) by MMP2, and the cleavage of E-cadherin by MMP3 [87].  
Matrilysin (i.e. MMP7), which is predominantly expressed in epithelium, is 
implicated in regulating myofibroblast function [73]. In the stomach, secreted 
MMP7 cleaves insulin-like growth factor binding protein-5 (IGFBP5) and 
subsequently releases IGF-II, which induces the proliferation and migration of 
gastric myofibroblasts [92]. Other substrates of MMP7 that mediate cell apoptosis 
and migration are membrane surface proteins, such as Fas ligand, E-cadherin and 
fibronectin [87].  
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1.4.2 Tissue inhibitors of metalloproteinases 
Tissue inhibitors of metalloproteinases (TIMPs) are negative regulators of MMPs, 
ADAMs and ADAMTS [93]. In tissue fluids, α2-macroglobulin, which is a 
plasma protein, serves as an important MMP inhibitor [87]. Nonetheless, other 
functions of TIMPs that have been studied include activation of pro-MMPs (e.g. 
pro-MMP2, pro-MMP9), inhibition of angiogenesis, and induction of cell 
proliferation and migration [93].  
The TIMP family consists of 4 members (i.e. TIMP1, TIMP2, TIMP3 and TIMP4) 
and they exhibit differential expression patterns and different affinities for various 
MMPs [82]. For example, previous studies using mouse tissues have shown that 
TIMP3 expression is abundant in the kidney, lung and brain [94] while TIMP4 
expression is abundant in the heart, brain, ovary and skeletal muscle [95]. In 
addition, H. pylori infection in human gastric tissue has been found to increase the 
abundance of TIMP1, TIMP3 and TIMP4 in glandular epithelial cells, and the 
abundance of TIMP3 in myofibroblast-like cells [96].  
Studies have shown that TIMP1 is a poor inhibitor for membrane type MMPs, 
such as MMP14, MMP16 and MMP24 [93]. Unlike other TIMPs, TIMP3 has low 
solubility, binds to the heparan sulphate proteoglycans within the ECM, and 
inhibits several members of ADAMs (e.g. ADAM10, ADAM17) and ADAMTS 
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1.4.3 Plasminogen activator-plasmin system 
uPA and tPA are serine proteases that generate plasmin from plasminogen [97]. 
Both uPA and tPA are inhibited by plasminogen activator inhibitor-1 (PAI1) and 
protease nexin-1 (PN1) while plasmin is effectively inhibited by α2-antiplasmin 
[97].  
Binding of uPA to its receptor (i.e. uPAR) converts plasminogen into plasmin, 
which is involved in degradation of ECM proteins and activation of several MMPs 
[84]. Conversely, receptor bound tPA converts plasminogen into plasmin that is 
involved in fibrinolysis and thrombolysis [97]. Increased expression of uPA and 
uPAR has been reported in subepithelial cells of H. pylori positive gastric corpus 
tissue, and this may influence the proliferation of epithelial cells through 
activation of HGF [97, 98].    
 
1.5 Gastrointestinal tract signalling pathways 
Myofibroblasts are believed to be a key mesenchymal cell type that maintains the 
integrity of epithelium [99]. Signalling pathways that are implicated in the 
maintenance of epithelial structure and function include: 1) Transforming growth 
factor-β/bone morphogenetic protein signalling, 2) Hedgehog signalling, 3) Notch 
signalling, 4) Wnt signalling and 5) growth factor signalling (e.g. hepatocyte 
growth factor, HGF, keratinocyte growth factor, KGF, insulin-like growth factor, 
IGF and epidermal growth factor, EGF) [99, 100].  
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1.5.1 Transforming growth factor-β/bone morphogenetic protein signalling  
The TGF-β or bone morphogenetic protein (BMP) signalling pathway normally 
inhibits the proliferation of epithelial cells, and induces myofibroblast 
differentiation and activation [101]. Members of the TGF-β superfamily include 
BMPs, activins and TGF-β isoforms 1, 2 and 3 encoded from three separate genes 
[101]. In the gastric mucosa, TGF-β3 expression is found in parietal, peptic/chief 
and mucous cells while TGF-β1 and TGF-β2 expression are mainly expressed in 
parietal and peptic/chief cells, respectively [102]. Upon binding by a ligand, 
serine/threonine kinase TGF-β type II receptor (TβR-II) activates TGF-β type I 
receptor (TβR-I), leading to phosphorylation of receptor-regulated Smads (e.g. 
Smad2 and Smad3) [101]. Phosphorylated Smad proteins form a heteromeric 
complex with common-partner Smads, known as Smad4 in mammals, and then 
the complex translocates into the nucleus to activate gene transcription [101]. In 
advanced stages of gastric carcinoma, TGF-β becomes an oncogene and activation 
of TGF-β signalling increases the expression of phosphorylated Smad2, which is 
associated with diffuse-type gastric cancer metastasis, and correlated with poor 
survival [103].  
 
1.5.2 Hedgehog signalling  
In the gastrointestinal tract, hedgehog signalling is implicated in anti-
inflammatory responses and is involved in regulating homeostasis and 
differentiation of progenitor cells [104, 105]. Studies have also implicated the role 
of hedgehog signalling in developmental patterning of the gastrointestinal tract 
and lung tissues [106]. The hedgehog family ligands, namely, sonic hedgehog 
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(SHH), indian hedgehog (IHH) and desert hedgehog (DHH), exhibit the same 
affinity for patched family receptors, PTCH1 and PTCH2 [107]. Upon binding of 
hedgehog ligand to a PTCH receptor, the inhibition of smoothened (SMO) by the 
receptor was released [108]. This results in stabilisation and nuclear localisation of 
the Gli family of transcriptional factors (e.g. GLI1, GLI2 and GLI3), which 
activate the transcription of target genes such as PTCH1 and GLI1 [104].  
The expression of SHH mRNA has been found in the gastric fundus, small 
intestinal and colonic crypts, but not in the oesophagus and gastric antrum [104]. 
Additionally, it was found that parietal cells express SHH and PTCH1, whereas 
peptic/chief cells in the gland base region express only PTCH1 [109, 110]. The 
expression of SHH in parietal cells is stimulated by gastrin and in turn, SHH 




-ATPase in parietal cells, suggesting a positive 
correlation of hedgehog signalling with gastric acid secretion [111].  
 
1.5.3 Notch signalling  
Progenitor cell populations in the gastrointestinal tract is regulated by Notch 
signalling, which can be classified into canonical and non-canonical signalling 
pathways [112]. Canonical Notch signalling pathway has been shown to induce 
the proliferation and inhibit the differentiation of progenitor cells in the isthmus 
region of gastric glands, basal layer of oesophageal epithelium and in the colonic 
crypt base region [112, 113].   
Notch family receptors (i.e. NOTCH1, NOTCH2, NOTCH3 and NOTCH4) and 
ligands (i.e. Jagged 1 and 2, Delta-like 1, 3 and 4) are single-pass transmembrane 
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proteins [114]. In the canonical Notch signalling pathway, a Notch ligand 
expressed on neighbouring cells binds to the extracellular domain of the Notch 
receptor, resulting in the cleavage of the extracellular domain that is mediated by 
ADAM type metalloproteases [114]. The extracellular domain is then internalised 
into ligand-expressing cells by endocytosis and is degraded by lysosomes while 
the Notch intracellular domain (NICD) is cleaved by γ-secretase [114]. After 
cleavage, the NICD translocates into the nucleus and forms a transcriptional 
complex with the CSL family of DNA binding factors and  mastermind-like 
family coactivators, resulting in the transcriptional activation of genes such as 
hairy and enhancer of split 1 (HES1) [112].    
 
1.5.4 Wnt signalling  
Physiologically, the Wnt signalling pathway is essential for regulation of 
epithelial lineage differentiation from progenitor cells and for regulation of 
progenitor cell proliferation [115]. In the human genome, a total of 19 WNT genes 
have been identified, and they belong to a family of cysteine-rich secreted 
glycoproteins which can activate two different pathways, known as canonical and 
non-canonical Wnt signalling pathways [116]. Activation of Wnt signalling is 
transduced by the Frizzled (FZD) family of receptors including ten mammalian 
receptors that have been identified [117]. When Wnt proteins bind to FZD 
receptors, there are 3 main signalling pathways that are transduced: a) the 
canonical Wnt/β-catenin pathway, b) the non-canonical Wnt/Ca2+ pathway and c) 
the non-canonical planar cell polarity (PCP) pathway [117] (Figure 1.2).     
  Introduction 
21 
 
In the canonical Wnt/β-catenin signalling pathway, the β-catenin cascade is 
induced when Wnt proteins (e.g. Wnt-1, Wnt-3a) bind to FZD receptors in the 
presence of low density lipoprotein receptor-related protein 5 or 6 (LRP5/6) co-
receptors [116].  In the absence of Wnt activation, β-catenin is bound to a 
complex, which consists of adenomatous polyposis coli (APC), axin, glycogen 
synthase kinase 3-beta (GSK3β) and casein kinase 1-alpha (CK1α), and is 
phosphorylated and subsequently ubiquitinated, resulting in rapid degradation of 
β-catenin by the proteasome [115]. Alternatively, β-catenin may be bound to 
cadherin at the plasma membrane [118]. Upon binding of Wnt protein to the FZD 
receptor, the kinase activity of GSK3β and CK1α is inhibited, preventing the 
phosphorylation and degradation of β-catenin. Subsequently, unphosphorylated β-
catenin accumulates in the cytosol and translocates into the nucleus, where it acts 
as a co-factor for T-cell factor/lymphocyte enhancer factor (TCF/LEF) 
transcriptional activation [116]. Recently, Clevers suggests that β-catenin is 
phosphorylated in the presence of Wnt activation but the subsequent 
ubiquitination of phosphorylated β-catenin is inhibited [119]. Eventually, the β-
catenin-APC complex becomes saturated with phosphorylated β-catenin, causing 
newly synthesised β-catenin to accumulate in the cytosol and then translocate into 
the nucleus [119].  
Activation of the non-canonical Wnt signalling pathway normally occurs when 
Wnt proteins (e.g. Wnt-4, Wnt-5a, Wnt-11) bind to FZD receptors in the presence 
of receptor tyrosine kinase-like orphan receptor 2 (ROR2) and receptor-like 
tyrosine kinase (RYK) co-receptors [116]. Studies have shown that Wnt-5a 
activates mainly non-canonical Wnt signalling pathways but under certain 
circumstances, Wnt-5a can activate the canonical Wnt/β-catenin signalling 
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/calmodulin-dependent protein kinase II (CAMKII) is activated by an influx 
of Ca
2+
 ions, resulting in nemo-like kinase (NLK) activation that leads to the 
phosphorylation of TCF/LEF and subsequently, inhibits the β-catenin-TCF/LEF 
complex to interact with DNA promoter site for transcriptional activation [121]. 
Additionally, the Wnt/Ca
2+ 
signalling pathway activates PKC and calcineurin, 
which causes the dephosphorylation and nuclear localisation of nuclear factor of 
activated T cells (NFAT) [122]. The other non-canonical PCP pathway is involved 
in the regulation of cell polarisation within the plane of epithelial cell sheet, and 






Figure 1.2 A schematic representation of Wnt signal transduction pathways. Binding 
of Wnt proteins to FZD receptors in the presence of LRP5/6 coreceptors activates the 
canonical Wnt signalling pathway in which β-catenin is stabilised in the cytosol and 
then translocates into the nucleus to activate the transcription of Wnt-responsive 
genes. The non-canonical Ca
2+
-dependent Wnt signalling pathway activates NLK via 
phosphorylation by CAMKII and stimulates NFAT-dependent transcription. The other 
non-canonical Wnt pathway activates JNK and induces cytoskeletal reorganisation.  
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The expression of Wnt-2, Wnt-4, Wnt-5a and Wnt-5b has been reported in murine 
intestinal myofibroblasts [123] and human colonic myofibroblasts [124]. 
Furthermore, the expression of FZD1, FZD4, FZD5, FZD6, FZD7 and LRP6 has 
been found in crypt epithelial cells and colonic myofibroblasts [124, 125]. This 
distribution suggests that the secretion of Wnt proteins by mesenchymal cells 
activates the Wnt pathways through autocrine and paracrine signalling, 
implicating mesenchymal-epithelial interactions [123].  
 
1.6 The biology of cancer 
Abnormal secretion of growth factors and cytokines, and deregulation of 
signalling pathways have been linked to neoplastic development [126]. Moreover, 
it is well established that genetic alterations (e.g. gene mutations) result in 
malignant transformation, and that transformed cells exhibit different phenotypes 
from normal cells in terms of promoting tumour growth and progression (Figure 
1.3) [127]. More recently, the discovery of miRNAs, which function as post-
transcriptional gene regulators, has been shown to influence carcinogenesis, and 
this provides an additional insight on the mechanisms that alter cancer cell 
behaviour, including proliferative and metastatic potential effects (Chapter 1.7). 
Metastasis is the ability of tumour cells to invade the surrounding tissue, 
disseminate into the bloodstream and induce neoplastic potential at the distant site 
[128]. This was first described by Paget in 1889 when he proposed the “seed and 
soil” hypothesis of metastasis, in which malignant tumour cells (‘seed’) 
preferentially grow at a particular organ site or microenvironment (‘soil’) [128, 
129]. About a hundred years later, Dvorak described tumours as “wounds that fail 
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to heal”, indicating there are similarities between tumour stromal inflammatory 
response and wound healing [130]. Indeed, chronic inflammation is linked to 
many types of malignant tumour, including chronic H. pylori infection-associated 
gastric carcinoma and Barrett’s induced oesophageal adenocarcinoma [131], and 
this clearly indicates the involvement of the microenvironment in cancer initiation 









Figure 1.3 Hallmarks of cancer cells in tumour growth and progression. Cancer 
cells exhibit characteristics that promote malignancy. Genetic changes and 
epigenetic regulation have been commonly found in cancer cells while stromal-
tumour interactions have been implicated in cancer progression. Recent research 
has focused on miRNAs that influence cancer cell behaviour and also miRNAs in 
stromal cells of the tumour microenvironment. The molecular interactions that 
promote cancer cell growth, invasion and metastasis could potentially be used for 
novel therapeutic strategies.    
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1.6.1 Hallmarks of cancer  
Six hallmark capabilities of cancer cells that dictate tumour growth and 
malignancy are originally proposed by Hanahan and Weinberg: a) self-sufficiency 
in growth signals; cancer cells release mitogenic signals so they reduce their 
dependence on exogenous growth stimulation, b) insensitivity to anti-growth 
factors; cancer cells evade anti-proliferative actions of tumour suppressor genes, 
c) evasion of apoptosis; cancer cells are resistant to apoptosis through 
deregulation of pro and anti-apoptotic proteins of the BCL2 family or by loss of 
tumour suppressor gene functions, d) immortalisation; cancer cells acquire 
unlimited proliferative potential, e) sustained angiogenesis; an ‘angiogenic switch’ 
is continuously activated that results in vasculature formation to support tumour 
growth and f) invasion-metastasis activation; the loss of ECM components and 
cell-cell adhesion molecules (e.g. E-cadherin) allow the cells to invade adjacent 
tissue and move to a distant site [132]. Subsequently, two additional hallmark 
capabilities have emerged from recent research development: g) cancer cells 
reprogram their energy metabolism to glycolysis for increased survival and 
effective proliferation, also known as the Warburg effect [133] and lastly, h) 
cancer cells acquire the ability to resist immunological destruction by 
lymphocytes, macrophages and natural killer cells [127].  
Nonetheless, Hanahan and Weinberg stress the involvement of genetic and 
epigenetic alterations in cancer cells, and the tumour microenvironment in 
contributing to the acquisition of hallmark capabilities. Tumour stromal cells play 
a role in promoting tumour angiogenesis, cancer cell growth and invasion through 
ECM remodelling, and secretion of cytokines and growth factors that activate 
cancer cell signalling pathways [134].   
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1.6.2 Genetic mutations 
Genetic mutations, which refer to the permanent, heritable change in nucleotide 
sequences, are already reported in many tumours and they occur in more than 1% 
of all genes in the human genome, mostly functioning as oncogenes, tumour 
suppressor or DNA mismatch repair genes [135]. Loss-of-function of tumour 
suppressor genes occurs when both copies of the gene are mutated, known as the 
“two-hit hypothesis” of tumour suppression [136], and this was originally 
identified by Knudson in 1971. He proposed that two mutational events in the 
retinoblastoma gene were required for the development of hereditary and sporadic 
retinoblastoma [137]. Hereditary retinoblastoma usually occurred at a younger age 
because the first mutation is inherited and tumour forms when the second 
mutation is acquired. In a similar manner, inactivation of E-cadherin (CDH1) gene 
in gastric cancer cells is the result of two genetic hits, suggesting the function of 
tumour suppressor genes in mediating cancer cell invasion and metastasis [138].  
Subsequently, the discovery of specific genetic alterations in colorectal 
carcinoma, by Fearson and Vogelstein, has provided a useful model to illustrate 
multi-hit events  in carcinogenesis [139]. In this case, mutations on chromosome 
5q containing APC in normal colon cells induce the formation of adenomatous 
polyp, and subsequent oncogenic mutation of v-Ki-ras2 Kirsten rat sarcoma viral 
oncogene homolog (KRAS) on chromosome 12p results in dysplasia [136, 139]. 
Furthermore, loss of chromosome 18q, point mutation on one allele of TP53 and 
allele loss of chromosome 17p that contains TP53 induce the development of 
colon carcinoma [139].   
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1.6.3 Genetic instability 
In addition to genetic mutation, genetic instability such as chromosomal instability 
and microsatellite instability is well characterised in tumours. Chromosomal 
instability, which has been detected in 84% of gastrointestinal tumours, is defined 
as chromosomal abnormalities including aneuploidy and loss of heterozygosity 
(LOH) [140]. Aneuploidy is described as variations in genomic copy number and 
is correlated with the expression of oncogenes and tumour suppressor genes [141]. 
Additionally, aneuploidy has been associated with lymph node metastasis and 
histological subtypes of gastric adenocarcinomas [141]. In addition, the second 
genetic hit that inactivates tumour suppressor genes is known as LOH [140]. For 
example, LOH of TP53 tumour suppressor gene is associated with early stage of 
gastric carcinogenesis. Furthermore, microsatellite instability has been reported in 
25% to 50% of sporadic gastric cancer and is usually caused by mutational or 
epigenetic inactivation of mismatch repair genes [142]. Microsatellite instability is 
defined as high frequency of replication errors that result in deletions or insertions 
of nucleotides within the microsatellite region [140]. 
 
1.6.4 Epigenetic alterations  
Changes in epigenetic modifications to DNA molecules and histone proteins 
contribute to cancer initiation and progression, and have been recognised in drug 
development for epigenetic therapy [143]. Epigenetics, which are defined as 
heritable and reversible modifications of chromatin structure without altering the 
DNA sequence, are important regulators of gene expression [144]. The main 
mechanisms involved are DNA methylation and covalent modifications of 
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histones. DNA methylation is the addition of a methyl group to cytosines in CpG 
dinucleotides and is catalysed by DNA methyltransferases such as DNMT1, 
DNMT3A and DNMT3B [144].  
High frequency of GC content and CpG dinucleotides, termed CpG islands, are 
present in the promoter region of about 50% of all genes [145]. Abnormal DNA 
methylation of CpG islands in the promoter regions is linked to the silencing of 
tumour suppressor genes such as CDH gene in gastric carcinoma [146]. There is 
increased DNA methylation in H. pylori infected gastric epithelial cells, suggesting 
the contribution of DNA methylation in chronic inflammation [147]. Additionally, 
a more recent study using Helicobacter-infected mice has indicated a decrease in 
global DNA methylation in gastric epithelial cells and stromal myofibroblasts 
during the early phase of dysplasia, prior to gastric carcinogenesis [148]. 
Furthermore, stromal myofibroblasts from gastric cancer has been associated with 
global DNA hypomethylation [149]. Taken all these findings, targeting DNA 
methylation for epigenetic therapy may be fundamental to prevent Helicobacter-
associated gastric cancer initiation and progression.  
 
1.7 MicroRNAs 
MicroRNAs (miRNAs) are small non-coding RNAs of 18 to 25 nucleotides in 
length that regulate post-transcriptional gene expression. In the gastrointestinal 
tract, miRNAs play a role in developmental and physiological processes [150] 
such as intestinal epithelial cell differentiation and maintenance of intestinal 
barrier function [151]. Additionally, altered miRNA expression in gastric and 
oesophageal carcinomas, and pre-neoplastic tissues, has been identified [152, 153] 
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and these deregulated miRNAs may contribute to chromosomal instability, 
epigenetic changes and altered transcriptional regulation [154]. Moreover, it has 
been suggested that about 50% of human miRNAs are located in chromosomal 
regions that are frequently altered in human cancers (e.g. LOH, fragile sites) 
[155]. During  the development of gastrointestinal tumours, there is increasing 
evidence to suggest the role of up and down-regulated miRNAs as oncogenes and 
tumour suppressor genes, respectively [154].  
 
1.7.1 MicroRNA expression and function 
MicroRNAs regulate gene expression by inducing translational repression or 
degradation of mRNAs through perfect or partial complementary binding of the 
5’end of mature miRNAs to the 3’ untranslated regions (UTRs) of the mRNA 
targets, known as the “seed” region (6 to 8 nucleotides) [156]. However, recent 
work suggests that miRNAs may bind to sites in the 5’UTR and within the coding 
region of mRNAs [153]. It is estimated that miRNAs represent 1% of the human 
genes [157], and they are commonly located within introns or in between protein-
coding genes [153]. Additionally, miRNAs are classified into sequence families 
based on similarity of their seed sequence and overall nucleotide sequence [7]. 
The mechanism of miRNA biogenesis and function is described in Figure 1.4. 
Briefly, primary miRNAs (pri-miRNAs) are produced when miRNA genes are 
transcribed by RNA polymerase II or excised as an intron from mRNA transcripts. 
Then, pri-miRNAs are cleaved by Drosha enzyme and its binding partner, 
DiGeorge syndrome critical region gene 8 (DGCR8) to form precursor miRNAs 
(pre-miRNAs) [153]. Pre-miRNAs, which have a stem loop hairpin structure, are 
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transported into the cytoplasm by exportin 5. In the cytoplasm, pre-miRNAs are 
cleaved by Dicer and its binding partner, trans-activation response RNA binding 
protein (TARBP), to produce short RNA duplexes of 19 to 24 nucleotides in 
length [7]. After unwinding, one of the miRNA strands is rapidly degraded while 
the other mature miRNA is incorporated into the RNA-induced silencing complex 
(RISC) [153]. The mature miRNA guides the RISC to the 3’UTR binding site of a 
mRNA target, resulting in inhibition of mRNA translation or degradation of 
mRNA that depends on the degree of complementarity of the base-pairing 







Figure 1.4 Biosynthesis and functions of miRNAs. A pri-miRNA is transcribed from a 
miRNA gene and is cleaved by Drosha to produce pre-miRNAs. A pre-miRNA is 
exported into the cytoplasm that is mediated by exportin 5. In the cytoplasm, pre-miRNA 
is cleaved by Dicer to give a miRNA duplex. After unwinding, the mature miRNA strand 
incorporates into the RISC and guides the complex to the site of 3’UTR of a mRNA 
target. The miRNA-complex induces either translational repression or mRNA 
degradation.       
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1.7.2 Altered miRNA expression in gastric and oesophageal cancers  
MicroRNA expression profiling of tumour samples has been used to identify 
histological tumour subtypes and to classify poorly differentiated tumours [159]. 
For example, distinct miRNA profiles between squamous cell carcinoma and 
adenocarcinoma of the oesophagus [160]. Altered expression of miRNAs has been 
shown to regulate the expression of mRNA targets that contribute to cancer 
progression [153]. Differential expression of miRNAs in gastric and oesophageal 
cancer tissues was identified using microarray or polymerase chain reaction 
(PCR)-based approach. For example, increased expression of miR-21 which is 
found in gastric carcinoma [161], oesophageal squamous cell carcinoma and 
oesophageal adenocarcinoma [160], down-regulates the expression of tumour 
suppressor, leading to tumour growth and invasion [150]. Additionally, decreased 
expression of miR-143 and miR-145 are commonly found in the gastrointestinal 
tract tumours (e.g. gastric carcinoma, oesophageal squamous cell carcinoma, 
oesophageal adenocarcinoma, colon carcinoma) and are associated with cancer 
cell growth and decreased sensitivity to chemotherapeutic treatment [153, 162]. 
On the other hand, the role of miRNAs in cancer progression may depend on the 
cellular context. For example, miR-192 and miR-215 are found to be up-regulated 
in gastric carcinomas compared to non-neoplastic tissues [163], but are down-
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1.7.3 Epigenetics in miRNAs 
It is recognised that epigenetics (i.e. DNA methylation and histone modifications) 
regulate gene expression (Chapter 1.6.4). In addition, epigenetic alterations play a 
role in the regulation of miRNA expression that may result in abnormal activation 
of oncogenes and silencing of tumour suppressor genes during cancer 
development and metastasis [165, 166]. A model, using DNMT1 and DNMT3B 
double knockout colon cancer cells, has shown that DNA methylation regulates 
approximately 10% of miRNA expression [167]. It is suggested that the 
expression of miRNAs is regulated: a) directly; through DNA methylation at CpG 
islands on the promoter region of miRNA genes and b) indirectly; through DNA 
methylation that affects the expression of transcription factors, which in turn, 
regulate miRNA gene transcription [167].  
In gastric cancer, down-regulated miRNAs such as miR-10b, miR-181c, miR-34b 
and up-regulated miRNAs such as miR-196b have been directly associated with 
DNA methylation [153]. Moreover, a recent study has shown that cagA of H. 
pylori indirectly induces the expression of DNMT3B, which in turn decreases the 
expression of let-7, and subsequently activates the oncogenic KRAS pathway for 
gastric carcinogenesis [168]. These may, therefore, indicate a role of DNA 
methylation in gastric cancer initiation and progression.  
Dysregulation of the epigenetic machinery by miRNAs (also termed epi-miRNAs) 
has also been implicated in carcinogenesis. For example, in lung cancer cells, 
down-regulation of miR-29 family members (i.e. miR-29a, miR-29b and miR-
29c) induces methylation-silencing of tumour suppressor genes through increased 
expression of miR-29 targets, DNMT3A and DNMT3B [169]. Another study 
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reveals genomic loss of the miR-101 gene in prostate cancer cells, resulting in the 
overexpression of enhancer of zeste homolog 2 (EZH2), which is a histone 
methyltransferase [169].  
 
1.8 Tumour microenvironment 
The tumour microenvironment consists of ECM, vasculature, soluble paracrine 
factors and non-malignant stromal cells, such as cancer-associated myofibroblasts 
(CAMs), inflammatory cells, endothelial cells, pericytes and bone marrow derived 
stromal cells [170]. In gastrointestinal tumours, stromal cells constitute 60% to 
90% of the tumour mass with CAMs being an important stromal cell type in 
tumour progression [171]. The abundance of gastric CAMs is positively correlated 
with tumour size and lymph node metastasis in gastric carcinoma [172]. 
Additionally, inflammatory cells (e.g. lymphocytes, macrophages, dendritic cells) 
are involved in tumour malignancy and suppression of anti-tumour immune 
response [173]. Endothelial cells and pericytes, also known as perivascular cells 
or mural cells, coordinate to maintain the normal physiology of vasculature, and 
also contribute to tumour angiogenesis and metastasis [174]. 
Distinct profiles of gene expression and proteome in cancer stromal cells from 
microdissected tissues of colorectal and bladder carcinomas, respectively, have 
been demonstrated [175, 176]. In addition, miRNA regulated gene expression in 
stromal cells and its influence on tumour progression has been reported. Some 
studies have suggested genetic alterations in the tumour stroma such as loss of 
TP53 gene in prostate cancer stromal cells [177]. However, there is no evidence to 
suggest this applies to all other cancers.   
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1.8.1 Cancer-associated myofibroblasts 
Cross-talk between CAMs and epithelial cancer cells, termed stromal-epithelial 
interactions, promotes cancer cell growth and induces malignant transformation 
[134]. Myofibroblasts, including CAMs, are generally characterised by the 
presence of mesenchymal surface markers, α-SMA and vimentin, and the absence 
of cytokeratin, smoothelin and CD31 [178]. Immunochemistry of α-SMA has 
been commonly used to identify CAMs, which are an abundant stromal cell type 
in epithelial tumours. A recent proteomic study has demonstrated differential 
expression of secreted proteins in gastric CAMs compared to their adjacent non-
tumour myofibroblasts (ATMs), and one of these proteins, transforming growth 
factor, beta-induced (TGFBI), is decreased in CAMs and may be associated with 
lymph node metastasis [179].  
The tumour-promoting properties in myofibroblasts from cancers have been 
studied widely and the term, cancer-associated fibroblasts, is often used. It is 
recognised that cancer-associated fibroblasts contain a higher number of 
myofibroblasts, which contribute to tumour progression, compared to normal 
fibroblast population [180]. For example, HGF secreted by cancer-associated 
fibroblasts is involved in oesophageal squamous carcinoma cell invasion [181]. In 
oesophageal squamous cell carcinoma, paracrine TGF-β signalling from 
carcinoma cells induces a myofibroblast phenotype in cancer-associated 
fibroblasts that results in the secretion of vascular endothelial growth factor 
(VEGF), which promote tumour angiogenesis by inducing endothelial cell 
migration and proliferation [182].  
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It has been suggested that CAM population is heterogeneous as studies have 
demonstrated their origins from: a) resident fibroblasts, b) bone marrow derived 
MSCs, c) epithelial cells through epithelial-mesenchymal transition (EMT), d) 
endothelial cells through endothelial-mesenchymal transition and e) pericytes by 
transdifferentiation [183]. Moreover, a recent study has shown the transformation 
of adipose tissue derived MSCs that is induced by ovarian cancer-derived 
exosomes [184]. 
Post-transcriptional gene regulation by miRNAs in cancer-associated fibroblasts 
has been studied in various cancers. In endometrial cancer, decreased expression 
of miR-31 and miR-148a in cancer-associated fibroblasts induces the expression 
of SATB homeobox 2 (SATB2) and WNT10B, respectively, resulting in increased 
migration and invasion of cancer cells [185, 186]. In addition, decreased miR-320 
expression in stromal fibroblasts of breast cancer regulates the secretome 
expression in fibroblasts, which in turn, results in tumour growth and invasion 
[187]. A more recent study has determined miRNA expression profiles in 
fibroblasts from breast cancer and non-neoplastic fibroblasts, and revealed the 
signalling pathways associated with target genes of differentially expressed 
miRNAs [188]. Other analyses include up-regulation of miR-16 and miR-320 in 
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1.8.2 Bone marrow derived mesenchymal stromal cells 
Studies using murine models have shown that bone marrow derived MSCs 
differentiate into CAMs, contributing to tumour growth and progression [190, 
191]. It is estimated that 20% to 25% of CAMs in the tumour stroma are derived 
from the bone marrow, and they exhibit increased expression of cytokines (e.g. 
Wnt-5a) [192, 193], implicating the contribution of deregulated signalling 
pathways in carcinogenesis. In addition, differentiation of MSCs into endothelial 
progenitor cells (EPCs) induces tumour angiogenesis [194] and increased levels of 
EPCs in the systemic circulation of cancer patients have been detected [195]. 
MSCs also exhibits anti-immune effect on tumours through suppression of T cells 
cytotoxicity [196].   
 
1.9 Aims and objectives  
The interaction between stromal and tumour cells contributes to malignancy 
[197], and it is recognised that CAMs, inflammatory cells, endothelial cells and 
bone marrow derived stromal cells are all involved in promoting tumour growth, 
angiogenesis and invasion (Figure 1.5).  
Myofibroblasts are physiologically important for maintaining tissue homeostasis 
and for wound healing [68]. However, the transformation of myofibroblasts to 
CAMs is not clearly understood even though a contribution of cancer cells that 
induce the distinct phenotype of CAMs has been suggested [198]. Results from 
the research group have revealed differential expression of mRNA transcripts and 
secretory proteins in CAMs of gastric and oesophageal carcinomas compared to  







corresponding ATMs. In addition, it has been shown that there is global DNA 
hypomethylation in gastric CAMs [149, 193].   
Over the last 10 years, miRNA research has become a hot topic in cancer biology. 
For example, miRNA expression profiling has revealed differential miRNA 
expression in tumour tissues as well as in serum samples from gastric and 
oesophageal cancer patients [153]. Nevertheless, the studies of miRNAs in CAMs 
are still limited. Therefore, the present study aimed to identify the expression of 
miRNAs that distinguish different populations of myofibroblasts (Figure 1.6) and 
Figure 1.5 Role in cancer growth and progression by the tumour microenvironment. 
Cancer-associated myofibroblasts, inflammatory cells, endothelial cells, MSCs and ECM 
constitute the microenvironment that surrounds cancer cells. Interactions between 
cancer cells and the tumour microenvironment contribute to tumour growth, invasion and 
metastasis. CAMs, a major component of the microenvironment in many epithelial 
tumours, secrete cytokines and proteases to induce tumour angiogenesis, EMT, cancer 
cell growth and invasion. Bone marrow derived MSCs and EPCs may differentiate into 
CAMs and endothelial cells, respectively. 
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to determine the contribution of miRNAs of remodelling the microenvironment of 
the upper gastrointestinal tract cancers. 
The specific objectives for this study were:  
1.9.1 To determine the miRNA expression signatures of gastric and oesophageal 
myofibroblasts, and bone marrow derived MSCs. 
1.9.2 To identify miRNA regulatory networks in gastric and oesophageal 
myofibroblasts. 
1.9.3 To investigate the role of canonical and non-canonical Wnt signalling 
pathways in gastric myofibroblasts and cancer cells. 
1.9.4 To demonstrate the biological significance of hsa-miR-181d in gastric 





Figure 1.6 Epithelial-stromal interactions in carcinogenesis and cancer 
progression. In normal mucosa, myofibroblasts (NTMs) are involved in regulating 
epithelial cell function and in tissue repair via inflammation response. Chronic 
inflammation induces genetic alterations in epithelial cells that lead to cancer 
development. Myofibroblasts of pre-neoplastic tissue (ATMs) undergo epigenetic 
changes and acquire the phenotype of CAMs. Paracrine signalling between 
cancer cells and CAMs results in cancer cell growth and invasion. Bone marrow 
derived MSCs play a role in contributing to myofibroblast population.  
























Dulbecco modified Eagle’s medium (DMEM), 0.25% trypsin-EDTA solution, 
penicillin-streptomycin (100 U/ml), MEM non-essential amino acid solution 
100X,  antibiotic-antimycotic Solution, Tween 20 for electrophoresis, N,N,N,N-
tetramethylethylene-diamine (TEMED), sodium dodecyl sulphate (SDS) and 10X 
Tris buffered saline were purchased from Sigma-Aldrich (Poole, UK). The 
miRNeasy Mini kit, Plasmid Maxi kit, and Cignal TCF/LEF Reporter (luciferase) 
construct were purchased from Qiagen (Crawley, UK). Phosphate-buffered saline 
10X, pH 7.4 (PBS) was obtained from Life Technologies (Paisley, UK) and 10X 
RIPA lysis buffer was from Merck Millipore (Billerica, MA, USA). Phosphatase 
inhibitor, cocktail set II and protease inhibitor, cocktail set III were purchased 
from Calbiochem (La Jolla, CA, USA). Fetal bovine serum (FBS) and the human 
dermal fibroblast Nucleofector kit were obtained from Lonza (Basel, 
Switzerland). Prestained protein ladder was obtained from Fermentas (Glen 
Burnie, MD, USA). Hybond-ECL nitrocellulose membrane was obtained from GE 
Healthcare Life Sciences (Little Chalfont, UK). Formaldehyde (16% solution 
microfiltered) was obtained from Agar Scientific (Stansted, UK). Biocoat control 
inserts (24 well-plate, 0.8 micron) and Falcon 4-well culture slides were obtained 
from BD (Franklin Lakes, NJ, USA). Protease-free bovine serum albumin (BSA) 
and normal donkey serum were obtained from Jackson Immuno Research 
Laboratories (West Grove, PA, USA). Vectashield mounting medium for 
fluorescence with and without DAPI were purchased from Vector Laboratories 
(Peterborough, UK). Microscope slides were obtained from Thermo Scientific 
Gerhard Menzel (Braunschweig, Germany) and cover slips were obtained from 
Scientific Laboratory Supplies (Hessle, UK). Microscope cover glass (13 mm in 
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diameter) was obtained from VMR (Darmstadt, Germany). The Click-iT EdU 
Alexa Fluor 488 Imaging kit was purchased from Invitrogen (Paisley, UK). 
ImmunStar WesterC kit was purchased from BioRad (Hemel Hempstead, UK). 
TransFast transfection reagent and Dual-Luciferase Reporter Assay System were 
obtained from Promega (Southampton, UK). CombiMag was purchased from OZ 
Biosciences (Marseille, France). Acrylamide (30%) stock solution was obtained 
from Severn Biotech Ltd (Kidderminster, UK). Tris base was obtained from VWR 
International BVBA (Leuven, Belgium) and methanol was obtained from Fisher 
Scientific (Loughborough, UK). All other chemicals were obtained from Sigma-
Aldrich.  
 
2.2 Recombinant proteins and antibodies 
Monoclonal rat anti-Wnt-5a and recombinant human IGF-II, Wnt-3a, Wnt-5a and 
TIMP-3 were purchased from R&D Systems (Abingdon, UK). Monoclonal mouse 
anti-β-catenin was obtained from Cell Signaling Technology (Danvers, MA, 
USA). Polyclonal rabbit anti-TIMP-3 (C-terminus) was obtained from Merck 
Millipore (Billerica, MA, USA). Mouse antibody to glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was purchased from Biodesign Int (Memphis, TN, 
USA). Fluorescein (FITC)-conjugated AffiniPure donkey anti-mouse antibody 
was obtained from Jackson Immuno Research Laboratories. Goat anti-mouse, and 
rabbit anti-rat conjugated to horseradish peroxidase were purchased from Sigma-
Aldrich. Goat anti-rabbit conjugated to horseradish peroxidase was purchased 
from Thermo Scientific Pierce Antibodies (Rockford, IL, USA).  
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2.3 Patients’ tissue specimens and ethical approval 
Myofibroblasts prepared from the upper gastrointestinal tract tumours and 
adjacent tissues, at least 5 cm away from the tumour margin, were obtained from 
the Department of Surgery, University of Szeged, Szeged, Hungary (Tables 2.3.1, 
2.3.2) [73]. Normal tissue myofibroblasts were prepared from 6 deceased 
transplant donors. Written and informed consent from patients had been obtained. 
Ethics approval was obtained from the Human Investigation Review Board, 
University of Szeged. Both normal and tumour tissues were confirmed by 
histopathology [179]. The TNM Classification of Malignant Tumour was applied 
according to Union for International Cancer Control (www.uicc.org).  
 
2.4 Cell culture 
Myofibroblasts were cultured in DMEM supplemented with 10% FBS, 1% 
penicillin-streptomycin (100 U/ml), 1% MEM non-essential amino acid solution 
100X and 1% antibiotic-antimycotic solution. Gastric carcinoma cells, AGS 
(American Type Culture Collection, Manassas, VA, USA) and MKN45 (RIKEN, 
Ibaraki, Japan), were cultured in DMEM supplemented with 10% FBS and 1% 
penicillin-streptomycin (100 U/ml). Cells were incubated in a humidified 
atmosphere at 37
o
C and 5% CO2. Medium was replaced every two days and cells 
were split at 90% confluence using 0.25% trypsin-EDTA solution. Human MSCs 
isolated from bone marrow aspirates of healthy donors (Table 2.3.3) were 
obtained from Lonza (Basel, Switzerland) and PromoCell GmbH (Heidelberg, 
Germany). Cells were cultured in mesenchymal stem cell basal medium 
(MSCBM) supplemented with 10% mesenchymal stem cell growth supplement 
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(MCGS), 2% L-Glutamine and 0.1% GA-1000. Medium was changed every 3 
days and cells were split at 90% confluence.  
 
2.5 Total RNA extraction and small RNA quantification 
Total RNA was extracted from myofibroblasts and MSCs using the miRNeasy 
Mini kit according to the manufacturer’s protocol. Total RNA concentration, 
ratios of A260/A280 (i.e. absorbance at 260 nm and 280 nm) and A260/A230 (i.e. 
absorbance at 260 nm and 230 nm) were determined using a NanoDrop 
2000/2000c Spectrophotometer (Thermo Scientific, Camberley, UK). 
Concentration of total RNA was expressed in µg/µl. The A260/A280 ratio 
indicates the presence of protein contamination while the A260/A230 ratio 
indicates the contamination with organic compounds such as phenol; values of 
~2.0 and ~1.4, respectively, were considered acceptable for subsequent 
applications (i.e. microarray). The protocol for small RNA enrichment was 
provided by the Ambion mirVana miRNA isolation kit (Life Technologies, 
Paisley, UK). Small RNA and miRNA concentrations in total RNA or enriched 
samples were assessed using an Agilent 2100 Bioanalyzer with a small RNA kit 

















1 Sz42 72 M >47 pT1N0M0 antrum corpus border 









3 Sz190 65 F 5 pT4N4M1 antrum corpus border mixed chronic gastritis 
4 Sz192 49 F 22 pT3N1M0 antrum corpus border diffuse chronic gastritis 













8 Sz271 72 M >34 pT3N1M0 corpus mixed chronic gastritis 
9 Sz294 84 F >31 pT3N0M0 antrum corpus border intestinal chronic gastritis 
10 Sz305 59 F 17 pT3N2M0 antrum and corpus diffuse chronic gastritis 
11 Sz308 51 M 9 pT1N3M0 antrum corpus border mixed chronic gastritis 
12 Sz389 67 M >30 pT3N1M0 antrum intestinal chronic gastritis 
13 Sz187 39 F 31 pT4N2M0 antrum corpus border intestinal no adjacent tissue 
14 Sz197 54 M >45 pT2aN0M0 antrum corpus border diffuse no adjacent tissue 
15 Sz196 67 M NA NA corpus NA NA 
16 Sz241 44 F NA NA corpus and antrum NA NA 
17 Sz246 45 M NA NA corpus and antrum NA NA 
18 Sz261 52 F NA NA corpus and antrum NA NA 
19 Sz279 60 M NA NA antrum NA NA 
20 Sz334 52 F NA NA corpus and antrum NA NA 
21 Sz351 41 M NA NA corpus and antrum NA NA 
 
 
Table 2.3.1 Characteristics of patients and tissue histology from which gastric 
myofibroblasts were generated. Identification number, age, gender, post-
operative survival (>; alive at the time of submission), TNM staging (p refers to 
stage given by pathologic examination of a surgical specimen, T describes 
tumour size, N describes regional lymph node involvement and M describes 
distant metastasis), tumour location, tumour classification and pathology 
assessment of adjacent non-tumour tissue of patients 1 to 14 from which 
gastric CAMs and ATMs were generated. Identification number, age and 
gender of patients 15 to 21 from which gastric NTMs were generated from 
normal corpus and antrum tissues.  








Location Classification Adjacent Tissue 
1 Sz173 72 M 18 pT3N1M0 oesophagus Barrett adenocarcinoma Barrett’s 
2 Sz193 64 M 19 pT2N3M0 cardia Barrett adenocarcinoma Barrett’s 
3 Sz282 70 F >25 pT3N1M1 cardia Barrett adenocarcinoma Barrett’s 
4 Sz306 56 M 34 pT3N1M0 oesophagus squamous carcinoma CIM, PAM (cardia) 
5 Sz360 52 M 31 pT3N1M0 oesophagus squamous carcinoma normal 
6 Sz373 49 M 35 pT2N1M0 oesophagus squamous carcinoma GERD 
7 Sz467 69 M 14 pT3N1M0 oesophagus squamous carcinoma PAM (cardia) 
8 Sz241 44 F NA NA oesophagus NA NA 
9 Sz246 45 M NA NA oesophagus NA NA 
10 Sz261 52 F NA NA oesophagus NA NA 
11 Sz279 60 M NA NA oesophagus NA NA 
12 Sz334 52 F NA NA oesophagus NA NA 







No.  Donor  Age Gender Tissue location Distributor 
1 HMSC-7F3914 21 M Bone marrow Lonza 
2 HMSC-7F3674 22 F Bone marrow Lonza 
3 HMSC-7F3753 43 M Bone marrow Lonza 
4 HMSC-7F3458 36 M Bone marrow Lonza 
5 HMSC-GF4393 19 M Bone marrow Lonza 
6 HMSC-PromoCell 64 M Bone marrow PromoCell GmbH 
 
`
Table 2.3.2 Characteristics of patients and tissue histology from which 
oesophageal myofibroblasts were generated. Identification number, age, 
gender, post-operative survival (>; alive at the time of submission), TNM 
staging (p refers to stage given by pathologic examination of a surgical 
specimen, T describes tumour size, N describes regional lymph node 
involvement and M describes distant metastasis), tumour location, tumour 
classification and pathology assessment of adjacent non-tumour tissue of 
patients 1 to 7 from which oesophageal CAMs and ATMs were generated. 
Identification number, age, gender and tissue location of patients 8 to 13 from 
which oesophageal NTMs were generated.  
 
Table 2.3.3 Characteristics of six donors from which 
bone marrow MSCs were obtained. Identification 
number, age, gender and tissue of six donors from 
which MSCs were obtained either from Lonza or 
PromoCell. HMSC represents human mesenchymal 
stromal cells. 
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2.6 MicroRNA array profiling  
Analysis of total RNA quality and miRNA microarray procedures were performed 
by “Exiqon Services” (Vedbaek, Denmark). The quality of total RNA was verified 
by an Agilent 2100 Bioanalyzer with RNA 6000 LapChip kit. A RNA Integrity 
Number (RIN) indicates integrity of ribosomal peaks and a value greater than 7.0 
is considered to indicate a good RNA quality. Total RNA from samples and 
references were labelled with Hy3™ and Hy5™ fluorescent labels, respectively, 
using the miRCURY™ LNA Array power labelling kit (Exiqon), according to the 
procedure described by the manufacturer. A reference sample contained all 
samples from the same tissue type (i.e. bone marrow, gastric and oesophageal 
tissues). The Hy3™-labelled samples and a Hy5™-labelled reference RNA 
sample were mixed pairwise and hybridised to the miRCURY™ LNA Array 
version 5th Generation (Exiqon), which contains capture probes targeting all 
miRNAs for human, mouse or rat registered in the miRBase version 14.0 at the 
Sanger Institute. The hybridisation was performed by using a Tecan HS 4800 
hybridisation station (Grodig, Austria) according to the miRCURY™ LNA array 
manual. After hybridisation, the microarray slides were scanned and stored in an 
ozone free environment (i.e. ozone level below 2.0 ppb) in order to prevent 
potential bleaching of the fluorescent dyes. The miRCURY™ LNA array slides 
were scanned using an Agilent G2565BA Microarray Scanner System (Agilent 
Technologies, Santa Clara, CA, USA), and image analysis was carried out using 
the ImaGene 8.0 software (BioDiscovery, Hawthorne, CA, USA). The quantified 
signals were background corrected (i.e. Normexp with offset value 10) [199] and 
normalised using the global locally weighted scatterplot smoothing (LOWESS)  
regression algorithm.  
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2.7 Data and bioinformatic analysis  
Log base 2 of transformed median Hy3/Hy5 ratios were calculated using median 
signals on capture probe replicates, and the average log2 median ratios across 
samples were obtained from Exiqon. The difference in log2 median ratio (ΔLMR) 
between sample groups were calculated and subjected to Student t-tests (two-
tailed) or ANOVA to find miRNAs that varied significantly, at p < 0.05 
(Bonferroni-corrected where applicable) across sample groups. The fold-
difference is equivalent to 2^ΔLMR. The miRNA data resource was assessed at 
miRBase (www.mirbase.org) [200]. Principal component analysis (PCA) and 
hierarchical clustering analysis on miRNA datasets were performed using DNA-
Chip Analyzer (dChip) software (www.dchip.org) [201]. Targets of miRNAs that 
have been validated by experiments were obtained from TarBase [202], 
miRecords [203] and MetaCore
®
 (GeneGO, St Joseph, MI, USA) databases. 
Network enrichment analysis of miRNA targets was performed using MetaCore
®
 
software. Statistically significant networks were identified, at p < 0.05 (FDR 5%). 
Predicted targets of hsa-miR-181d were retrieved from TargetScan Release 5.1 
[204] using a context score below -0.2 for high efficacy targets [205]. Gene 
expression profiles of gastric myofibroblasts, previously carried out using 
GeneChip Human Genome U133 Plus 2.0 Array (Affymetrix, High Wycombe, 
UK) (Appendix 2.1), were used to determine the abundance of transcripts that are  
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2.8 MicroRNA real-time quantitative reverse transcription PCR analysis  
MicroRNA reverse transcription polymerase chain reaction (RT-PCR) analysis 
was used to verify the miRNA array data and was performed by “Exiqon 
Services” (Vedbaek, Denmark). For the latter, 50 ng total RNA was reverse 
transcribed in 10 µl reactions using the miRCURY LNA™ Universal RT 
microRNA PCR, polyadenylation and cDNA synthesis kit (Exiqon); each sample 
was processed in triplicate. cDNA was diluted 100 times and 4 µl was used in 10 
µl PCR reactions according to the protocol for miRCURY LNA™ Universal RT 
microRNA PCR. Each miRNA was assayed once by RT-PCR using triplicate per 
cDNA. The amplification was performed in a LightCycler® 480 Real-Time PCR 
System (Roche, Basel, Switzerland) in 384-well plates.  
MicroRNA real-time RT-PCR analysis was also carried out in-house as part of 
this project, and made used of total RNA extracted using the Ambion mirVana 
miRNA Isolation kit (Life Technologies). RNA concentration was determined and 
2 µg RNA per sample was reverse transcribed. RT-PCR was carried out using a 
7500 real time PCR system (Applied Biosystems, Warrington, UK) and the All-in-
One miRNA qRT-PCR Detection kit (GeneCopoeia, Rockville, MD, USA) 
according to the manufacturer’s protocol. Briefly, Poly A polymerase was added 
to extend the 3’ end of miRNAs, and at the same time, an Oligo-dT Adaptor 
primer reverse transcribed the poly-A miRNAs. The reverse transcribed miRNAs 
(i.e. cDNA) was diluted at 1:50, and 2 µl was used in 20 µl PCR reactions. Each 
sample was carried out in triplicate. Mature sequences for miRNA primers were:  
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5’-AACAUUCAUUGUUGUCGGUGGGU for hsa-miR-181d (MIMAT0002821),    
5’-UAGCACCAUUUGAAAUCAGUGUU for hsa-miR-29b (MIMAT0000100),     
5’-ACAGCAGGCACAGACAGGCAGU for hsa-miR-214 (MIMAT0000271),        
5’-CAGCAGCAAUUCAUGUUUUGAA for hsa-miR-424 (MIMAT0001341) and   
5’-UCCCUGAGACCCUUUAACCUGUGA for hsa-miR-125a-5p 
(MIMAT0000443). 
 
2.9 Data pre-processing  
The LightCycler® 480 software was used to determine the Cp value, and to 
generate amplification and melting curves by Exiqon. LinRegPCR (11.5) software 
was used to determine the amplification efficiency. The average amplification 
efficiency was used to correct raw Cp values. Reference miRNAs were analysed 
for stability using the SLqPCR algorithm which is similar to geNorm, and a 
selection of the most stable reference miRNAs, namely, hsa-miR-125a-5p, hsa-
miR-24 and hsa-miR-22 were used to normalize all measurements on a well-to-
well basis.  
For in-house analysis, SDS v1.4 software was used to determine the Ct value and 
product melting curve. The abundance of hsa-miR-181d, hsa-miR-214 or hsa-
miR-424 was normalised to hsa-miR-125a-5p abundance in the same sample. 
Relative miRNA expression was performed using the 2
-ΔΔCt
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2.10 MicroRNA knockdown and overexpression 
Knockdown of hsa-miR-181d expression was carried out using the miArrest 
miRNA inhibitor expression clone (GeneCopoeia). Overexpression of hsa-miR-
181d was carried out using the miExpress precursor miRNA expression clone of 
hsa-miR-181d (GeneCopoeia). 
 
2.11 Plasmid amplification and transient nucleofection  
The hsa-miR-181d inhibitor and precursor hsa-miR-181d expression clones were 
amplified and purified by using the Plasmid Maxi kit prior to transfection using an 
Amaxa Nucleofector and the human dermal fibroblast Nucleofector kit. Briefly, 
harvested cells (500,000 cells per nucleofection) were centrifuged at 200 g for 10 
min (4
o
C). The cell pellet per nucleofection sample was resuspended in 100 µl 
human dermal fibroblast Nucleofector solution, and added with 3 µg DNA 
plasmid. The sample was transferred to an Amaxa certified cuvette and 
Nucleofector program U-23 was selected. After nucleofection, 500 µl pre-warmed 
supplemented DMEM was added to the sample and it was placed in a culture flask 
or 6-well plate containing supplemented DMEM. Cells were incubated in a 
humidified atmosphere at 37
o
C and 5% CO2 for 24 h before replacing with a fresh 
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2.12 SDS-polyacrylamide gel electrophoresis and Western blot analysis 
Gastric myofibroblasts or carcinoma cells were washed twice using PBS and lysed 
using 100 µl RIPA lysis buffer containing 1% protease inhibitor and 1% 
phosphatase inhibitor. Cell lysates were sonicated for 5 min, kept in ice for 30 
min, and then centrifuged for 3 min at 12,000 g (4
o
C). Supernatants were collected 
and stored at -80
o
C until required. Protein quantification was carried out using the 
Pierce BCA Protein Assay kit (Thermo Scientific). The 10% resolving gel 
consisted of 8.25 ml acrylamide, 10 ml distilled water, 6.25 ml 1.5 M Tris-HCl pH 
8.8, 0.25 ml 10% (w/v) SDS, 0.125 ml 10% ammonium persulphate and 0.01 ml 
TEMED. The 4% stacking gel consisted of 1.3 ml acrylamide, 6.1 ml distilled 
water, 2.5 ml 0.5 M Tris-HCl pH 6.8, 0.1 ml 10% (w/v) SDS, 0.05 ml 10% 
ammonium persulphate and 0.01 ml TEMED. 5X Running buffer (pH 8.3) 
consisted of 25 mM Tris base, 192 mM glycine and 0.1% SDS. Protein samples 
(60 µg) and 5 µl prestained protein ladder were loaded and resolved in gels by 
running buffer at 100 V for 110 min. After SDS-PAGE, resolving gels were 
soaked in transfer buffer, which contained glycine, Tris base and methanol, for 5 
min and transfer of proteins from gels to nitrocellulose membranes was carried out 
at 100 V for 1 h. Membranes were washed 3 times for 10 min using 0.1% Tween-
20 in Tris buffered saline (TBST), and incubated in blocking buffer (i.e. 5% non-
fat milk in TBST) for 1 h. Membranes were incubated overnight with TIMP-3 or 
Wnt-5a antibody diluted in blocking buffer at 4
o
C. Next day, membranes were 
washed 3 times for 10 min using TBST, and incubated in blocking buffer 
containing goat anti-rabbit or rabbit anti-rat conjugated to horseradish peroxidase 
for 1 h at room temperature. After 1 h, membranes were washed 3 times for 10 
min by using TBST, and incubated with peroxide solution and luminol solution 
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(1:1) for 5 min. Membranes were exposed and proteins were detected using a 
ChemiDoc XRS+ with ImageLab software (BioRad). Membranes were re-probed 
with mouse monoclonal anti-GAPDH. Relative expression levels were determined 
by ImageLab software, and normalised to the corresponding GAPDH level.   
 
2.13 Immunocytochemistry 
Gastric myofibroblasts (60,000 cells per well) and MKN45 cells (80,000 cells per 
well) were seeded on 4-well culture slides and incubated overnight in 
supplemented DMEM. Gastric myofibroblasts and MKN45 cells were serum-
starved for 24 h and 48 h, respectively and stimulated with 1 µg/ml human 
recombinant Wnt-3a or Wnt-5a in serum-free DMEM for 60 min. Cells were 
washed twice using PBS and fixed using 4% paraformaldehyde for 10 min at 
room temperature. The fixative was removed and cells were washed three times 
using PBS for 5 min. Fixed cells were covered with ice-cold 100% methanol and 
incubated at -20
o
C for 5 min. Cells were then washed using PBS for 5 min and 
incubated with 5% normal donkey serum in PBS with 0.3% Triton X-100 for 30 
min. After that, cells were incubated with β-catenin mouse monoclonal antibody 
(1:200 dilutions) overnight at 4
o
C and protected from light. Primary antibody was 
aspirated and cells were washed sequentially using 0.14 M NaCl, 0.5 M NaCl and 
again 0.14 M NaCl for 5 min each. Cells were incubated with FITC-conjugated 
donkey anti-mouse antibody diluted in 10 mM HEPES (pH 7.5) for 1 h at room 
temperature and protected from light. Cells were washed three times using PBS 
for 10 min and applied with mounting medium for fluorescence containing DAPI. 
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Cover slips were placed on top of the slides, and the edges were sealed with nail 
polish. Three independent experiments were performed. 
 
2.14 Assay of proliferating cells using EdU incorporation 
Procedures were adapted using the protocol for Click-iT EdU Imaging kit. Gastric 
myofibroblasts, AGS and MKN45 cells (10,000 cells per well) were seeded and 
incubated overnight in supplemented DMEM followed by serum starvation for 24 
h and 48 h, respectively. Gastric myofibroblasts, AGS and MKN45 cells were 
incubated in conditioned medium (CM) or serum-free DMEM containing 1 µg/ml 
recombinant Wnt-3a or Wnt-5a for 24 h, and in the meantime, they were 
incubated with 10 µM 5-ethynyl-2’-deoxyuridine (EdU) for 24 h and 2 h, 
respectively. After 24 h incubation, cells were washed twice using PBS and fixed 
using 4% paraformaldehyde for 30 min at room temperature. The fixative was 
removed and cells were washed twice using 3% BSA in PBS. Cells were 
permeabilised using 0.5% Triton X-100 in PBS for 20 min at room temperature 
and then washed twice using 3% BSA in PBS. Cells per well were incubated with 
500 µl Click-iT reaction cocktail, which was prepared according to the 
manufacturer’s protocol, on a shaker for 30 min at room temperature and 
protected from light. The reaction cocktail was removed and cells were washed 
using 3% BSA in PBS followed by PBS. For DNA staining, cells were incubated 
in Hoechst 33342 (2 µg/ml) for 30 min at room temperature and protected from 
light. Cells were washed twice using PBS and applied with mounting medium for 
fluorescence without DAPI. Cover slips were placed on the upper surface of the 
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A Zeiss AxioCam HRM fluorescence microscope (Carl Zeiss, Welwyn Garden 
City, UK) on 40x objective lens was used to determine the total number of cell 
nuclei at 10 different fields using the UV (blue) channel. EdU positive nuclei and 
β-catenin immunofluorescence were identified using the FITC (green) channel. 
The proportion of proliferating cells was determined by taking the total number of 
EdU positive nuclei divided by the total number of cell nuclei and expressed as a 
percentage. The proportion of cells containing nuclear β-catenin was determined 
by taking the total number of cells with nuclear localisation of β-catenin divided 
by the total number of cell nuclei and expressed as a percentage. 
 
2.16 Migration assay 
The migration of gastric myofibroblasts and AGS cells was studied using 8 µm 
pore Biocoat control inserts on 24 well-plates. Cells were harvested after 
incubation with 0.25% trypsin-EDTA Solution for 4 to 8 min, and neutralised with 
DMEM containing 1% FBS. Cell counts were performed using a haemocytometer. 
Cell suspensions were diluted in serum-free DMEM such that 500 µl DMEM in 
each upper chamber contained 10,000 cells. 750 µl CM or serum-free DMEM 
containing 1 µg/ml recombinant Wnt-3a or Wnt-5a was added to each of the 
bottom chambers. Cells were incubated for 16 h, and migrated cells were stained 
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on the lower surface of the membranes using the Reastain Quick-Diff kit 
(Reagena, Takojantie, Finland). Membranes were removed and placed on 
microscope slides with immersion oil (Sigma-Aldrich) underneath and covered 
with cover slips. Cells were visualised and counted from 5 different fields using 
10x objective lens and a Zeiss Axiovert25 Microscope. Each experiment was 
performed in triplicate. 
 
2.17 Magnetofection and luciferase assays 
Gastric myofibroblasts (100,000 cells per well) were seeded on 6-well plates and 
incubated overnight in supplemented DMEM. Transfection solution was prepared 
according to the manufacturer’s protocol, and consisted of 1 µg Cignal TCF/LEF 
Reporter (luciferase) construct, 6 µl TransFast transfection reagent and 2 µl 
CombiMag in 500 µl serum-free DMEM. Medium was removed and 
myofibroblasts were incubated with the transfection solution on a magnetic plate 
for 20 min at room temperature. The transfection solution was removed and 
replaced with pre-warmed supplemented DMEM. Myofibroblasts were incubated 
in a humidified atmosphere at 37
o
C and 5% CO2 for 24 h. Myofibroblasts were 
washed twice using serum-free DMEM and incubated with 1 µg/ml recombinant 
Wnt-3a or Wnt-5a diluted in serum-free DMEM for 8 h. Myofibroblasts were 
washed once using PBS and lysed using 500 µl passive lysis buffer on a shaker for 
15 min at room temperature. Luciferase assay buffer II and Stop & Glo Reagent 
were prepared according to the manufacturer’s protocol. Activities of firefly 
luciferase and Renilla luciferase were measured by Dual Luciferase assay using a 
Lumat LB 9507 tube luminometer (Berthold Technologies, Bad Wildbad, 
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Germany). Firefly luciferase activity is driven by the promoter of interest and 
Renilla luciferase activity is the internal control. Data was presented as a ratio of 
firefly luciferase to Renilla luciferase values. Each experiment was performed in 
triplicate. 
2.18 Statistics 
Results were presented as mean ± standard error of the mean. Comparisons were 
made using Student’s t-test or analysis of variance (ANOVA), where appropriate, 





















MicroRNA expression profiling of myofibroblasts          
and mesenchymal stromal cells




This work focuses on a group of myofibroblasts that have been generated from 
gastric and oesophageal cancers, adjacent non-tumour tissues, and normal tissues 
of the stomach and oesophagus. These cultured primary myofibroblasts have also 
been studied in detail. Gastric myofibroblasts have been characterised by staining 
positive for vimentin and α-SMA. They have been shown to express MMP1, 
MMP2, MMP3 and MMP9, and all TIMP1 to TIMP4 [73]. In addition, gastric 
myofibroblasts exhibit increased proliferation and migration in response to 
epithelial-derived MMP7 by activating IGF-II [73]. Furthermore, a recent study 
has indicated increased rates of proliferation and migration in gastric CAMs 
compared to ATMs or NTMs [179]. Using methylation-sensitive SNP array 
analysis, it was found that there is hypomethylation of genomic DNA in gastric 
CAMs compared to normal myofibroblasts [149]. Microarray and proteomic 
analyses have also indicated transcriptomes (Steele and Varro, preliminary data) 
and secretomes [179] of gastric CAMs are significantly different from 
corresponding ATMs.  
In addition, functional characterisation of oesophageal myofibroblasts has been 
studied recently. For example, there is an increased rate of proliferation in 
oesophageal CAMs compared to corresponding ATMs and NTMs. Moreover, 
conditioned medium from oesophageal CAMs increases migration and 
proliferation of oesophageal cancer cell lines (Kumar and Varro, personal 
communication).
Changes in miRNA expression have been described in gastric and oesophageal 
tumours and their pre-neoplastic tissues [153]. Additionally, a recent study using 
  MicroRNA expression profiling of myofibroblasts and mesenchymal stromal cells 
59 
 
microdissected tissues has indicated increased expression of oncogenic miRNAs 
in colorectal cancer stromal tissue compared to normal stromal tissue [207], 
suggesting there may be altered miRNA expression in myofibroblasts, which are 
abundant in the tumour stroma. However, the miRNA expression profiles of 
myofibroblasts from gastric and oesophageal cancers and their counterparts from 
non-tumour tissues have yet to be determined. 
The aims for the work described in this chapter were: 
3.1.1 To determine the miRNA expression profiles of upper gastrointestinal tract 
    myofibroblasts and their putative precursors (i.e. bone marrow MSCs). 
3.1.2 To characterise differentially abundant miRNAs in myofibroblasts from      
    different pathological conditions. 
3.1.3 To compare myofibroblasts and MSCs by applying PCA and hierarchical 













Gastric and oesophageal myofibroblasts had previously been generated from 
human tissue specimens, namely, CAMs, ATMs and NTMs [179] (Chapter 2.3). 
Total RNA of myofibroblasts and MSCs was analysed for RNA concentration, 
RNA purity and RIN (Appendix 3.2.1). Examples of total RNA profiles which 
were verified by Agilent 2100 Bioanalyzer are illustrated in Appendix 3.2.2. 
Small RNA and miRNA concentrations (Appendix 3.2.3), the integrity of small 
RNAs (6 to 150 nucleotides) (Appendix 3.2.4) and minimal miRNA degradation 
after six months storage (Appendix 3.2.5) [208] were determined in selected 
samples. An increase in miRNA concentration in enriched RNA samples 
(Appendix 3.2.6) was demonstrated using the Ambion mirVana miRNA Isolation 
Kit. 
MicroRNA expression profiling was determined by using locked nucleic acid 
(LNA) microarrays and the Hy5-reference and Hy3-sample labelling method 
(Chapter 2.6). Spike-in controls were used to assess the quality of the data from 
MSCs (Appendix 3.2.7), gastric myofibroblasts (Appendix 3.2.8) and oesophageal 
myofibroblasts (Appendix 3.2.9). To validate the microarray data, quantitative 
RT-PCR analysis was performed on specific miRNAs using the LNA Universal 
RT microRNA PCR or All-in-One miRNA qRT-PCR Detection kit. A single Hy3 
channel analysis of miRNA abundance was used to compare arrays from different 
type of tissues. Dual channel analysis of miRNA abundance was determined using 
the ratio intensity of Hy3 to Hy5 (i.e. internal control) and was used for inter-array 
comparisons of the same tissue type. Hierarchical clustering analysis and PCA 
were performed using dChip software. MicroRNAs that exhibited difference in 
abundance by ≥ 20% or 40%, at p < 0.05, were considered significant. 
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3.3.1 Global miRNA expression profiles in myofibroblasts and MSCs 
Using dual channel analysis (i.e. Hy3 and Hy5), an average of 28%, 25% and 27% 
of the microarray probes were detected in MSCs (n =6), gastric NTMs (n =12) and 
oesophageal NTMs (n =6), respectively. From the analysis, it was found that 317, 
276 and 300 mature human miRNAs were expressed in all MSCs, all gastric 
NTMs and all oesophageal NTMs, respectively (Table 3.3.1). When miRNA 
detection in at least 80% of the samples was taken into account, the number of 
detected miRNAs in MSCs, gastric NTMs and oesophageal NTMs corresponded 
to 342, 295 and 320 mature human miRNAs, respectively. Full lists of expressed 
miRNAs are presented in the appendices: MSCs (Appendix 3.3.1), gastric corpus 
NTMs (Appendix 3.3.2a), gastric antral NTMs (Appendix 3.3.2b) and 
oesophageal NTMs (Appendix 3.3.3).  
In contrast, a single Hy3 channel analysis of miRNA abundance in all MSCs and 
all NTMs was used to compare samples from different type of tissues. Using this 
method, 246, 255 and 248 miRNAs were detected in at least 80% of MSCs, 
gastric NTMs and oesophageal NTMs, respectively. Of these, 218 miRNAs were 
expressed in MSCs, gastric and oeosphageal NTMs while 17 miRNAs were 
expressed in both gastric and oesophageal NTMs, but not in MSCs (Figure 3.3.1). 
Furthermore, there were small numbers of miRNAs that were detected specifically 
in MSCs (13 miRNAs), gastric NTMs (11 miRNAs) and oesophageal NTMs (7 
miRNAs).  
 






Cell type Number of common miRNAs 
100% of samples >80% of samples 
MSC (n = 6) 317 342 
Gastric corpus NTM (n = 6) 278 298 
Gastric antral NTM (n = 6) 291 301 
Gastric NTM (n = 12) 276 295 











Table 3.3.1 Numbers of miRNAs expressed in at 
least 80% of MSCs, gastric NTMs or 
oesophageal NTMs using dual channel 
microarray analysis. 
 
Figure 3.3.1 Numbers of miRNAs expressed in at least 80% of all 
MSCs, all gastric NTMs and all oesophageal NTMs using a single 
Hy3 channel microarray analysis. 
 




3.3.2 Validation of miRNA expression using quantitative RT-PCR 
To validate the microarray data, RT-PCR analysis was used to measure the 
abundance of hsa-miR-29b, hsa-miR-214 and hsa-miR-424. These miRNAs were 
selected because they were highly expressed in all MSCs, gastric and oesophageal 
myofibroblasts, but also exhibited differential expression in cancer (as described 
later).  
Consistent with the microarray data, RT-PCR analysis showed that the abundance 
of hsa-miR-29b was significantly (ANOVA p < 0.001, compared to MSCs) 
increased in gastric CAMs, ATMs and NTMs (Figure 3.3.2A). When comparing 
each myofibroblast sample to the mean of MSCs, a similar trend was obtained, 
with relative abundance of hsa-miR-29b greater than 1.0 in most of the gastric 
samples (Figure 3.3.2B). A scatter plot indicated a positive correlation (correlation 
coefficient = 0.901) between microarray and PCR analyses (Figure 3.3.2C).  
On the other hand, both microarray and RT-PCR analyses showed the abundance 
of hsa-miR-214 was significantly (ANOVA p < 0.001, compared to MSCs) 
decreased in all oesophageal CAMs, ATMs and NTMs (Figure 3.3.3A). When 
each oesophageal sample was compared to the mean of MSCs, the relative 
abundance of hsa-miR-214 was less than 1.0 in all oesophageal samples (Figure 
3.3.3B). Again, a significant correlation (correlation coefficient = 0.685) between 











































Figure 3.3.2 Validation of hsa-miR-29b abundance in gastric myofibroblasts 
compared to MSCs. (A) The abundance of hsa-miR-29b in gastric CAMs, 
ATMs and NTMs was determined by array and RT-PCR analyses (ANOVA p 
< 0.001, compared to MSCs). Values represent the mean of all relevant 
samples. (B) The abundance of hsa-miR-29b in each gastric CAM, ATM or 
NTM compared to MSCs (n=6, mean abundance = 1.0) was determined by 
array and RT-PCR analyses. (C) A scatter plot of PCR versus array (n = 43) 
reveals a Pearson correlation coefficient of 0.901 at p < 0.05. (*p < 0.05) 
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Figure 3.3.3 Validation of hsa-miR-214 abundance in oesophageal 
myofibroblasts compared to MSCs. (A) The abundance of hsa-miR-214 in 
oesophageal SC-CAMs, AC-CAMs, SC-ATMs, AC-ATMs and NTMs was 
determined by array and RT-PCR analyses (ANOVA p < 0.001, compared to 
MSCs). Values represent the mean of all relevant samples. (B) The 
abundance of hsa-miR-214 in each oesophageal CAM, ATM or NTM 
compared to MSCs (n=6, mean abundance = 1.0) was determined by array 
and RT-PCR analyses. (C) A scatter plot of PCR versus array (n = 21) reveals 
a Pearson correlation coefficient of 0.685 at p < 0.05. (*p < 0.05) 
 
 


























































In the third example, the abundance of hsa-miR-424 was significantly (ANOVA p 
< 0.05, compared to NTMs) decreased in gastric CAMs and ATMs by using 
microarray and RT-PCR analyses (Figure 3.3.4A). When comparing each sample 
of CAM and ATM to the mean of NTMs, the relative abundance of hsa-miR-424 
was less than 1.0 with just 4 exceptions, namely, Sz42/1, Sz45/1, Sz42/2 and 
Sz305/22 (Figure 3.3.4B). A scatter plot indicated a positive correlation 
(correlation coefficient = 0.926) between microarray and PCR analyses (Figure 
3.3.4C).  
 
3.3.3 Unsupervised clustering analysis of global miRNA expression  
To determine the relations of MSCs, gastric and oesophageal myofibroblasts, 
single Hy3 channel data of miRNA abundance were analysed by PCA and 
hierarchical clustering analysis. Distinct clusters of MSCs (n = 6), gastric NTMs 
(n = 12) and oesophageal NTMs (n = 6) were obtained by PCA (Figure 3.3.5A). 
When hierarchical clustering analysis was performed on the same set of samples, 
it was found that gastric NTMs were grouped into one cluster while MSCs and 
oesophageal NTMs were in the other distinct cluster (Figure 3.3.5B).  
The same methodology was then extended to the analysis of MSCs and CAMs 
from gastric and oesophageal carcinomas. In Figure 3.3.6A, the PCA shows 
distinct clusters of MSCs (n = 6), gastric CAMs (n = 14), oesophageal squamous 
cell carcinoma derived CAMs (SC-CAMs, n = 4) and oesophageal 
adenocarcinoma derived CAMs (AC-CAMs, n = 3). It was noted that SC-CAMs 
and AC-CAMs were closely associated even though they were clustered 
separately. When hierarchical clustering analysis was performed, gastric CAMs 








































Figure 3.3.4 Validation of hsa-miR-424 abundance in gastric CAMs and 
ATMs compared to NTMs. (A) The abundance of hsa-miR-424 in gastric 
CAMs and ATMs was determined by array and RT-PCR analyses (ANOVA p 
< 0.05, compared to NTMs). Values represent the mean of all relevant 
samples. (B) The abundance of hsa-miR-424 in each gastric CAM or ATM 
compared to NTMs (n=12, mean abundance = 1.0) was determined by array 
and RT-PCR analyses. (C) A scatter plot of PCR versus array (n = 31) 




















































Figure 3.3.5 Distinct global miRNA expression profiles of MSCs and 
NTMs. (A) Separate clusters of MSCs (blue), oesophageal NTMs 
(green) and gastric NTMs (red) were determined by PCA. (B) The heat 
map of gastric NTMs (red), MSCs (blue) and oesophageal NTMs 
(green) on global miRNA expression. The colour scale below illustrates 
the relative expression level of a miRNA across all samples: red - 
expression level above mean; blue - expression level below mean.  
 
 








Figure 3.3.6 Distinct global miRNA expression profiles of MSCs, gastric 
and oesophageal CAMs. (A) Separate clusters of MSCs (blue), gastric 
CAMs (red), oesophageal SC-CAMs (green) and oesophageal AC-CAMs 
(light blue) were determined by PCA. (B) The heat map of MSCs (blue), 
oesophageal CAMs (black) and gastric CAMs (red) on global miRNA 
expression. The colour scale below illustrates the relative expression 
level of a miRNA across all samples: red - expression level above mean; 
blue - expression level below mean.  
 
 




and MSCs were in two separate clusters, whereas oesophageal CAMs were found 
in both clusters (Figure 3.3.6B). 
 
 3.3.4 Frequency distribution of miRNA abundance in MSCs and 
myofibroblasts 
After analysing global miRNA profiles of MSCs and myofibroblasts, the next step 
was to identify miRNAs that distinguish different populations. Using miRNA 
abundance from single Hy3 channel data, the frequency of altered miRNA 
abundance between two populations was plotted into histograms followed by the 
identification of those miRNAs that exhibited significant difference in abundance. 
When gastric NTMs were compared to oesophageal NTMs, the frequency of 
miRNA abundance followed a normal distribution, but a distinct group of 19 
miRNAs, which exhibited a difference in abundance by ≥ 40%, were significantly 
different (p < 0.001) (Figure 3.3.7A).  
When comparing the frequency distribution of miRNA abundance in MSCs 
relative to gastric NTMs, there were 48 miRNAs that were significantly different 
in abundance (p < 0.001) (Figure 3.3.7B). In addition, there were 9 miRNAs that 
were significantly different (p < 0.001) when MSCs were compared to 
oesophageal NTMs (Figure 3.3.7C). When miRNA abundance in gastric CAMs 
was compared to SC-CAMs, a distinct group of 38 miRNAs were significantly 
up-regulated (p < 0.001) (Figure 3.3.7D). The comparison of gastric CAMs and 
AC-CAMs showed a slight positively skewed distribution, with 13 miRNAs that 
were significantly up-regulated (p < 0.001) in gastric CAMs (Figure 3.3.7E).  




Full lists of significantly different miRNAs and their relative abundance from the 
above comparisons are presented in the appendices: gastric NTMs compared to 
oesophageal NTMs (Appendix 3.3.4); MSCs compared to gastric NTMs 
(Appendix 3.3.5); MSCs compared to oesophageal NTMs (Appendix 3.3.6); 
gastric CAMs compared to SC-CAMs (Appendix 3.3.7) and gastric CAMs 
compared to AC-CAMs (Appendix 3.3.8).  
 
3.3.5 Differentially abundant miRNAs in myofibroblasts from gastric 
carcinoma, adjacent non-tumour and normal gastric tissues 
The data presented so far indicates myofibroblasts from different tissue 
microenvironments exhibit distinct miRNA profiles. This analysis was then 
extended to a comparison of miRNA abundance in gastric CAMs, ATMs and 
NTMs. Using dual channel microarray analysis, a total of 286 miRNAs was 
detected in at least 80% of all CAMs, all ATMs and all NTMs (Figure 3.3.8). The 
number of miRNAs which were detected specifically in gastric CAMs, ATMs and 
NTMs were 0, 5 and 1, respectively. 
The frequency of miRNA abundance in 12 gastric CAMs compared to their 
corresponding ATMs followed a normal distribution (Figure 3.3.9A). A relatively 
small subset of 12 miRNAs exhibited a significant (paired t-test, p < 0.05) 
difference in abundance by ≥ 20% (Table 3.3.2A). The less stringent criterion 
compared to the previous 40% cut-off was applied due to lower overall variation 
between CAM and ATM because they were from the same individual, and unlike 
previously, inter-individual variation was not relevant. The relative  
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Figure 3.3.7 Using single channel microarray analysis, the frequency 
distribution of miRNA relative abundance in (A) gastric NTMs compared to 
oesophageal NTMs; there were 19 differentially abundant miRNAs (≥ 1.4-fold, 
p < 0.001), (B) MSCs compared to gastric NTMs; there were 48 differentially 
abundant miRNAs (≥ 1.4-fold, p < 0.001), (C) MSCs compared to 
oesophageal NTMs; there were 9 differentially abundant miRNAs (≥ 1.4-fold, 
p < 0.001), (D) gastric CAMs compared to SC-CAMs; there were 38 
differentially abundant miRNAs (≥ 1.4-fold, p < 0.001) and in (E) gastric CAMs 
compared to AC-CAMs; there were 13 differentially abundant miRNAs (≥ 1.4-
fold, p < 0.001). 
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Figure 3.3.8 Numbers of miRNAs that were expressed in at least 80% 
of gastric NTMs (n = 12), ATMs (n = 17) and CAMs (n = 14) by using 
dual channel microarray analysis.  
 




abundance of 10 of these miRNAs, which were available in MetaCore
®
 database 
and were found in all 12 pairs of gastric CAMs and ATMs, are presented in the 
appendix (3.3.9). 
Next, comparisons of miRNA abundance in CAMs and ATMs with NTMs were 
analysed so as to identify miRNAs that may be altered in the stroma during the 
early stage of gastric carcinogenesis. The frequency distribution of miRNA 
abundance in gastric CAMs compared to NTMs showed tails at both sides (Figure 
3.3.9B), with 23 miRNAs exhibiting a significant (p < 0.05) difference in 
abundance by ≥ 40% (Table 3.3.2B). Of these miRNAs, 13 miRNAs were down-
regulated while 10 miRNAs were up-regulated. When gastric ATMs were 
compared to NTMs, the frequency of miRNA abundance followed a normal 
distribution (Figure 3.3.9C), with 16 miRNAs that were significantly different (p 
< 0.05) (Appendix 3.3.10).  
 
3.3.6 Validation of miRNA abundance in gastric CAM comparisons 
Pairwise analysis of 12 gastric CAMs compared to their corresponding ATMs 
showed that hsa-miR-181d exhibited the highest mean difference in abundance 
(Figure 3.3.10A). Relative abundances of hsa-miR-181d in CAMs of Sz190, 
Sz192 and Sz268 compared to their respective ATMs were 2.5, 1.5 and 1.1, 
respectively, and validation using quantitative RT-PCR indicated values of 1.8, 
2.3 and 0.9, respectively (Figure 3.3.10B). In addition, both microarray and RT-
PCR analyses showed decreased abundance of hsa-miR-214 and hsa-miR-424 in 
CAMs of Sz192, Sz268 and Sz389, when compared to Sz246 (NTMs) (Figures 
3.3.10C, 3.3.10D).  
























Figure 3.3.9 Using dual channel microarray analysis, the frequency 
distribution of miRNA relative abundance in (A) gastric CAMs compared 
to ATMs; there were 12 differentially abundant miRNAs (≥ 1.2-fold, p < 
0.05), (B) gastric CAMs compared to NTMs; there were 23 differentially 
abundant miRNAs (≥ 1.4-fold, p < 0.05) and in (C) gastric ATMs 
compared to NTMs; there were 16 differentially abundant miRNAs (≥ 
1.4-fold, p < 0.05).    
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Probe Id Annotation Relative abundance p-value 
1 46561 hsa-miRPlus-E1168 -1.32 3.34E-02 
2 146076 hsa-miR-483-3p -1.16 2.85E-02 
3 145901 hsa-miR-494 -1.16 2.53E-02 
4 145740 hsa-miR-625* -1.16 2.50E-02 
5 19582 hsa-miR-106b 1.17 2.57E-02 
6 30687 hsa-miR-93 1.18 3.22E-02 
7 10936 hsa-miR-130b 1.19 3.91E-02 
8 11053 hsa-miR-32 1.20 6.83E-03 
9 27720 hsa-miR-15a 1.21 3.96E-02 
10 17280 hsa-miR-15b 1.21 3.20E-02 
11 13143 hsa-miR-301a 1.21 3.60E-02 




No. Probe Id Annotation Relative abundance p-value 
1 146016 hsa-miR-1978 -2.13 9.22E-04 
2 145725 hsa-miR-518b -1.59 1.70E-03 
3 146076 hsa-miR-483-3p -1.52 8.93E-03 
4 46749 hsa-miRPlus-E1033 -1.52 6.58E-03 
5 42679 hsa-miR-642 -1.49 4.33E-04 
6 42641 hsa-miR-145 -1.45 4.43E-02 
7 42806 hsa-miR-886-3p -1.43 1.03E-02 
8 46630 hsa-miRPlus-F1064 -1.41 1.09E-03 
9 11014 hsa-miR-214 -1.39 5.49E-03 
10 42965 hsa-miR-424 -1.39 2.19E-02 
11 
12 
42513 hsa-miR-300 -1.37 9.86E-04 
12 17354 hsa-miR-637 -1.37 4.64E-02 
13 46733 hsa-miRPlus-E1117 -1.35 3.08E-03 
14 46739 hsa-miR-1308 1.35 6.55E-04 
15 46328 hsa-miR-1274b 1.36 8.92E-05 
16 21526 hsa-miRPlus-E1031 1.36 2.55E-02 
17 46537 hsa-miRPlus-E1038 1.37 2.13E-04 
18 10977 hsa-miR-183 1.38 3.35E-02 
19 46698 hsa-miR-1280 1.40 9.68E-05 
20 42825 hsa-miR-888* 1.42 2.65E-05 
21 46732 hsa-miR-1264 1.44 4.18E-05 
22 46292 hsa-miR-1274a 1.45 2.33E-03 
23 145978 hsa-miRPlus-E1258 1.59 1.47E-04 
 
 
Table 3.3.2A Relative abundance of significantly 
different miRNAs in pairwise analysis of gastric CAMs 
compared to ATMs, at p < 0.05 (paired t-test).  
Table 3.3.2B Relative abundance of significantly different 
miRNAs in gastric CAMs compared to NTMs, at p < 0.05. 
 


















































Figure 3.3.10 Abundances of hsa-miR-181d, hsa-miR-214 and hsa-miR-
424 in single samples of gastric CAMs compared to ATMs or NTMs were 
determined by microarray and RT-PCR analyses. (A) The abundance of 
hsa-miR-181d in individual paired samples of gastric CAMs compared to 
corresponding ATMs from 12 patients was determined by microarray 
analysis. (B) An increase in hsa-miR-181d abundance in CAMs of Sz190 
and Sz192 compared to corresponding ATMs was confirmed by using RT-
PCR. No abundance difference was found in CAMs of Sz268 compared to 
corresponding ATMs. (C) When compared to Sz246 (NTMs; abundance = 
1.0), the abundance of hsa-miR-214 was decreased in CAMs of Sz192, 
Sz268 and Sz389. (D) When compared to Sz246 (NTMs, abundance = 1.0), 
the abundance of hsa-miR-424 was decreased in CAMs of Sz192, Sz268 













































































































































3.3.7 Differentially abundant miRNAs in myofibroblasts from oesophageal 
squamous cell carcinoma, adjacent non-tumour and normal oesophageal 
tissues 
The miRNA data analysis of gastric myofibroblasts as described above was then 
extended to oesophageal myofibroblasts. When SC-CAMs was compared to their 
adjacent non-tumour tissue derived myofibroblasts (SC-ATMs), the frequency of 
miRNA abundance showed a positively skewed distribution (Figure 3.3.11A), 
with 16 miRNAs that were significantly (paired t-test, p < 0.05) different between 
two groups (Appendix 3.3.11). In a comparison of each SC-CAM and 
corresponding SC-ATM, the relative abundance of 14 of these miRNAs, which 
were available in MetaCore
®
 database, is indicated in the appendix (3.3.12).  
When SC-CAMs were compared to oesophageal NTMs, the frequency of miRNA 
abundance followed a normal distribution with a small peak at the positive tail 
(Figure 3.3.11B) and with 18 miRNAs that exhibited significant (p < 0.05) 
difference in abundance (Appendix 3.3.13). Additionally, when SC-ATMs were 
compared to NTMs, the frequency distribution of miRNA abundance was 
positively skewed (Figure 3.3.11C), with a total of 26 miRNAs that were 
significantly (p < 0.05) different (Appendix 3.3.14).  



































Figure 3.3.11 Using dual channel microarray analysis, the frequency 
distribution of miRNA relative abundance in (A) SC-CAMs compared to SC-
ATMs; there were 16 differentially abundant miRNAs (≥ 1.2-fold, p < 0.05), 
(B) SC-CAMs compared to NTMs; there were 18 differentially abundant 
miRNAs (≥ 1.4-fold, p < 0.05), (C) SC-ATMs compared to NTMs; there were 
26 differentially abundant miRNAs (≥ 1.4-fold, p < 0.05), (D) AC-CAMs 
compared to AC-ATMs; there were 5 differentially abundant miRNAs (≥ 1.2 
fold, p < 0.05), (E) AC-CAMs compared to NTMs; there were 9 differentially 
abundant miRNAs (≥ 1.2 fold, p < 0.05) and in (F) AC-ATMs compared to 
NTMs; there were 10 differentially abundant miRNAs (≥ 1.4 fold, p < 0.05). 
Relative abundance






















































































3.3.8 Differentially abundant miRNAs in myofibroblasts from oesophageal 
adenocarcinoma, adjacent non-tumour and normal oesophageal tissues 
The comparison of AC-CAMs with adjacent tissue derived myofibroblasts (AC-
ATMs) showed the frequency distribution of miRNA abundance was positively 
skewed (Figure 3.3.11D), with only 5 miRNAs that were significantly different 
(paired t-test, p < 0.05) (Appendix 3.3.15). In a comparison of each AC-CAM and 
corresponding AC-ATM, the relative abundance of 4 of these miRNAs that were 
found in MetaCore
®
 is indicated in the appendix (3.3.16).  
The frequency of miRNA abundance in AC-CAMs compared to NTMs followed a 
normal distribution (Figure 3.3.11E). There were 9 miRNAs that exhibited a 
significant (p < 0.05) difference in abundance by ≥ 20% (Appendix 3.3.17). When 
AC-ATMs were compared to NTMs, the frequency of miRNA abundance showed 
a slight positively skewed distribution (Figure 3.3.11F), with a group of 10 
miRNAs that exhibited a significant difference in abundance by ≥ 40% (Appendix 
3.3.18).  
 
3.3.9 Hierarchical clustering analysis of differentially abundant miRNAs 
After the identification of differential miRNA abundance in myofibroblasts from 
cancer, adjacent non-tumour and normal tissues, hierarchical clustering analysis 
was performed to determine whether these miRNA expression profiles could 
distinguish myofibroblasts from different types of tissue. Heat maps of 
differentially abundant miRNAs did not distinguish between gastric CAMs and 




ATMs (Figure 3.3.12A), but gastric CAMs (86%) and ATMs (76%) were 
segregated from NTMs (Figures 3.3.12B, 3.3.12C). 
When hierarchical clustering analysis was performed using differential miRNA 
abundance in oesophageal myofibroblasts, there were distinct clusters between 
SC-CAMs and SC-ATMs (Figure 3.3.13A), SC-CAMs and NTMs (Figure 
3.3.13B), and between SC-ATMs and NTMs (Figure 3.3.13C). Heat maps of 
differential miRNA abundance, however, could not clearly segregate AC-CAMs 
from AC-ATMs (Figure 3.3.14A). Distinct clusters between AC-CAMs and 






































Figure 3.3.12 Two-way hierarchical clustering analysis of significantly 
different miRNAs in gastric myofibroblasts. (A) The heat map of 
differential miRNA abundance (p < 0.05) in pairwise analysis of gastric 
CAMs and ATMs. (B) The heat map of differential miRNA abundance 
(p < 0.001) shows segregation of 86% CAMs (red; n = 14) from NTMs 
(black; n = 12). (C) The heat map of differential miRNA abundance (p < 
0.001) shows segregation of 76% ATMs (blue; n = 17) from NTMs 
(black; n = 12). Clusters of differentially abundant miRNAs are shown 
on the left. The colour scale below illustrates the relative abundance of 
a miRNA across all samples: red - abundance above mean; blue - 
abundance below mean.  
 









 Figure 3.3.13 Two-way hierarchical clustering analysis of significantly 
different miRNAs in osophageal SC-CAMs, SC-ATMs and NTMs. (A) The 
heat map of differential miRNA abundance (p < 0.05) in pairwise analysis of 
SC-CAMs (red) and SC-ATMs (blue). (B) The heat map of differential 
miRNA abundance (p < 0.01) shows segregation of SC-CAMs (red) from 
NTMs (black). (C) The heat map of differential miRNA abundance (p < 0.01) 
shows segregation of SC-ATMs (blue) from NTMs (black). Clusters of 
differentially abundant miRNAs are shown on the left. The colour scale 
below illustrates the relative abundance of a miRNA across all samples: red 
- abundance above mean; blue - abundance below mean. 
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Figure 3.3.14 Two-way hierarchical clustering analysis of significantly 
different miRNAs in osophageal AC-CAMs, AC-ATMs and NTMs. (A) The 
heat map of differential miRNA abundance (p < 0.05) in pairwise analysis 
of AC-CAMs (red) and AC-ATMs (blue). (B) The heat map of differential 
miRNA abundance (p < 0.05) shows segregation of AC-CAMs (red) from 
NTMs (black). (C) The heat map of differential miRNA abundance (p < 
0.01) shows segregation of AC-ATMs (blue) from NTMs (black). Clusters 
of differentially abundant miRNAs are shown on the left. The colour scale 
below illustrates the relative abundance of a miRNA across all samples: 
red - abundance above mean; blue - abundance below mean. 
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MicroRNAs are recognised as important regulators of gene expression. However, 
the study of miRNAs in stromal cells is currently limited. In this chapter, the 
results showed that: (a) myofibroblasts from different tissue microenvironments 
exhibit distinct global miRNA expression profiles, (b) miRNA expression of 
MSCs is distinct from NTMs and that (c) differentially abundant miRNAs 
distinguish different populations of myofibroblasts. Using pairwise comparison in 
gastric CAMs and ATMs, miRNA analysis identified 12 miRNAs that were 
significantly different in abundance, suggesting these miRNAs may contribute to 
the myofibroblast phenotype during gastric carcinogenesis and progression. 
Moreover, the comparison of gastric CAMs and NTMs identified a set of 23 
differentially abundant miRNAs that may be involved in stromal-induced tumour 
progression. Additionally, the comparison of gastric ATMs and NTMs revealed a 
set of 16 miRNAs whose abundance may be altered by chronic inflammation (e.g. 
H. pylori induced inflammation). Although there is a low sample size of 
oesophageal myofibroblasts, a similar approach has been applied to these samples. 
Lastly, the microarray data for a set of 4 miRNAs, namely, hsa-miR-181d, hsa-
miR-29b, hsa-miR-214 and hsa-miR-424, were validated by quantitative RT-PCR.  
The present study used LNA miRNA arrays to determine miRNA expression 
profiles in MSCs and myofibroblasts. MicroRNA detection may be subjected to 
poor specificity and low sensitivity (i.e. hybridisation efficiency) due to short 
nucleotide length and sequence homology in miRNAs,  [209]. The development 
of chemically modified probes, such as LNA-modified oligonucleotides, aims to 
overcome these problems. Indeed, LNA probes have been used successfully in
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applications such as northern blotting [210], in-situ hybridization [211], 
microarray [212] and RT-PCR analysis [213]. Moreover, a comparison of 
quantitative miRNA expression between LNA microarray and next-generation 
sequencing indicates there is a higher sensitivity and better correlation between 
microarray data and RNA content [214].  
Besides mature miRNA sequences, there were miRPLUS and miR* sequences on 
the LNA miRNA array which was used for the present study. A total of 308 
miRPLUS sequences from the array were not found in miRBase and MetaCore
®
 
databases, but these were considered potentially as functional miRNA sequences. 
In addition, miR* sequences were thought to be non-functional and in low 
abundance [200]. It has been suggested that when miRNA duplexes unwind, the 
mature miRNA strand is incorporated into the RISC while the other strand 
containing miR* sequence is degraded [215]. As a result, most miRNA studies 
have focused on the dominant form of miRNA sequences.  
The latest version of Exiqon LNA miRNA array contains only 25 miRPLUS 
sequences, suggesting many miRPLUS sequences have been validated and 
deposited in miRBase database. In addition, mature miRNA and miR* sequences 
in miRBase have been renamed as miRNA sequences from the 5’ or 3’ arms, and 
one of the two is the miRNA that is predominantly expressed. These amendments 
suggest rapidly increasing knowledge of miRNAs over the past few years that are 
attributable to advances in miRNA research tools and increased interest in miRNA 
research. Despite shortfalls at the time of performing microarray analysis, the 
results from this study have, nevertheless, characterised miRNA expression 
profiles previously unknown in MSCs and myofibroblasts.  
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For miRNA expression analysis, miRNAs that exhibited difference in abundance 
between group comparisons at p < 0.05 across samples were considered 
significant in the present study. A fold-difference of at least 1.2 or 1.4 was applied 
to identify differential abundant miRNAs that were distinctly different between 
group comparisons. The Bonferroni Test was attempted to prevent false positive 
results, but comparisons between different populations of myofibroblasts failed in 
this testing. This may not be unexpected, especially in paired samples of 
myofibroblasts that exhibit genetic similarity.     
Hierarchical clustering analysis and PCA are common tools for analysing 
expression data. Hierarchical clustering analysis classifies samples according to 
similarities in their expression profiles, and segregates samples into two main 
clusters followed by sub-clusters. On the other hand, PCA, which can produce two 
or more clusters, is a mathematical method that contains principal components 
with the highest variance across samples. Using global miRNA expression 
profiles, hierarchical clustering analysis revealed an association of MSCs with 
oesophageal NTMs, but not gastric NTMs, whereas PCA indicated distinct 
clusters of MSCs, gastric and oesophageal NTMs.  
MicroRNAs are involved in many biological processes, and their functions may 
vary depending on cell types. There are currently no miRNA studies that compare 
stromal cells from different type of tissues. The present analysis of miRNA 
abundance identified significant up-regulation of hsa-miR-138-1*, hsa-miR-320d, 
hsa-miR-301a and hsa-miR-101 in gastric NTMs compared to oesophageal 
NTMs. Hsa-miR-320d is a member of the miR-320 family which has been found 
to induce apoptosis in cardiomyocytes [216]. In addition, hsa-miR-301a and hsa-
miR-101 are involved in the regulation of immune response in T cells and 
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macrophages, respectively [217, 218]. The role of these significantly different 
miRNAs in NTMs has not been determined, but the results suggest myofibroblasts 
in different tissue microenvironments exhibit different properties that may 
determine epithelial function in the stomach and oesophagus.  
There is emerging evidence indicating that MSCs are a source of myofibroblasts 
in the tissue stroma during inflammation, wound healing and cancer progression 
[193, 219]. However, the role of miRNAs in myofibroblast differentiation has not 
been addressed. When MSCs were compared to gastric and oesophageal NTMs, it 
was found that hsa-miR-29c was significantly decreased while hsa-miR-140-3p 
and hsa-miR-15a were significantly increased. The expression of miR-29 and 
miR-140 has been linked to Wnt signalling in osteoblasts [220] and chondrocytes 
[221], respectively.   
When MSCs were compared to gastric NTMs, hsa-miR-125b was identified as top 
up-regulated miRNA. Additionally, it was found that hsa-miR-34a was 
significantly down-regulated in MSCs compared to oesophageal NTMs. Studies 
have shown that hsa-miR-125b is highly abundant in mouse embryonic stem cells 
and progenitor cells, and that it is involved in the inhibition of myeloid cell 
differentiation [222] and cardiomyocyte differentiation [223]. Furthermore, hsa-
miR-34a has been shown to induce neuronal differentiation [224, 225], and is 
associated with the suppression of canonical Wnt signalling [215]. These 
significantly different miRNAs in MSCs are, therefore, presumably involved in 
regulating cell differentiation and determining cell fate.      
The present study also identified up-regulation of several miRNAs (e.g. hsa-miR-
933, hsa-miR-491-3p, hsa-miR-551b, hsa-miR-30d) when gastric CAMs were 
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compared to CAMs from both subtypes of oesophageal cancer. Hsa-miR-30d has 
been identified as an oncogene (i.e. oncomiR) that correlated with poor survival in 
ovarian cancer patients [226]. Additionally, it has been shown that hsa-miR-491-
3p functions as a tumour suppressor in colorectal cancer cells by inducing cell 
apoptosis [227]. However, the role of these miRNAs in stromal cells needs to be 
investigated.   
In reviewing this field, Aprelikova noted cancer-associated fibroblasts from 
endometrial cancer exhibited differential miRNA expression (e.g. miR-31), and 
these miRNAs might be important in tumour biology [11]. Using hierarchical 
clustering analysis, differentially abundant miRNAs in group comparisons could 
potentially distinguish between CAMs and ATMs, CAMs and NTMs, and 
between ATMs from NTMs. However, gastric CAMs and ATMs are not clearly 
distinguished between each other even though gastric CAMs and ATMs are 
functionally different.  
When gastric CAMs were compared to their corresponding ATMs, there were 12 
miRNAs that exhibited significant difference in abundance. Hsa-miR-181d was 
then selected as the miRNA of interest because it exhibited the highest difference 
in abundance between CAMs and ATMs. Using PCR analysis, validation of hsa-
miR-181d was performed in 3 paired samples of gastric CAMs and ATMs. 
Importantly, up-regulation of miR-181b has been found in cancer-associated 
fibroblasts of endometrial cancer but no further studies have been carried out [11]. 
Hsa-miR-181d belongs to the miR-181 family which consists of three other 
members (i.e. hsa-miR-181a, hsa-miR-181b and hsa-miR-181c). The members 
exhibit a common seed region and their sequences differ from one another by one 
nucleotide [228]. Increased expression of miR-181 in hepatocellular cancer stem 
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cells has been associated with cell migration and invasion [229]. Additionally, an 
increase in miR-181a expression is correlated with increased sensitivity to foreign 
antigens in immature T cells, thus implicating the role of miR-181a in regulating 
adaptive immune response [230].  
In the following chapter 4, the regulatory role of differentially abundant miRNAs 






































Many primary studies of miRNAs focus on determining miRNA targets and their 
biological roles. To help to identify miRNA targets, several computational 
algorithms (e.g. TargetScan, PicTar, miRanda) have been developed to predict 
targets. However, predicted targets can differ between programs and the rate of 
false positives has been shown to be more than 30% [231, 232]. As a result, 
experimental evidence for identifying true targets of a particular miRNA is 
essential [233].  
Recent developments suggest that a large number of transcripts may be regulated 
by each miRNA and that the same transcript can be regulated by multiple 
miRNAs [232, 234]. An integrated analysis of miRNA and gene expression 
profiles can be used to identify biological processes that are regulated by co-
expressed miRNAs. The advantage of this approach is the ability to identify 
putative downstream mRNA targets by using an inverse correlation with altered 
miRNA expression [235]. However, this approach could not detect miRNA 
targets, whose abundance is unchanged at the transcript level but is regulated at 
the translational level. 
An example of recent work relating to miRNAs in stromal cells is studies in 
prostate cancer-associated fibroblasts, which exhibit decreased expression of miR-
15a and miR-16, leading to activation of FGF signalling pathway and increased 
cancer cell proliferation and migration [236]. In the previous chapter, comparisons 
between different populations of myofibroblasts, which were generated from 
tumour, adjacent non-tumour or normal tissues, have identified a set of miRNAs 
that exhibit significant differences in abundance. To predict the biological 
functions that are associated with these miRNAs, a network enrichment analysis 
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was performed using targets of miRNAs that are expressed in myofibroblasts and 
that have been validated experimentally as targets of a specific miRNA.  
The aims for the work described in this chapter were: 
4.1.1 To identify targets of miRNAs that exhibited significant differences 
  in abundance in gastric and oesophageal myofibroblasts. 
4.1.2 To analyse the abundance of hsa-miR-181d targets in gastric  
  myofibroblasts.   
4.1.3  To identify significant networks that are enriched with targets of  
  differentially abundant miRNAs in gastric and oesophageal  















Targets of differentially abundant miRNAs that were previously validated by 
direct experimental studies, termed here validated targets, were obtained from 
MetaCore
®
, TarBase [202] and miRecords [203]. Targets of miR* sequences and 
a small number of newly identified miRNAs were excluded as work on these 
miRNAs is too limited. Predicted targets of hsa-miR-181d were obtained from 
TargetScan 5.1 [204]. The term “network” is used here to describe the extended 
interactions of proteins that are involved in a particular biological mechanism. 
Differential analysis of the connectivity of miRNA targets, and other interacting 
proteins, in a particular functional category, was performed using network 
enrichment by MetaCore
®
. Networks that were enriched were considered 
significant, at p < 0.05 (FDR 5%).  
Microarray gene expression profiling of myofibroblasts was previously performed 
in the Liverpool Genome Facility using GeneChip Human Genome U133 Plus 2.0 
Arrays (Affymetrix, High Wycombe, UK). The mRNA abundance of putative 
targets of hsa-miR-181d, TIMP3, NLK and GATA binding protein 6 (GATA6) 
was analysed. The expression of TIMP3 was determined in gastric myofibroblasts 










4.3.1 Validated targets of miRNAs that exhibited significant differences in 
abundance in gastric and oesophageal myofibroblasts 
To predict the functional role of miRNAs that distinguish different populations of 
myofibroblasts, validated targets and chromosomal locations of differentially 
abundant miRNAs were determined. These miRNAs in gastric and oesophageal 
myofibroblasts had been determined previously in chapter 3. Using the database 
from MetaCore
®
, and occasionally miRecords and TarBase, target genes of 
significantly different miRNAs in gastric CAMs compared to ATMs (Table 
4.3.1), gastric CAMs compared to NTMs (Table 4.3.2), and gastric ATMs 
compared to NTMs (Table 4.3.3) were identified.  
In oesophageal myofibroblasts, target genes of differentially abundant miRNAs in 
oesophageal SC-CAMs compared to SC-ATMs (Table 4.3.4), oesophageal SC-
CAMs compared to NTMs (Table 4.3.5), and oesophageal SC-ATMs compared to 
NTMs (Table 4.3.6) were identified. Similarly, target genes of differentially 
abundant miRNAs were identified in AC-CAMs compared to AC-ATMs (Table 
4.3.7), AC-CAMs compared to NTMs (Table 4.3.8), and AC-ATMs compared to 
NTMs (Table 4.3.9). Validated targets of miRNAs that are listed in all these tables 
were subsequently used in the network analysis. 








Target genes   
1 145740 hsa-miR-625* -1.17 2.50E-02   
2 145901 hsa-miR-494 -1.17 2.53E-02 14q32.31 CDK6, PTEN, FGFR2, LIF, 
BIRC5, CAMK2D 
3 146076 hsa-miR-483-3p -1.17 2.85E-02 11p15.5 PUMA, CTNNB1, ASH2L, 
SOCS3 
4 19582 hsa-miR-106b 1.17 2.57E-02 7q22.1 VEGFA, ITCH, CDKN1A, 
E2F1, APP, PCAF, 
MAPK14, TGFBR2, 
NCOA3, STAT3 
5 30687 hsa-miR-93 1.18 3.22E-02 7q22.1 CDKN1A, E2F1, VEGFA, 
ESR1, ITGB8, P53DINP1A, 
MICA, SP1, TGFBR2 
6 10936 hsa-miR-130b 1.19 3.91E-02 22 RUNX3, P53DINP1A, 
PPARG, CSF1 
7 11053 hsa-miR-32 1.20 6.83E-03 9q31.3 FXR1, E2F1, PCAF, 
BCL2L11 
8 13143 hsa-miR-301a 1.21 3.60E-02 19q32 ESR1, MOX2, SERPINE1, 
PUMA, PTEN, FOXF2 
9 27720 hsa-miR-15a 1.21 3.96E-02 13q14.2 BCL2, CCND1, CADM1, 
VEGFA, BMI1, MYB, 
DMTF1, WNT3A, CSE1L, 
FGFR1, IGF1R, MCM5, 
AKT3, MYB, CDC25A, 
CDK4, CHEK1 
     10 17280 hsa-miR-15b 1.21 3.20E-02 3q25.33 BCL2, RECK, CCNE1, 
MKK4, MAP2K4 
11 145636 hsa-miR-181d 1.24 2.71E-02 19p13.13 NLK, CDX2, GATA6, BCL2, 
TIMP3, VSNL1, TCL1A, 
PLAG1, KRAS, IL2, GRIA2, 
CYLD, CDKN1B, AICDA, 
NOTCH4, RASSF1A, 
CDKN1B, PROX1, KPNA4 
 
Table 4.3.1 Relative abundance, chromosomal location and validated targets 
of differentially abundant miRNAs in pairwise analysis of gastric CAMs 
compared to ATMs. No data available at the time of analysis is indicated by 
shading in grey. 









1 146016 hsa-miR-1978 -2.13 9.22E-04    
2 145725 hsa-miR-518b -1.59 1.70E-03 19q13.42   
3 146076 hsa-miR-483-3p -1.51 8.93E-03 11p15.5 PUMA 











IGF1R, PARP8, IRS1, 
MYC, CBFB, RTKN, KRT7, 
FSCN1, MUC1, PPP3CA, 
CLINT1, MMP11, SOX2, 
STAT1, KLF4, ESR1, 
CCNA2, ICAD, CLINT1, 
HOXA9, OCT4, FSCN1 











PLAG1, NFIA, FGFR1, 
MAP2K1, CCNE1, CCND1, 
CCNF, CDK6, MKLP1, 
CDC25A, CHEK1, CCND3, 
CDC14A, ATF6A, WEE1, 
ANLN, MYB, SIAH1 
8 11014 hsa-miR-214 -1.38 5.49E-03 1q24.3 PTEN, MAPK8, MAP2K3, 
POU4F2, EZH2 
9 42513 hsa-miR-300 -1.37 9.86E-04 14q32.31   
10 17354 hsa-miR-637 -1.37 4.64E-02 19p13.3   
11 11022 hsa-miR-221 1.17 2.13E-02 Xp11.3 KIT, CDKN1C, CDKN1B, 
ESR1, BMF, BIM, DDIT4, 
ICAM1, DDIT4, BNIP3L, 
TNFA, REDD1, MDM2, 
ESR1, TIMP3, PUMA, 
FOXO3A, FOS, CDK11B 
12 42724 hsa-miR-34b 1.18 2.89E-03 11q23.1 CREB1, TCL1A, MYC, 
NOTCH4/2/1, SFRS2, 
CDK6, MYB, BCL2, HGFR, 
HMGA2, CCNE2 
13 46739 hsa-miR-1308 1.35 6.55E-04    
14 46328 hsa-miR-1274b 1.36 8.92E-05 19   
15 10977 hsa-miR-183 1.38 3.35E-02 7q32.2 BTRC, FOXO1, KIF2A, 
VIL2, SLC1A1 
16 46698 hsa-miR-1280 1.40 9.68E-05 3   
17 42825 hsa-miR-888* 1.42 2.65E-05    
18 46732 hsa-miR-1264 1.44 4.18E-05 X   
19 46292 hsa-miR-1274a 1.45 2.33E-03 5   
 
Table 4.3.2 Relative abundance, chromosomal location and validated targets of 
differentially abundant miRNAs in gastric CAMs compared to NTMs. No data 
available at the time of analysis is indicated by shading in grey. 









1 146016 hsa-miR-1978 -1.98 7.78E-04   
2 42965 hsa-miR-424 -1.66 6.02E-04 Xq26.3 PLAG1, NFIA, FGFR1, 
MAP2K1, CCNE1, CCND1, 
CCNF, CDK6, MKLP1, 
CDC25A, CHEK1, CCND3, 
CDC14A, ATF6A, WEE1, 
ANLN, MYB, SIAH1 
       
3 42641 hsa-miR-145 -1.58 1.48E-02 5q32 IGF1R, PARP8, IRS1, 
MYC, CBFB, RTKN, KRT7, 
FSCN1, MUC1, PPP3CA, 
CLINT1, MMP11, SOX2, 
STAT1, KLF4, ESR1, 
CCNA2, ICAD, CLINT1, 
HOXA9, OCT4, FSCN1 
4 11014 hsa-miR-214 -1.48 5.82E-04 1q24.3 PTEN, MAPK8, MAP2K3, 
POU4F2, EZH2 
5 145725 hsa-miR-518b -1.47 3.98E-03 19q13.42  
6 42679 hsa-miR-642 -1.36 3.38E-03 19q13.32  
7 11030 hsa-miR-26a -1.36 1.03E-03 3p22.2 SERBP1, SMAD1, PLAG1, 
TGFBR2, EZH2, CSK3B, 
CPEB2/3/4, PTEN, IL6, 
HMGA2, IFNB, CCNE2, 
GDAP1, PGR 
8 42513 hsa-miR-300 -1.36 5.46E-04 14q32.31  
9 46732 hsa-miR-1264 1.38 6.95E-05 X  
10 46698 hsa-miR-1280 1.40 2.38E-05 3  
11 42825 hsa-miR-888* 1.42 2.79E-05   
12 46292 hsa-miR-1274a 1.61 1.94E-04 5  
 
 
Table 4.3.3 Relative abundance, chromosomal location and validated targets of 
differentially abundant miRNAs in gastric ATMs compared to NTMs. No data 
available at the time of analysis is indicated by shading in grey. 









1 46258 hsa-miR-1184 -1.45 2.37E-02 X   
2 145801 hsa-miR-184 -1.20 3.20E-02 15q25.1 NFAT1, AKT2 
3 17482 hsa-miR-411 1.16 1.66E-02 14q32.31   
4 11038 hsa-miR-299-5p 1.19 2.24E-02 14q32.31 SPP1, OPN, VEGFA, ESR1, 
AR 
5 11182 hsa-miR-98 1.22 8.20E-03 Xp11.22 FUS1, HMGA2, SOCS4, 
TUSC2, E2F2, MYC, CISH, 
EZH2, TP53 
6 145820 hsa-let-7c 1.27 3.45E-02 21q21.1 HMGA2, MYC, TGFBR1, 











LIN28, HMGA2, KRAS, 
RAVER2, NF2, ITGB3, 
NRAS, TRIM71,  CASP3, 
DICER1, PRDM1, EIF2C4, 
HRAS, E2F2, HOXA9, 
CCND2, MYC, UHRF2, 
KRAS1P,  KBRAS2, DICER, 
IL13 
8 17944 hsa-miR-337-5p 1.30 2.68E-02 14q32.2   
9 10987 hsa-miR-193b 1.37 5.92E-03 16p13.12 PLAU, ETS1, CCND1, ESR1 
10 46483 hsa-miR-27a 1.40 2.38E-02 19p13.13 SP1, PHB, RUNX1, FOXO1, 
FADD, PEX7, RXRA, APC, 
GCA, EDAR, SOCS6, 
SPRY2, AML1, FKHR, BAG2 
11 42744 hsa-miR-23a 1.40 2.56E-02 19p13.13 GLSK, IL6RA, ES1, HMGA2 
12 145944 hsa-miR-27b 1.42 4.81E-02 9q22.32 NOTCH1, MMP13, PPARG, 
ST14, CYP1B1, RXRA, 
C/EBPalpha, A2BAR, EYA4, 
EDNRA 
13 11052 hsa-miR-31 1.62 4.48E-03 9p21.3 MMP16, ITGA5, FIH1, RDX, 
FZD3, FGF10, FOXP3, 
MPRIP, RHOA, SELE, 
KRT17, KRT16, LATS2, 
KSR2, E2F6, DICER, 
PPP2R2A, BMPR2, DLX3, 
DKK1, DACT3 
14 11065 hsa-miR-335 2.87 3.68E-03 7q32.2 SOX4, MERTK, PTPRN2, 
RUNX2, SP1, DKK1, IGF1R, 
ESR1, SOD2, ID4 
 
 
Table 4.3.4 Relative abundance, chromosomal location and validated targets 
of differentially abundant miRNAs in pairwise analysis of oesophageal SC-
CAMs compared to SC-ATMs. No data available at the time of analysis is 
indicated by shading in grey. 
 









1 10998 hsa-miR-19b -1.61 2.25E-04 13q31.3 ESR1, SOCS1, FMR1, 
PTEN 
2 31026 hsa-miR-101 -1.59 8.03E-03 1p31.3 MYCN, MCL1, ICOS, 
EZH2, PTGS2, ATM, 
MTOR, ATXN1, COX2, 
MAGI2, DNAPK 
3 145693 hsa-miR-92a -1.55 3.60E-04 13q31.3 ITGA5, BMPRII, GAM 
4 10997 hsa-miR-19a -1.50 3.28E-04 13q31.3 PTEN, THBS1, ESR1, 
BIM, CCND1, BMPRII, 
ERBB4, NR4A2, PP2A, 
DOCK5, PRMT5, NURRI, 
SOCS1, ATXN, AMPK 
5 42708 hsa-miR-99a -1.46 3.97E-02 21q21.1 IGF1R, RPTOR, MTOR, 
RAVER2, FGFR3 











VEGFA, E2F1, BCL2, 
E2F3, CCND1, RUNX1, 
IL8, BIM, BMPRII, MEF2D, 
MAP3K12, JAK1, MICA, 
HLF, LRF,  
CCNE2, BMPR2, AIB1, 
APP, GAM, RB1, RASA2, 
PTENP1, PCAF, MAPK14, 
CDKN1A 
8 17927 hsa-miR-491-3p -1.40 8.91E-04 9p21.3 BCL2L1 
9 46801 hsa-miR-106a -1.38 1.31E-02 Xq26.2 RB1, CCKN1A, MYLIP, 
HIPK3, ARID4B, APP 
10 32884 hsa-miR-342-3p -1.36 5.75E-03 14q32.2   
 11023 hsa-miR-222 1.46 4.01E-03 Xp11.3 CDKN1B, KIT, CDKN1C, 
ESR1, BIM, SOD2, MMP1, 
FOS, PPP2R2A, ICAM1, 












DND1, CCNA2, CDK4, 
BRCA1, AURKB, CDC2, 
FEN1, CDK1, MYC, ALK4, 
AE1, NOTCH1, NIPK, 
MAP2K4, HNF4A, FURIN, 
FAF1, E2F2, MKK4, 
DHFR, MAPK14, CDKN2A 
12 146086 hsa-miR-30a 1.51 4.72E-02 6q13 NOTCH1, LIN28, ITGA2, 
BDNF, BECN1, KRT7, 
TNRC6A 
13 11022 hsa-miR-221 1.54 9.86E-04 Xp11.3 KIT, CDKN1C, CDKN1B, 
ESR1, BMF, BIM, DDIT4, 
ICAM1, DDIT4, BNIP3L, 
TNFA, REDD1, MDM2, 
ESR1, TIMP3, PUMA, 












TCF7L2, SDHD, NDUFA4, 
RAD52, PTP1B, HOXA9, 
HOXA1, FGFRL1, E2F3, 
EFNA3, COX10, ALK4, 
ISCU 
15 13140 hsa-miR-138 1.62 1.88E-02 3p21.32 KRT, EID1, TERT, 
ROCK2, RIMS2, APT1, 
EFNB3, PHRET1, RHOC,  
16 145981 hsa-miR-1285 1.93 5.40E-03 7q21-q22 TP53, TGM2 
 
 
Table 4.3.5 Relative abundance, chromosomal location and validated targets 
of differentially abundant miRNAs in oesophageal SC-CAMs compared to 
NTMs. No data available at the time of analysis is indicated by shading in grey. 









1 42965 hsa-miR-424 -1.72 2.18E-02 Xq26.3 ANLN, ATF6, CDC14A, 
CCND3, CCND1, CDC25A, 
CHEK1, CCNE1, VEGFR2, 
FGFR1, SIAH1, MKLP1, 
PLAG1, TARBP2, VEGFA, 
NFIA, CDK6, WEE1 
2 42708 hsa-miR-99a -1.66 2.98E-02 21q21.1 IGF1R, RPTOR, MTOR, 
RAVER2, FGFR3, 
3 145820 hsa-let-7c -1.63 2.32E-03 21q21.1 HMGA2, MYC, TGFBR1, 
TRIM71, KRT19, BCL2L1 
4 10306 hsa-miR-146b-5p -1.60 1.55E-02 10q24.32 CARD10, IL8, IL6, EGFR, 
ESR1, CEGP1, MMP16, 
PSMC6, SMAD4 
5 31026 hsa-miR-101 -1.58 2.54E-02 1p31.3 APP, ATXN1, ATM, EED, 
EZH2, ICOS, MAGI2, 
MCL1, ABCA1, MTOR, 
ABCC5, PTGS2, STMN1, 
RAB5A, ATG4D, NKCC1 
6 10987 hsa-miR-193b -1.55 5.03E-04 16p13.12 CCND1, ETS1, ESR1, 
AKR1C2, SHMT2, YWHAZ, 
ETO, MCL1, STARD7, 
PLAU 
7 11052 hsa-miR-31 -1.51 1.82E-02 9p21.3 MMP16, ITGA5, FIH1, 
RDX, FZD3, FGF10, 
FOXP3, MPRIP, RHOA, 
SELE, KRT17, KRT16, 
LATS2, KSR2, E2F6, 
DICER, PPP2R2A, BMPR2, 
DLX3, DKK1, DACT3 
8 46320 hsa-miR-31* -1.50 1.54E-02    
9 11030 hsa-miR-26a -1.48 3.46E-02 3p22.2 CPEB3, GSK3B, GDAP1, 
IL6, EZH2, MTDH, IFNB1, 
BDNF, CDK6, CCNE1, 
PHF6, HMGA2, RLI 
10 17749 hsa-let-7b -1.48 7.93E-03 22q13.31 KRT, CDK6, CDC25A, 
BCL7A, LIN28, CCND1, 

















BCL7A, APAF1, ZNF75, 
DOCK9, ZADH2, UBE2D3, 
TIMP3, THRB, SMAD7, 
SP1, SPG20, SPRY2, 
TGFBR2, PDCD4, PTEN, 
TP73L, PPIF, BMPR2, 
TP53BP2, TIAM1, SREBF1, 
RECK, RHOB, PPARA, 
PACE4, OLR1, NUSAP1, 
NT3, MSH2, MEF2C, 
MAN1, LRRC57, MATN2, 
GRHL3, HMGN2, ICAM1, 
IL1B, PLAT, IP10, IL12A, 
DOCK4, DOCK5, DOCK7, 
DICER, CDC25A, CCL1, 
ALX1, ANKRD46, AIM1L, 
JAG1, WNT1, SPRY2, 
ANP32A, LRRFIP1, 
SMARCA4 













AP1M1, BAK1, BCL2, BMF, 
BMPR1B, JUN, MYC, 
CBX7, CBFB, CCR5, 
CDC25C, TP53, ZAC1, 
PPP2CA, PRKRA, E2F3, 
ETS1, FGFR2, IL2RB, 
IL10RA, PRDM1, IFNG, 
IRF4, VDR, TDG, STAT3, 
PUMA, PSMB7, PSMB8 
13 10998 hsa-miR-19b -1.41 3.23E-02 13q31.3 TLR2, PTEN, TGFBR2, 
NDF1, MYCN, DKK3, 
BCL2L11 











LIN28, HMGA2, KRAS, 
RAVER2, NF2, ITGB3, 
NRAS, TRIM71,  CASP3, 
DICER1, PRDM1, EIF2C4, 
HRAS, E2F2, HOXA9, 
CCND2, MYC, UHRF2, 
KRAS1P,  KBRAS2, 
DICER, IL13 
16 145832 hsa-miR-381 -1.35 5.69E-03 14q32.31 BDNF, ESR1  











CDK6, PIK3R1, CXXC6, 
DNMT3A, DNMT3B, DKK1, 
COL3A1, CDC42, CD276, 
BCL2, BACE1, ZFP36, 
SFRP2, PMP22, RAN, 
GLUL, INSIG1, MCL1, 
SPARC, KREMEN2 
19 146001 hsa-miR-1977 1.36 2.17E-02    
20 11022 hsa-miR-221 1.41 7.99E-04 Xp11.3 ETS1, ESR1, DICER, 
CDKN1B, BMF, KIT, ARHI, 
MDM2, APAF1, REDD1, 
PUMA, TIMP3, PTEN, 
FOXO3A, PTPRM, PIK3R1, 













COL4A1, COL15A1, TDG, 
FUSIP1, COL1A1, 
COL1A2, COL4A2, PIK3R1, 












MMP1, SOD2, HOXA4, 
FOXO3A, ETS1, ESR1, 
DICER, CDK4, KIT, ARHI, 
APAF1, PAK1, CDKN1B, 
SNTB1, PPP2R2A, TIMP3, 
PTEN, PUMA, CDKN1C, 
CXCL12, STAT5A, TRPS1 
23 146165 hsa-miR-1973 1.65 7.62E-03 3   











BMP1, ADAM12, NKIRAS2, 
MCL1, ID1, COL1A1, 
COL5A3, COL4A2, 
EOMES, DNMT3A, MMP2, 
BACE1, YY1, CDK6, 
VAMP3, HDAC4, DUSP2, 
ACVR2A, SP1, RHOBTB1, 
PUMA, BCL2L11, CDC42, 
TBX21, RAX, PIK3R1, 
IFNG, IP30 
Table 4.3.6 Relative abundance, chromosomal location and validated targets of 
differentially abundant miRNAs in oesophageal SC-ATMs compared to NTMs. No 
data available at the time of analysis is indicated by shading in grey. 
 









1 27533 hsa-miR-320a 1.15 2.29E-02 8p21.3 MCL1, TAC1, HSPB6, 
MMP9, ETS2, BIRC5, CD71 
2 46324 hsa-miR-320b 1.16 2.73E-02 1   
3 10967 hsa-miR-16 1.19 7.88E-03 13q14.2 BLC2, ARL2, TPPP3, 
RARS, FGF2, CCND1, 
RTN4, AXIN2 
4 31867 hsa-miR-145* 1.34 3.59E-02     
5 42641 hsa-miR-145 1.82 1.90E-02 5q32 ACE1, CBFB, PPP3CA, 
CLINT1, IFNB1, BNIP3, 
STAT1, CFTR, DAB2, 
MUC1, MMP11, PAI1, 
SOX9, SOX2, KLF4, OCT4 
 
Table 4.3.7 Relative abundance, chromosomal location and validated 
targets of differentially abundant miRNAs in pairwise analysis of 
oesophageal AC-CAMs compared to AC-ATMs. No data available at the 
time of analysis is indicated by shading in grey. 
 









1 10306 hsa-miR-146b-5p -1.86 8.18E-03 10q24.32 EGFR, IL8, IL6, ESR1, 
SMAD4, PSMC6, MMP16 
2 29379 hsa-miR-452 -1.39 2.39E-02 Xq28 WNT5A 
3 145981 hsa-miR-1285 1.44 2.31E-02 7q21-q22 TP53, TGM2 
 
Table 4.3.8 Relative abundance, chromosomal location and validated targets of 
differentially abundant miRNAs in oesophageal AC-CAMs compared to NTMs. 
No data available at the time of analysis is indicated by shading in grey.  
 











1 42965 hsa-miR-424 -1.69 2.18E-02 Xq26.3 ANLN, ATF6, CDC14A, 
CCND3, CCND1, CDC25A, 
CHEK1, CCNE1, VEGFR2, 
FGFR1, SIAH1, MKLP1, 
PLAG1, TARBP2, VEGFA, 
NFIA, CDK6, WEE1 
2 11030 hsa-miR-26a -1.50 8.78E-03 3p22.2 CPEB3, GSK3B, GDAP1, IL6, 
EZH2, MTDH, IFNB1, BDNF, 
CDK6, CCNE1, PHF6, 
HMGA2, RLI 
3 31026 hsa-miR-101 -1.48 7.17E-03 1p31.3 APP, ATXN1, ATM, EED, 
EZH2, ICOS, MAGI2, MCL1, 
ABCA1, MTOR, ABCC5, 
PTGS2, STMN1, RAB5A, 
ATG4D, NKCC1 
4 42708 hsa-miR-99a -1.47 4.44E-02 21q21.1 FRAP1, SMARCA5, 
SMARCD1, IGF1R, FGFR3, 
RPTOR 
5 10306 hsa-miR-146b-5p -1.44 2.87E-02 10q24.32 CARD10, IL8, IL6, EGFR, 










11q24.1 AP1M1, BAK1, BCL2, BMF, 
BMPR1B, JUN, MYC, CBX7, 
CBFB, CCR5, CDC25C, 
TP53, ZAC1, PPP2CA, 
PRKRA, E2F3, ETS1, FGFR2, 
IL2RB, IL10RA, PRDM1, 
IFNG, IRF4, VDR, TDG, 










1p36.22 WNT1, WNT3, LRP6, LEF1, 
CTNNB1, VCL, ULBP2, YY1, 
LDHA, MTA2, AXL, SYT1, 
STX1A, BIRC5, MSI1, MYT1, 
AXIN2, MEK1, MET, MAD2B, 
E2F3, MAD2L2, CDK4, 
FOXP1, CDC25A, AGBL5, 
AF9, ACSM3, CCND1, BCL2 









7q32.3 BMP1, ADAM12, NKIRAS2, 
MCL1, ID1, COL1A1, 
COL5A3, COL4A2, EOMES, 
DNMT3A, MMP2, BACE1, 
YY1, CDK6, VAMP3, HDAC4, 
DUSP2, ACVR2A, SP1, 
RHOBTB1, PUMA, BCL2L11, 
CDC42, TBX21, RAX, 
PIK3R1, IFNG, IP30 
10 46292 hsa-miR-1274a 1.50 4.33E-02     
 
Table 4.3.9 Relative abundance, chromosomal location and validated targets 
of differentially abundant miRNAs in oesophageal AC-ATMs compared to 
oesophageal NTMs. No data available at the time of analysis is indicated by 
shading in grey.  
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4.3.2 Integrated analysis of hsa-miR-181d targets and their mRNA 
abundance in gastric myofibroblasts    
In chapter 3, hsa-miR-181d was identified as the most up-regulated miRNA in 
gastric CAMs by using pairwise analysis of miRNA abundance in 12 gastric 
CAMs and their corresponding ATMs. Here, validated targets of the miR-181 
family, including TIMP3, NLK and GATA6, were identified and briefly described 
in Table 4.3.10. Using the existing microarray gene expression data, the mRNA 
abundance of TIMP3 (Figure 4.3.1A), NLK (Figure 4.3.1B) and GATA6 (Figure 
4.3.1C) in each gastric CAM compared to corresponding ATM from 12 patients 
was analysed. The analysis showed that the mRNA abundance of TIMP3 was 
decreased in several paired samples of gastric CAMs and ATMs, including Sz190 
and Sz192. Paired samples from Sz190 and Sz192 were selected for more detailed 
studies because increased hsa-miR-181d abundance in each gastric CAM 
compared to corresponding ATM had already been validated by quantitative RT-
PCR (Chapter 3.3.6). Further analysis using RT-PCR confirmed decreased 
abundance of TIMP3 mRNA in CAMs of Sz190 and Sz192 compared to 
respective ATMs (Figure 4.3.2A). In addition, Western blot analysis of TIMP-3 
showed that the intensity of bands at 24 kDa and 15 kDa was reduced in CAMs 
compared to corresponding ATMs in these two paired samples (Figure 4.3.2B). 
The above description demonstrated the association of hsa-miR-181d and TIMP3 
expression in gastric myofibroblasts. As TIMP-3 is an ECM protein that inhibits 
the activity of MMPs, it was suggested that targets of hsa-miR-181d regulate 
extracellular interactions. To test this hypothesis, enriched network analysis of 
predicted hsa-miR-181d targets was performed. Firstly, target genes of  







Name Biological significance References 
1 AICDA activation-induced cytidine 
deaminase 
Down-regulated miR-181b is involved in B 
cell malignant transformation. 
[237] 
2 BCL2 B cell leukemia/lymphoma 2 Down-regulated miR-181a/b induces multi-
drug resistance in gastric and lung cancer 
cell lines and modulates radiosensitivity in 
malignant glioma cells. 
[238, 239] 
 
3 CDKN1B cyclin-dependent kinase 
inhibitor 1B 
Down-regulated mir-181a blocks cell cycle 
progression during myeloid cell 
differentiation. 
[240] 
4 CDX2 caudal type homeobox 2 High expression of miR-181 in hepatic 
cancer stem cells which express epithelial 
cell adhesion molecule induce cell 
proliferation and tumour initiating ability. 
[241] 
5 NLK nemo-like kinase 
6 GATA6 GATA binding protein 6 
7 CYLD cylindromatosis (turban tumor 
syndrome)  
Up-regulated miR-181b is associated with 
cellular transformation. 
[242] 
8 VSNL1 visinin-like 1 Up-regulation of miR-181b in the temporal 
cortex in schizophrenia compared to control. 
[243] 
9 GRIA2 glutamate receptor, ionotropic, 
AMPA 2 
10 IL2 interleukin 2 Down-regulation of miR-181c during the 
process of CD4 positive T- cell activation. 
[244] 
11 KRAS v-Ki-ras2 Kirsten rat sarcoma 
viral oncogene homolog  
Down-regulated miR-181a/c is involved in 
tumour cell growth of gastric and oral 
squamous cell carcinomas.  
[245, 246]  
 
12 NOTCH4 notch 4 
13 PLAG1 pleiomorphic adenoma gene 1 Down-regulation of miR-181a/b in chronic 
lymphocytic leukaemia. 
[247, 248]  
14 TCL1A T-cell leukemia/lymphoma 1A 
15 TIMP3 tissue inhibitor of 
metalloproteinase 3 
Up-regulated miR-181b is associated with 




16 KPNA4 karyopherin alpha 4 Expression of miR-181b down-regulates 
endothelial cells activation and vascular 
inflammation. 
[251] 
17 HOXA11 homeobox A11 Up-regulation of miR-181 during the process 
of mammalian skeletal-muscle 
differentiation. 
[252] 
18 RALA v-ral simian leukemia viral 
oncogene homolog A (ras 
related) 
Overexpression of miR-181a is associated 
with cell growth inhibition and apoptosis in 
chronic myeloid leukaemia. 
[253] 
Table 4.3.10 Validated targets of miR-181 family members and their biological 
significance. 
 








Figure 4.3.1 Microarray analysis of hsa-miR-181 targets in paired 
individual samples of gastric CAMs and ATMs from 12 patients. The 
relative mRNA abundance of (A) TIMP3, (B) NLK and (C) GATA6 in each 
CAM compared to corresponding ATM (abundance = 1.0). TIMP3, NLK 
and GATA6 were represented by 4, 3 and 1 oligonucleotides, respectively 
and were normalised to GAPDH. 
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Figure 4.3.2 Decreased expression of TIMP3 in gastric CAMs of 
Sz190 and Sz192. (A) Relative abundance TIMP3 mRNA in CAMs 
compared to corresponding ATMs (abundance = 1.0) was determined 
by array and RT-PCR analyses. Expression of TIMP3 mRNA was 
normalised to GAPDH mRNA. (B) Western blot analysis of TIMP-3 in 
CAMs and ATMs using paired samples from Sz190 and Sz192. 
GAPDH was the loading control. 
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hsa-miR-181d that encode extracellular proteins were predicted and retrieved from 
TargetScan 5.1. Using gene expression data in comparisons of CAMs and 
corresponding ATMs from Sz190 and Sz192, those target genes that exhibited ≥ 
50% decrease in mRNA abundance in CAMs compared to ATMs were analysed 
by MetaCore
®
. Significant (p < 0.05) enrichment of hsa-miR-181d targets in paired 
sample analysis of Sz190 and Sz192 are shown in Tables 4.3.11A and 4.3.11B, 
respectively. The most significant networks that were common in both Sz190 and 
Sz192 analyses were chemotaxis, connective tissue degradation, neutrophil 
activation and ECM remodelling. The results indicate a predicted function of hsa-
miR-181d in promoting cell motility by using bioinformatics.  
 
4.3.3 Significant networks associated with targets of differentially abundant 
miRNAs in gastric myofibroblasts 
The identification of miRNA targets that had been validated by independent 
studies leads to the investigation of biological processes that are regulated by 
multiple miRNAs. It was because differential miRNA abundance could alter 
cellular processes that might distinguish between different myofibroblast 
populations. To do so, network enrichment analysis was performed to identify 
networks that were significantly enriched by potential targets of differentially 
abundant miRNAs in myofibroblasts. 
In pairwise analysis of 12 gastric CAMs with corresponding ATMs, published and 
validated targets of 10 differentially abundant miRNAs were obtained from 
MetaCore
®
, and the top three enriched networks were G1-S growth factor 
regulation, G1-S interleukin regulation and Wnt signalling (Table 4.3.12A).  

















1 Chemotaxis 2.35E-08 
2 Cell adhesion_Leucocyte chemotaxis 1.99E-05 
3 Proteolysis_Connective tissue degradation 1.23E-04 
4 Inflammation_Neutrophil activation 5.66E-04 
5 Proteolysis_ECM remodeling 9.30E-04 
6 Immune response_Th17-derived cytokines 1.13E-03 
7 Inflammation_Jak-STAT Pathway 3.87E-03 
8 Cell adhesion_Platelet-endothelium-leucocyte 
interactions 
4.86E-03 
9 Cell dhe ion_Cell-matrix interactions 9.98E-03 
10 Blood coagulation 1.07E-02 
11 Proliferation_Positive regulation cell proliferation 1.63E-02 
12 Inflammation_Protein C signaling 1.81E-02 
 
No. Networks p-value 
1 Chemotaxis 7.98E-06 
2 Cell adhesion_Leucocyte chemotaxis 8.81E-06 
3 Cell adhesion_Cell-matrix interactions 4.06E-04 
4 Proteolysis_Connective tissue degradation 5.45E-04 
5 Inflammation_Neutrophil activation 2.40E-03 
6 Proteolysis_ECM remodeling 2.77E-03 
7 Immune response_Th17-derived cytokines 3.34E-03 
Table 4.3.11B Significant networks enriched with hsa-
miR-181d target genes that encode extracellular 
proteins (predicted from TargetScan5.1) in Sz192. A 
total of 7 networks (indicated in bold) were found in 
both Sz190 and Sz192.  
Table 4.3.11A Significant networks enriched with 
hsa-miR-181d target genes that encode extracellular 
proteins (predicted from TargetScan5.1) in Sz190. 
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Significant networks that were associated with cell cycle progression (G1 to S 
phase) were not unexpected because it is recognised that gastric CAMs exhibit an 
increased rate of proliferation when compared to ATMs [179]. Wnt signalling was 
of interest as the canonical Wnt/β-catenin signalling pathway has been shown to 
induce the expression of hsa-miR-181d [254]. Furthermore, some of the proteins 
that were annotated in Wnt signalling are already identified as validated targets of 
differentially abundant miRNAs; NLK and GATA6 are target genes of hsa-miR-
181d while CTNNB1 and CAMK2D are target genes of hsa-miR-483-3p and hsa-
miR-494, respectively (Table 4.3.1).    
When potential targets of differentially abundant miRNAs in gastric CAMs 
compared to NTMs, and gastric ATMs compared to NTMs were analysed, the top 
three enriched networks were common in both analyses: a) G1-S growth factor 
regulation, b) G1-S interleukin regulation and c) regulation of epithelial-to-
mesenchymal transition (Tables 4.3.12B, 4.3.12C). Again, cell cycle progression 
was not unexpected because myofibroblasts have been shown to exhibit increased 
proliferation when incubated in media from H. pylori-infected gastric epithelial 
cells [73], indicating H. pylori infection alter myofibroblast phenotype in the early 
stage of gastric cancer development.  
All significant networks of differentially abundant miRNAs are listed in the 
appendices: gastric CAMs compared to ATMs (Appendix 4.3.1), gastric CAMs 
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No. Networks  p-value 
1 Cell cycle_G1-S Growth factor regulation 1.956E-14 
2 Cell cycle_G1-S Interleukin regulation 3.169E-14 
3 Signal transduction_WNT signalling 6.083E-11 
4 Development_Hemopoiesis, Erythropoietin pathway 3.348E-09 
5 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 5.769E-09 
6 Development_EMT_Regulation of epithelial-to-mesenchymal transition 6.642E-09 
7 Reproduction_Male sex differentiation 4.016E-08 
8 Cell cycle_G0-G1 1.475E-07 
9 Proliferation_Positive regulation cell proliferation 1.943E-07 
10 Signal Transduction_TGF-beta, GDF and Activin signalling 2.951E-07 
 
 
No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 7.626E-11 
2 Development_EMT_Regulation of epithelial-to-mesenchymal transition 1.694E-09 
3 Cell cycle_G1-S Interleukin regulation 1.376E-07 
4 Reproduction_FSH-beta signalling pathway 2.353E-06 
5 Signal Transduction_TGF-beta, GDF and Activin signalling 3.952E-06 
6 Development_Hemopoiesis, Erythropoietin pathway 6.901E-06 
7 Inflammation_IL-10 anti-inflammatory response 1.572E-05 
8 DNA damage_Checkpoint 2.295E-05 
9 Signal transduction_Leptin signalling 2.394E-05 
10 Signal transduction_WNT signalling 3.577E-05 
 
 
No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 7.361E-13 
2 Cell cycle_G1-S Interleukin regulation 2.075E-10 
3 Development_EMT_Regulation of epithelial-to-mesenchymal transition 2.360E-08 
4 Signal Transduction_TGF-beta, GDF and Activin signalling 1.292E-07 
5 Signal transduction_WNT signalling 1.620E-07 
6 Development_Hemopoiesis, Erythropoietin pathway 2.342E-07 
7 DNA damage_Checkpoint 9.375E-07 
8 Reproduction_FSH-beta signalling pathway 7.032E-06 
9 Inflammation_IL-10 anti-inflammatory response 7.076E-06 




Table 4.3.12A Networks enriched by targets of differentially abundant 
miRNAs in pairwise analysis of gastric CAMs compared to ATMs.  
Table 4.3.12B Networks enriched by targets of differentially abundant 
miRNAs in gastric CAMs compared to NTMs. 
Table 4.3.12C Networks enriched by targets of differentially abundant 
miRNAs in gastric ATMs compared to NTMs. 
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4.3.4 Significant networks associated with targets of differentially abundant 
miRNAs in oesophageal myofibroblasts 
Using MetaCore
®
, potential targets of 11 differentially abundant miRNAs in 
oesophageal SC-CAMs compared to SC-ATMs were highly enriched for TGF-β, 
GDF and activin signalling, BMP and GDF signalling, and G1-S growth factor 
regulation (Table 4.3.13A). In the comparison between SC-CAMs and NTMs, G1-
S growth factor regulation and G1-S interleukin regulation were identified as 
networks significantly enriched by targets of differentially abundant miRNAs 
(Table 4.3.13B). Additionally, the analysis of SC-ATMs compared to NTMs 
indicated the top three networks were: regulation of epithelial-mesenchymal 
transitions, TGF-β, GDF and activin signalling, and G1-S growth factor regulation 
(Table 4.3.13C). The results suggest that cell cycle progression, and TGF-β, GDF 
and activin signalling are targeted by differentially abundant miRNAs in 
oesophageal myofibroblasts during the development of oesophageal squamous 
cell carcinoma.  
When network analysis was performed using potential targets of 4 differentially 
abundant miRNAs in oesophageal AC-CAMs compared to AC-ATMs, the top 
three networks were: G1-S growth factor regulation, G1-S interleukin regulation 
and regulation of epithelial-mesenchymal transition (Table 4.3.14A). In the 
comparisons between AC-CAMs and NTMs and between AC-ATMs and NTMs, 
the top enriched network was TGF-β, GDF and activin signalling (Table 4.3.14B), 
and G1-S growth factor regulation, respectively (Table 4.3.14C).  
 
 




No. Networks p-value 
1 Signal Transduction_TGF-beta, GDF and Activin signalling 2.429E-11 
2 Signal Transduction_BMP and GDF signalling 3.065E-07 
3 Cell cycle_G1-S Growth factor regulation 6.057E-07 
4 Development_Hedgehog signalling 6.216E-07 
5 Reproduction_Feeding and Neurohormone signalling 1.828E-06 
6 Signal transduction_ESR1-nuclear pathway 1.963E-06 
7 Cell cycle_G1-S Interleukin regulation 2.853E-06 
8 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 1.026E-05 
9 Development_Blood vessel morphogenesis 1.151E-05 
10 Signal transduction_NOTCH signalling 1.395E-05 
 
 
No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 2.553E-12 
2 Cell cycle_G0-G1 7.493E-12 
3 Cell cycle_G1-S Interleukin regulation 1.352E-11 
4 Cell cycle_G1-S 5.318E-10 
5 Development_Hemopoiesis, Erythropoietin pathway 7.016E-10 
6 Development_Hedgehog signalling 3.328E-09 
7 Signal transduction_NOTCH signalling 3.772E-09 
8 Development_EMT_Regulation of epithelial-to-mesenchymal transition 5.174E-09 
9 Cell cycle_Core 9.081E-09 
10 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 9.133E-09 
           
            
No. Networks p-value 
1 Development_EMT_Regulation of epithelial-to-mesenchymal transition 3.251E-16 
2 Signal Transduction_TGF-beta, GDF and Activin signalling 3.434E-14 
3 Cell cycle_G1-S Growth factor regulation 6.050E-13 
4 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 1.050E-12 
5 Reproduction_Feeding and Neurohormone signalling 2.405E-11 
6 Signal Transduction_BMP and GDF signalling 1.799E-09 
7 Inflammation_MIF signalling 3.133E-09 
8 Signal transduction_Androgen receptor signaling cross-talk 3.463E-09 
9 Signal transduction_WNT signalling 3.948E-09 
10 Development_Cartilage development 9.792E-09 
Table 4.3.13A Networks enriched by targets of differentially abundant 
miRNAs in pairwise analysis of oesophageal SC-CAMs compared to 
SC-ATMs.  
 
Table 4.3.13B Networks enriched by targets of differentially abundant 
miRNAs in oesophageal SC-CAMs compared to NTMs.  
 
Table 4.3.13C Networks enriched by targets of differentially abundant 
miRNAs in oesophageal SC-ATMs compared to NTMs.  
 




No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 1.026E-14 
2 Cell cycle_G1-S Interleukin regulation 2.779E-10 
3 Development_EMT_Regulation of epithelial-to-mesenchymal transition 2.814E-09 
4 Inflammation_MIF signalling 4.128E-09 
5 Reproduction_Feeding and Neurohormone signalling 6.526E-09 
6 Signal Transduction_TGF-beta, GDF and Activin signalling 2.959E-08 
7 DNA damage_Checkpoint 1.363E-07 
8 Development_Hemopoiesis, Erythropoietin pathway 1.918E-07 
9 Inflammation_IL-2 signalling 2.769E-07 
10 Proliferation_Negative regulation of cell proliferation 8.930E-07 
 
            
No. Networks p-value 
1 Signal Transduction_TGF-beta, GDF and Activin signalling 3.320E-04 
2 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 4.523E-04 
3 Signal transduction_ESR1-membrane pathway 7.999E-04 
4 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 8.117E-04 
5 Proliferation_Negative regulation of cell proliferation 9.834E-04 
6 Development_Regulation of angiogenesis 1.471E-03 
7 Inflammation_MIF signalling 1.712E-03 
8 Signal transduction_ESR1-nuclear pathway 2.107E-03 
9 Signal transduction_NOTCH signalling 2.292E-03 
10 Inflammation_TREM1 signalling 2.552E-03 
           
            
No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 1.147E-11 
2 Development_EMT_Regulation of epithelial-to-mesenchymal transition 1.465E-11 
3 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 2.528E-10 
4 Signal transduction_WNT signalling 2.860E-09 
5 Reproduction_Feeding and Neurohormone signalling 7.628E-09 
6 Proliferation_Negative regulation of cell proliferation 2.446E-08 
7 Reproduction_Progesterone signalling 7.273E-08 
8 Inflammation_MIF signalling 9.110E-08 
9 Signal transduction_ESR1-membrane pathway 2.318E-07 
10 Signal Transduction_TGF-beta, GDF and Activin signalling 2.858E-07 
Table 4.3.14A Networks enriched by targets of differentially abundant 
miRNAs in pairwise analysis of oesophageal AC-CAMs compared to 
AC-ATMs. 
 
Table 4.3.14B Networks enriched by targets of differentially abundant 
miRNAs in oesophageal AC-CAMs compared to NTMs.  
 
Table 4.3.14C Networks enriched by targets of differentially abundant 
miRNAs in oesophageal AC-ATMs compared to NTMs.  
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All the significant networks from the above enriched network analysis of 
oesophageal myofibroblasts are presented in the appendices: SC-CAMs compared 
to SC- ATMs (Appendix 4.3.4), SC-CAMs compared to NTMs (Appendix 4.3.5), 
SC-ATMs compared to NTMs (Appendix 4.3.6), AC-CAMs compared to AC-
ATMs (Appendix 4.3.7), AC-CAMs compared to NTMs, (Appendix 4.3.8) and 
AC-ATMs compared to NTMs (Appendix 4.3.9).  
 
4.3.5 Significant networks associated with targets of miRNAs that exhibited 
different abundance in 12 paired samples of gastric myofibroblasts  
To determine any inter-patient variation about enriched networks that were 
associated with significantly different miRNAs, network analysis was performed 
in each paired sample of CAM and ATM. The number of miRNAs which 
exhibited at least 50% difference in abundance in CAMs compared to 
corresponding ATMs was determined in each of the 12 patients (Table 4.3.15). 
The potential targets of these altered miRNAs in each paired sample were 
obtained from MetaCore
®
. Network analyses showed that Wnt signalling was the 
only enriched network that was significant in all of the 12 patients while 4 other 
networks were found to be significant in all patients except Sz42 (Patient 1) 
(Figure 4.3.3). In total, 30 enriched networks were significant in at least 8 of the 
12 patients (Appendix 4.3.10). There were a total of 7, 10 and 8 networks that 
were significant in 10, 9 and 8 patients, respectively. As both pairwise and 
individual analyses indicated Wnt signalling was deregulated by altered miRNA 
abundance, Wnt signalling pathways in gastric myofibroblasts were studied in the 
following chapter. 




No. Patient Number of up and down-regulated miRNAs  
Patient 1 Sz42 5 
Patient 2 Sz45 8 
Patient 3 Sz190 62 
Patient 4 Sz192 54 
Patient 5 Sz194 22 
Patient 6 Sz198 8 
Patient 7 Sz268 43 
Patient 8 Sz271 42 
Patient 9 Sz294 5 
Patient 10 Sz305 28 
Patient 11 Sz308 3 
Patient 12 Sz389 31 
 
Table 4.3.15 Numbers of miRNAs that exhibited at 
least 50% change in abundance in paired samples of 
gastric myofibroblasts (CAMs compared to ATMs) from 
12 patients. Each Sz identification number is 
represented by a patient number for the purpose of 
cross-referencing. 
 
































Figure 4.3.3 Top five networks that were significantly enriched by targets of 
miRNAs that exhibited at least 50% difference in abundance in each gastric 
CAM compared to corresponding ATM from 12 patients. Targets of all 12 pairs 
were enriched for Wnt signalling and 11 pairs were enriched for G1-S growth 
factor regulation, IL10 anti-inflammatory response, negative regulation of cell 
proliferation and Th17-derived cytokines. (Y-axis: patient number in 
descending magnitude of enrichment. X-axis: log p-value). Each patient 
number that represents a Sz identification number is indicated in Table 4.3.15.   
 
0.0                5.0             10.0            15.0             20.0            25.0 
-log(p-value) 
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 4.3.6 Significant networks associated with targets of miRNAs that exhibited 
different abundance in 7 paired samples of oesophageal myofibroblasts  
Network analysis was then extended to each paired sample of oesophageal 
myofibroblasts. The number of miRNAs that exhibited at least 50% change in 
abundance was determined in oesophageal SC-CAMs compared to corresponding 
SC-ATMs from 4 patients (Table 4.3.16). Network analysis using targets of 
altered miRNAs in all 4 patients identified G1-S growth factor regulation, G1-S 
interleukin regulation, NOTCH signalling, and TGF-β, GDF and activin signalling 
as highly significant networks (Figure 4.3.4). A total of 33 networks were 
significantly enriched in all 4 patients (Appendix 4.3.11). 
In the comparison between each oesophageal AC-CAM and corresponding AC-
ATM, the number of miRNAs that exhibited at least 50% difference in abundance 
was determined (Table 4.3.17). Networks that were significantly enriched by 
targets of altered miRNAs in all 3 patients, were regulation of epithelial-
mesenchymal transition, TGF-β, GDF and activin signalling, Wnt signalling and 
G1-S growth factor regulation (Figure 4.3.5). The analysis also showed that a total 
of 50 networks were significantly enriched in at least 1 of the 3 patients 










Patient Number of up and down-regulated miRNAs  





Table 4.3.16 Numbers of miRNAs that exhibited 
at least 50% change in abundance in paired 
samples of oesophageal myofibroblasts (SC-
CAMs compared to SC-ATMs) from 4 patients.   
 
 MicroRNA targets and regulatory networks     
123 
 
     


































Figure 4.3.4 Top networks that were significantly enriched by targets of 
miRNAs that exhibited at least 50% difference in abundance in each SC-
CAM compared to corresponding SC-ATM from 4 patients. Targets of all 4 
pairs were enriched for G1-S growth factor regulation, G1-S interleukin 
regulation, NOTCH signalling and TGFβ, GDF and activin signalling. (Y-axis: 
patient in descending magnitude of enrichment. X-axis: log p-value). 
 




Patient Number of up and down-regulated miRNAs 













Table 4.3.17 Numbers of miRNAs that 
exhibited at least 50% change in abundance in 
paired samples of oesophageal myofibroblasts 
(AC-CAMs compared to AC-ATMs) from 3 
patients. 
 
Figure 4.3.5 Top networks that were significantly enriched by targets of 
miRNAs that exhibited at least 50% difference in abundance in each 
AC-CAM compared to corresponding AC-ATM from 3 patients. Targets 
of all 3 pairs were enriched for regulation of epithelial-mesenchymal 
transition, TGFβ, GDF and activin signalling, Wnt signalling and G1-S 
growth factor regulation. (Y-axis: networks in descending magnitude of 
enrichment of Sz173. X-axis: log p-value). 
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4.4 Discussion  
Network enrichment is a differential network analysis to identify the link between 
miRNA targets and interacting proteins that are involved in different biological 
mechanisms [255]. Network enrichment analysis was performed by using targets 
of miRNAs, which exhibited different abundance between myofibroblasts 
populations. The miRNA targets that were obtained from MetaCore
®
 have been 
published and mostly experimentally validated. Validated targets of differentially 
abundant miRNAs that have been listed are useful to predict the functional roles 
of a particular miRNA. Significant networks that were associated with altered 
miRNA abundance in CAMs may indicate the biological processes that are 
deregulated in stromal cells, thus contributing to cancer initiation and progression.  
Importantly, Wnt signalling was found to be highly significant in both pairwise 
and paired individual sample analyses of gastric CAMs and corresponding ATMs. 
The results suggest that the Wnt signalling pathway is altered in gastric CAMs 
and may contribute to the tumour-promoting properties of CAMs. In addition, 
TGF, GDF and activin signalling was one of the top ten networks that were 
significantly enriched by targets of miRNAs in pairwise and individual 
comparisons between oesophageal SC-CAMs and SC-ATMs, and between 
oesophageal AC-CAMs and AC-ATMs.  
Comparisons between CAMs and NTMs were performed to identify cellular 
processes that may be altered in myofibroblasts during carcinogenesis. The results 
suggest that regulation of cell cycle progression is commonly altered in CAMs of 
upper gastrointestinal tract cancers, and this is consistent with the current 
knowledge of biology in CAMs [179]. It is also suggested that CAMs of 
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oesophageal adenocarcinoma exhibited properties that were found in CAMs from 
both gastric and oesophageal squamous cell carcinomas. Moreover, comparisons 
between ATMs and NTMs would be useful to identify changes in myofibroblasts 
that are induced by chronic inflammation (e.g. H. pylori infection, Barrett’s 
metaplasia). In both gastric and oesophageal myofibroblasts, the results from 
network enrichment analysis identified Wnt signalling, TGF, GDF and activin 
signalling, and cell cycle regulation as highly significant networks.      
There are some limitations of the network analysis for identifying miRNA 
functions. Firstly, the results may be biased because miRNA targets from 
MetaCore
®
 may be associated with networks which have been studied widely 
while other networks are less populated with targets. Secondly, some of the 
significantly enriched networks may not apply to the context of myofibroblasts in 
the microenvironment (e.g. EMT). Thirdly, the present study used cultured 
myofibroblasts, which do not interact with other cell types in a tissue or tumour, 
so they do not accurately reflect the properties of stromal cells in the 
microenvironment. Lastly, there could be more functional miRNA targets that 
have not yet been identified and validated. As a result, enriched networks which 
have been identified may not truly represent the cellular functions that are 
influenced by miRNA regulation. Nonetheless, using current knowledge of 
miRNAs and cellular biology, network enrichment analysis is a time efficient 
approach for predicting cellular processes that are regulated by multiple miRNAs, 
which in turn, can be exploited for experimental work to support the findings.  
 





, other software, such as Ingenuity System Pathway Analysis 
software and DAVID (system 6.7), could be used for identifying the biological 
function of a set of target genes. Typically in these studies, different results may 
be obtained when different software is used. In addition, advances in miRNA 
bioinformatics have led to the development of DIANA-miRPath (v2.0), which 
allows the integrated analysis of miRNA targets with Kyoto Encyclopedia of 
Genes and Genomes (KEGG) pathway enrichment. The main advantage of using 
this software is that miRNA targets can be retrieved directly from TarBase or 
prediction algorithms. Moreover, a recent study has used co-expression meta-
analysis in which miRNAs and target genes are associated by the degree of co-
expression, so that the biological function of these associated targets is determined 
[256]. This has identified, for example, the association of miR-519d, miR-190 and 
miR-340 with TGF-β signalling pathway, thus demonstrated the synergy of 
coexpressed miRNAs in the regulation of gene expression [231, 256].  
In chapter 3, hsa-miR-181d had been shown to be significantly up-regulated in 
gastric CAMs compared to their corresponding ATMs. The microarray data 
indicated higher abundance of hsa-miR-181d in 5 of the 12 pairs of gastric CAMs 
and ATMs (i.e. Sz190, Sz389, Sz192, Sz198 and Sz45), and validation using RT-
PCR analysis was carried out using paired samples of Sz190 and Sz192. In 
addition, other studies have shown that miR-181 expression is regulated by 
nuclear factor-kappa B (NF-Kβ) signalling [251], Wnt/β-catenin signalling [254] 
and TGF-β signalling [250, 257]. Taken all the data together, it seems there may 
be a relationship between hsa-miR-181d and Wnt signalling in gastric CAMs.  
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Microarray gene expression analysis of three validated targets of the miR-181 
family, namely, TIMP3, GATA6 and NLK was carried out. TIMP3 was chosen 
because it has been shown to regulate the activity of MMPs and may contribute to 
ECM remodelling and wound healing [258]. Consistent with this, predicted 
mRNA targets of the miR-181 family that encode extracellular proteins were 
enriched for networks associated with ECM remodelling and connective tissue 
degradation. Additionally, the mRNA abundance of GATA6 and NLK was 
analysed as they have been shown to activate and inhibit the canonical Wnt/β-
catenin signalling pathway, respectively [121, 259]. The results from gene 
expression analysis showed that the mRNA abundance of TIMP3 was down-
regulated in gastric CAMs from paired samples of Sz190, Sz192 and Sz389. The 
results also indicated an inverse correlation between TIMP3 and hsa-miR-181d, 
compatible with the idea that TIMP3 is regulated by hsa-miR-181d in gastric 
CAMs. In gastric CAMs, GATA6 and NLK might be regulated by hsa-miR-181d 
at the translational level, but Western blot analysis still needs to be performed.  
After analysing miRNA expression profiles and miRNA regulatory networks, the 
next chapter aimed to validate the Wnt signalling pathway that was regulated by 
altered miRNA abundance and to demonstrate Wnt signalling in gastric CAMs 
and their influence in cancer progression.         
 








Wnt signalling in gastric myofibroblasts and cancer cells 




The previous chapter aimed to identify biological processes associated with 
differential miRNA abundance in different populations of myofibroblasts. Using 
MetaCore
®
, enriched networks were identified using validated targets of miRNAs 
that exhibited difference in abundance in gastric CAMs compared to their 
corresponding ATMs. The results from both pairwise and individual comparisons 
showed that Wnt signalling was the most significantly affected network. 
Nevertheless, the molecular biology of deregulated Wnt signalling pathway in 
gastric CAMs compared to ATMs is not at all understood.      
Wnt glycoproteins (e.g. Wnt-3a, Wnt-5a) are ligands for transmembrane FZD 
receptors, and they activate the so-called canonical or non-canonical Wnt 
signalling pathway [260]. The canonical Wnt/β-catenin signalling pathway has 
been associated with gastric carcinogenesis [261]. This may be attributable to 
chronic H. pylori infection or mutations of Wnt signalling-associated genes (e.g. 
APC), resulting in translocation of β-catenin into the nucleus and subsequent 
activation of β-catenin dependent gene transcription in gastric epithelial cells 
[262, 263]. Additionally, abnormal Wnt-5a expression has been found in about 
30% of human gastric cancer samples and is associated with gastric cancer cell 
migration and invasion through the non-canonical Wnt/Ca
2+
 signalling pathway; 
there may also be antagonism of the canonical Wnt/β-catenin signalling pathway 
[264].  
In normal gastric mucosa, Wnt-5a has previously been shown to be expressed in 
peptic/chief cells using immunocytochemistry [264]. However, the expression of 
WNT5A mRNA in many gastric cancer cell lines has been found to be low or 
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undetectable using quantitative PCR [264, 265]. It is possible that Wnt-5a is 
expressed by tumour stromal cells, and this is supported by evidence from other 
studies. Gene expression profiling has indicated increased Wnt-5a expression in 
microdissected stromal tissue of pancreatic carcinoma compared to stromal tissue 
of chronic pancreatitis, and this was validated by using immunohistochemistry 
[266]. In addition, ribonuclease protection analysis and in situ RNA hybridisation 
have indicated Wnt-5a transcripts to be up-regulated in macrophages during the 
formation of colorectal carcinoma [267]. Moreover, using microarray analysis of 
gene expression, it was found that Wnt-5a was up-regulated in fibroblasts from 
oesophageal squamous cell carcinoma compared to normal fibroblasts, and this 
was validated by using quantitative PCR [268]. Since little is known about Wnt 
signalling in gastric cancer stromal cells, the expression and function of Wnt-5a 
were investigated in the present study. 
The aims for the work described in this chapter were: 
5.1.1 To determine the expression of Wnt pathway-associated genes in 
  12 paired samples of gastric CAMs and ATMs from existing  
  microarray data.   
5.1.2 To study the activity of Wnt signalling pathway in gastric   
  myofibroblasts. 
5.1.3 To determine molecular and phenotypic changes in paired samples of 
  gastric myofibroblasts, and gastric cancer cells, after incubation with 
  recombinant Wnt-3a or Wnt-5a.  
 




Proteins that were annotated in Wnt signalling pathways were retrieved from 
MetaCore
®
. Using GeneChip Human Genome U133 Plus 2.0 Array (Appendix 
2.2), the relative abundance of transcripts selected from Wnt signalling networks 
was determined in each gastric CAM compared to its corresponding ATM from 
12 patients. Each patient was identified by a Sz identification number and in the 
gene analysis, each was represented by a Patient number listed in Table 5.2.1. The 
abundance of WNT5A mRNA in gastric myofibroblasts was determined using 
quantitative RT-PCR (performed by Dr Islay Steele, Appendix 2.1). The 
expression of Wnt-5a in gastric myofibroblasts and cancer cell lines (AGS, 
MKN45) was analysed by Western blotting (Chapter 2.12). Immunocytochemistry 
using β-catenin mouse monoclonal antibody (Chapter 2.13) was performed in 
gastric myofibroblasts and MKN45 cells, and expressed as a percentage of cells 
containing nuclear β-catenin. A promoter reporter construct, which was associated 
with β-catenin-dependent TCF/LEF transcriptional activation, was transfected into 
gastric myofibroblasts, and the ratio of firefly luciferase is to Renilla luciferase 
(internal control) was determined (Chapter 2.17). Proliferation assays using EdU 
incorporation (Chapter 2.14) and migration assays using Boyden chambers 










Patient 1 Sz42 
Patient 2 Sz45 
Patient 3 Sz190 
Patient 4 Sz192 
Patient 5 Sz194 
Patient 6 Sz198 
Patient 7 Sz268 
Patient 8 Sz271 
Patient 9 Sz294 
Patient 10 Sz305 
Patient 11 Sz308 














Table 5.2.1 Paired individual samples of gastric 
CAMs and ATMs from 12 patients. Each patient 
number represents a Sz identification number. 




5.3.1 Gene expression analysis of Wnt signalling networks 
To investigate the biology of Wnt signalling pathways in gastric myofibroblasts, 
analysis of selected genes associated with Wnt signalling networks was performed 
using previously generated microarray data. In total, there are more than 150 
proteins that comprise the MetaCore
®
 Wnt signalling network. These include Wnt 
proteins, FZD receptors, co-receptors, putative Wnt-responsive genes and relevant 
intracellular signalling molecules. Initial microarray analysis showed that the 
transcriptomes of gastric CAMs and ATMs encoded a subset of these proteins 
only. For example, of all the 18 WNT genes that were represented by 
oligonucleotides (i.e. probes) bound to the array, WNT5A and WNT5B were 
found to be expressed in all samples of gastric CAMs and ATMs while the 
remaining genes were either undetectable or in low expression.        
From gene expression data, a total of 20 transcripts were selected as they were 
included in Wnt signalling networks and were expressed in all samples of CAMs 
and ATMs. These were then classified according to their protein class, namely, 
receptor ligands, receptors, transcription factors, binding proteins and enzymes. In 
microarray analysis, there were a variable number of oligonucleotides on the array 
for every transcript and the signal intensity varied among oligonucleotides of a 
particular transcript. Thus, the mRNA abundance of each relevant oligonucleotide 
for selected transcripts was determined in each paired sample of gastric CAMs 
and ATMs from 12 patients.     
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The relative mRNA abundance of (A) WNT5A, (B) WNT5B and (C) TGFB2 that 
encode protein ligands, in each gastric CAM compared to corresponding ATM, 
was shown in Figure 5.3.1. Of 12 patients, a total of 10 patients, except for Sz294 
and Sz305, were found to exhibit WNT5A mRNA abundance greater than 1, 
indicating WNT5A mRNA is up-regulated in CAMs compared to ATMs. 
Additionally, WNT5B mRNA abundance was found to be distinctively up-
regulated in CAMs from Sz190 and Sz389. It was also found that the mRNA 
abundance of TGFB2 was up-regulated in paired samples from 8 of the 12 
patients. When the average mRNA abundance of all relevant oligonucleotides for 
a transcript was determined in all CAMs and all ATMs, the results showed that 
the mRNA abundance of WNT5A and TGFB2 was significantly (paired t-test, p < 
0.05) different with a fold-increase of 1.8 and 2.4, respectively, in gastric CAMs 
compared to ATMs (Figures 5.3.1D, 5.3.1E).          
The same approach was used to analyse the abundance of other transcripts that 
were selected. Using 12 paired individual samples of CAMs compared to its 
ATMs, the relative mRNA abundance of: (A) FZD1, (B) FZD2, (C) FZD4, (D) 
FZD6, (E) FZD7 and (F) FZD8 that encode frizzled receptors, (G) LRP6 and (H) 
RYK that encode co-receptors and (I) PLAUR, which encodes uPA receptor, were 
determined (Figure 5.3.2). Across all 12 paired samples, FZD2 and RYK did not 
exhibit a great difference in mRNA abundance between CAMs and corresponding 
ATMs. Additionally, it was found that some individual CAMs exhibited 
abundance increase of more than 2-fold compared to their corresponding ATMs: 
FZD1 from Sz308, FZD4 from Sz190 and Sz305, FZD6 from Sz190, and FZD8 
from Sz192, Sz194, Sz268 and Sz308. The mRNA abundance of PLAUR was  
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Figure 5.3.1 Microarray analysis of transcripts that encode receptor ligands 
in paired samples of gastric myofibroblasts from 12 patients. The abundance 
of (A) WNT5A which was represented by three oligonucleotides, (B) WNT5B 
which was represented by one oligonucleotide and (C) TGFB2 which was 
represented by one oligonucleotide in each gastric CAM compared to 
corresponding ATM (abundance = 1.0). (D) The average signal intensity of 
WNT5A in CAMs (n =12) and ATMs (n = 12). (E) The average signal intensity 
of TGFB2 in CAMs (n =12) and ATMs (n = 12). Values were normalised to 
GAPDH. Each patient number representing a Sz identification number is 
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Figure 5.3.2 Microarray analysis of transcripts that encode FZD and uPA 
receptors in paired samples of gastric myofibroblasts from 12 patients. The 
abundance of (A) FZD1 which was represented by two oligonucleotides, (B) 
FZD2 which was represented by one oligonucleotide, (C) FZD4 which was 
represented by one oligonucleotide, (D) FZD6 which was represented by one 
oligonucleotide, (E) FZD7 which was represented by two oligonucleotides, (F) 
FZD8 which was represented by two oligonucleotides, (G) LRP6 which was 
represented by two oligonucleotides, (H) RYK which was represented by 
three oligonucleotides and (I) PLAUR which was represented by three 
oligonucleotides, in each gastric CAM compared to corresponding ATM 
(abundance = 1.0). Values were normalised to GAPDH. Each patient number 
representing a Sz identification number is indicated in Table 5.2.1. 
 Wnt signalling in gastric myofibroblasts and cancer cells      
139 
 
also found to be up-regulated in paired samples from 8 of the 12 patients. 
However, pairwise comparisons indicated no significant difference between 
CAMs and their corresponding ATMs in the expression of these receptors.           
Subsequently, the relative mRNA abundance in CAMs compared to their 
corresponding ATMs was analysed for transcripts that encode transcription 
factors, for example, (A) JUN, (B) MYC, (C) PPARD and (D) TCF7 (Figure 
5.3.3), binding proteins, for example, (A) APC and (B) CTNNB1 (Figure 5.3.4) 
and enzymes, for example, (A) CAMK2D and (B) MMP2 (Figure 5.3.5). In the 
comparison between CAMs and ATMs, the abundance difference of these 
transcripts was generally low and again, there was no significant difference in the 
expression of these transcripts that were associated with Wnt signalling.     
 
5.3.2 Validation of Wnt-5a expression in gastric myofibroblasts by Western 
blotting and quantitative RT-PCR analyses     
Validation was performed to demonstrate an increase in Wnt-5a expression in 
gastric CAMs compared to ATMs. The expression of Wnt-5a was analysed in 6 
pairs of gastric CAMs and their corresponding ATMs by Western blotting (Figure 
5.3.6A). Western blots showed a band at 49 kDa and the average band intensity 
was significantly increased (4-fold) in gastric CAMs compared to ATMs (Figure 
5.3.6B). Additionally, quantitative RT-PCR analysis using paired samples from 
Sz190, Sz192 and Sz268 showed a significant increase (1.7-fold) in WNT5A 
mRNA abundance when gastric CAMs were compared to ATMs (Figure 5.3.6C). 
 




Figure 5.3.3 Microarray analysis of transcripts that encode transcription 
factors in paired samples of gastric myofibroblasts from 12 patients. The 
abundance of (A) JUN which was represented by three oligonucleotides, (B) 
MYC which was represented by one oligonucleotide, (C) PPARD which was 
represented by one oligonucleotide and (D) TCF7 which was represented by 
one oligonucleotide, in each gastric CAM compared to corresponding ATM 
(abundance = 1.0). Values were normalised to GAPDH. Each patient number 
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Figure 5.3.4 Microarray analysis of transcripts that encode binding proteins 
in paired samples of gastric myofibroblasts from 12 patients. The 
abundance of (A) APC which was represented by two oligonucleotides and 
(B) CTNNB1 which was represented by three oligonucleotides, in each 
gastric CAM compared to corresponding ATM (abundance = 1.0). Values 
were normalised to GAPDH. Each patient number representing a Sz 
identification number is indicated in Table 5.2.1. 
Figure 5.3.5 Microarray analysis of transcripts that encode enzymes in 
paired samples of gastric myofibroblasts from 12 patients. The abundance of 
(A) CAMK2D which was represented by four oligonucleotides and (B) MMP2 
which was represented by one oligonucleotide, in each gastric CAM 
compared to corresponding ATM (abundance = 1.0). Values were normalised 
to GAPDH. Each patient number representing a Sz identification number is 
indicated in Table 5.2.1. 
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Figure 5.3.6 Increase in Wnt-5a expression in gastric CAMs. (A) Western 
blot analysis of Wnt-5a in 6 pairs of gastric CAMs and corresponding ATMs 
by using cell lysates. GAPDH was the loading control. (B) The average band 
intensity of Wnt-5a expression in CAMs (n = 6) and ATMs (n = 6) was 
determined by Western blotting. (C) The average abundance of WNT5A 
mRNA in CAMs (n = 3) and ATMs (n = 3) was determined by quantitative RT-
PCR. Each experiment was performed in triplicate. Values were normalised 
to GAPDH. Each patient number representing a Sz identification number is 
indicated in Table 5.2.1. (*p < 0.05) 
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5.3.3 Activation of the canonical Wnt signalling pathway in gastric CAMs but 
to a lesser extent in their corresponding ATMs  
Previously in Chapter 4, Wnt signalling was suggested to be targeted by 
differential miRNA abundance in gastric CAMs compared to their corresponding 
ATMs, but the molecular mechanism was unknown. To investigate the activity of 
canonical Wnt/β-catenin signalling in gastric CAMs and ATMs, 
immunocytochemistry using β-catenin mouse antibody was performed followed 
by quantification of myofibroblasts containing nuclear β-catenin.  
Fluorescence images showed cytoplasmic and nuclear staining of β-catenin in 
paired samples of gastric CAMs and ATMs from Sz192 (Figure 5.3.7A). The cell 
number was determined by DAPI nuclear staining. The identification of nuclear β-
catenin was generally complicated by high background when myofibroblasts were 
cultured in medium containing serum. Despite this, the immunocytochemistry 
results showed that gastric CAMs contained a higher number of myofibroblasts 
with nuclear localisation of β-catenin, compared to corresponding ATMs, in all 4 
paired samples from Sz45, Sz190, Sz192 and Sz268, (Figure 5.3.7B).  
Since an increase in nuclear β-catenin is linked to the transcriptional activity of 
TCF/LEF in gastric CAMs, a paired sample of gastric CAMs and ATMs from 
Sz192 was selected to test the hypothesis that TCF/LEF activity was increased in 
CAMs. It was selected because previous RT-PCR analyses validated the higher 
abundance of WNT5A and hsa-miR-181d in gastric CAMs compared to ATMs. 
Using TCF/LEF reporter assay, luciferase activity of TCF/LEF was 50% higher in 
CAMs than in ATMs (Figure 5.3.8). The above hypothesis was validated, thus 
indicating increased activity of the canonical Wnt/β-catenin pathway in CAMs.  

















Figure 5.3.7 Increased nuclear localisation of β-catenin in gastric 
CAMs compared to corresponding ATMs. (A) Representative 
immunofluorescence images of nuclear β-catenin using a paired 
sample of gastric CAMs and ATMs. Scale bars 20µm. Nuclei of 
myofibroblasts are outlined, and arrows indicate nuclear staining of β-
catenin. (B) Percentage of myofibroblasts containing nuclear β-catenin 
was determined using 4 paired samples of CAMs and corresponding 
ATMs. (*p < 0.05) 
 
 





































































































Figure 5.3.8 Gastric CAMs exhibit higher TCF/LEF activity. Using 
TCF/LEF reporter construct, luciferase expression was significantly 
increased in CAMs compared to corresponding ATMs. Each experiment 
was performed in triplicate. (*p < 0.05) 
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 5.3.4 Increased nuclear localisation of β-catenin in MKN45 cells and gastric 
myofibroblasts by recombinant Wnt-3a   
Wnt-3a is a well-known Wnt protein that activates the canonical Wnt/β-catenin 
signalling pathway, which prevents cytoplasmic degradation of β-catenin and 
subsequently induces nuclear translocation of β-catenin [116]. MKN45 cells were 
used to identify nuclear localisation of β-catenin in the presence of recombinant 
Wnt-3a and to determine the optimal conditions for β-catenin 
immunocytochemistry. Fluorescence images showed membranous and nuclear 
staining of β-catenin in MKN45 cells (Figure 5.3.9A). The cell number was 
determined by DAPI nuclear staining. There was an intense staining for β-catenin 
on cell membranes of MKN45 control cells, indicating a role in cell adhesion. 
After stimulation with 1 µg/ml Wnt-3a for 1 h, cytoplasmic and nuclear staining 
of β-catenin was clearly seen in MKN45 cells while staining intensity on cell 
membranes was decreased. The percentage of MKN45 cells containing nuclear β-
catenin was significantly increased (4.4-fold) after incubation with Wnt-3a (Figure 
5.3.9B).  
Similarly, when a paired sample of gastric CAMs and ATMs was incubated with 1 
µg/ml Wnt-3a for 1 h, localisation of β-catenin in the nuclei of myofibroblasts was 
observed even though there was some background staining (Figure 5.3.10A). 
There was cytoplasmic staining of β-catenin in control myofibroblasts. After 































































Figure 5.3.9 Increased nuclear localisation of β-catenin in MKN45 cells 
by recombinant Wnt-3a. (A) Representative immunofluorescence images 
showed localisation of β-catenin on cell membranes and in the nuclei 
before and after incubation with Wnt-3a (1 µg/ml, 1 h). Cell nuclei are 
outlined. Blue arrows indicate staining of membrane bound β-catenin and 
white arrows indicate nuclear staining of β-catenin. (B) Percentage of 
cells containing nuclear β-catenin was determined in MKN45 cells before 
and after incubation with Wnt-3a. Each experiment was performed in 
triplicate. (*p < 0.05) 
 







   



























































Figure 5.3.10 Increased nuclear localisation of β-catenin in gastric 
myofibroblasts by recombinant Wnt-3a. (A) Representative 
immunofluorescence images of β-catenin localisation in gastric 
myofibroblasts before and after incubation with Wnt-3a (1 µg/ml, 1 
h). Cell nuclei are outlined and arrows indicate nuclear staining of β-
catenin. Scale bars 20 µm. (B) Percentage of gastric myofibroblasts 
containing nuclear β-catenin was significantly increased in a paired 
sample of CAMs and ATMs after incubation with Wnt-3a. Each 
experiment was performed in triplicate. (*p < 0.05) 
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The percentage of myofibroblasts containing nuclear β-catenin was significantly 
increased in CAMs (10-fold) and ATMs (9-fold) after incubation with Wnt-3a 
(Figure 5.3.10B).  
Since Wnt-5a expression was found to be increased in gastric CAMs, the 
biological role of Wnt-5a in gastric myofibroblasts was investigated. The same 
pair of CAMs and ATMs being used for the above experiment was stained with β-
catenin antibody after incubation with recombinant Wnt-5a so as to determine 
whether Wnt-5a induced nuclear localisation of β-catenin in gastric 
myofibroblasts. Fluorescence images did not clearly show nuclear staining of β-
catenin in gastric myofibroblasts after incubation with Wnt-5a (Figure 5.3.11A). 
Also, the percentage of CAMs and ATMs that contained nuclear β-catenin before 
and after Wnt-5a incubation was not significantly different (Figure 5.3.11B).  
 
5.3.5 Increased TCF/LEF activity and WNT5A mRNA in gastric CAMs by 
recombinant Wnt-3a 
In the earlier section, the activity of TCF/LEF was found to be up-regulated in 
CAMs compared to ATMs. Here, luciferase activity of TCF/LEF was determined 
in CAMs and ATMs after incubation with 1 µg/ml Wnt-3a or Wnt-5a for 8 h. The 
results showed that Wnt-3a, but not Wnt-5a, significantly increased (2.3-fold) 
luciferase activity of TCF/LEF in CAMs (Figure 5.3.12A). Luciferase activity of 
TCF/LEF in ATMs was significantly decreased (1.8-fold) by Wnt-5a, but no 
significant change was found by Wnt-3a (Figure 5.3.12B).  
 


























































Figure 5.3.11 No significant change in nuclear localisation of β-
catenin in gastric myofibroblasts by Wnt-5a. (A) Representative 
immunofluorescence images of β-catenin localisation in gastric 
myofibroblasts before and after incubation with Wnt-5a (1 µg/ml, 1 h). 
Cell nuclei are outlined and arrow indicates nuclear staining of β-
catenin. Scale bars 20 µm. (B) Percentage of myofibroblasts 
containing nuclear β-catenin in a paired sample of CAMs and 
corresponding ATMs. Each experiment was performed in triplicate.  
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Figure 5.3.12 Wnt-3a induces TCF/LEF activity in gastric CAMs, but not in 
ATMs. (A) Luciferase activity of TCF/LEF reporter was significantly 
increased in CAMs after incubation with Wnt-3a (1 µg/ml, 8 h) but not Wnt-
5a. (B) In ATMs, luciferase activity of TCF/LEF reporter was not significantly 
changed after incubation with Wnt-3a but a significant decrease was found 
after incubation with Wnt-5a (1 µg/ml, 8 h). Each experiment was performed 
in triplicate. (*p < 0.05) 
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Furthermore, RT-PCR analysis showed that the mRNA abundance of WNT5A 
was significantly increased (1.7-fold) in gastric CAMs after incubation with 1 
µg/ml Wnt-3a for 24 h (Figure 5.3.13). The mRNA abundance of WNT5A was 
not significantly altered in CAMs when incubated with Wnt-5a. The results, 
therefore, suggest that Wnt-3a increases the activity of β-catenin-dependent 
TCF/LEF and induces the abundance of WNT5A in gastric CAMs.    
 
5.3.6 Increased migration of gastric myofibroblasts and AGS cells by 
recombinant Wnt-5a   
To investigate if Wnt proteins influenced migration in myofibroblasts and AGS 
cells, Boyden chambers were used to determine the number of cells that migrated 
through the membrane pores in the presence of 1 µg/ml recombinant Wnt-3a or 
Wnt-5a. The results showed that Wnt-3a significantly increased the migration of 
CAMs (2-fold), but not ATMs (Figure 5.3.14A) and that Wnt-5a significantly 
increased the migration of CAMs (3.5-fold) and ATMs (5.9-fold) (Figure 
5.3.14B). In AGS cells, both Wnt-3a and Wnt-5a stimulated cell migration with a 
fold-increase of 2.7 and 3.3, respectively (Figure 5.3.14C).  
 
 





































Figure 5.3.13 Wnt-5a expression in gastric CAMs is induced by Wnt-3a. 
The mRNA abundance of WNT5A was significantly increased in gastric 
CAMs after incubation with Wnt-3a (1 µg/ml, 24 h), but not Wnt-5a. Each 
experiment was performed in triplicate. (*p < 0.05) 
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Figure 5.3.14 Increase in migration of gastric myofibroblasts and AGS 
cells by Wnt-5a. (A) There was a significant increase in the migration of 
CAMs, but not in ATMs after incubation with Wnt-3a (1 µg/ml, 16 h). (B) 
Incubation with Wnt-5a (1 µg/ml, 16 h) significantly increased the 
migration of CAMs and ATMs. (C) The migration of AGS cells was 
significantly increased after incubation with Wnt-3a or Wnt-5a (1 µg/ml, 16 
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 5.3.7 Proliferation of gastric myofibroblasts is stimulated by Wnt-5a and 
Wnt-3a  
Using EdU incorporation assay, proliferation of gastric myofibroblasts, AGS and 
MKN45 cells was determined after incubation with 1 µg/ml Wnt-3a or Wnt-5a. 
Proliferating cells that incorporated with EdU were counted, and IGF-II was used 
as a positive control for gastric myofibroblasts (Figure 5.3.15A). The results 
showed that Wnt-3a and Wnt-5a significantly increased the rate of proliferating 
CAMs (Figure 5.3.15B) and ATMs (Figures 5.3.15C), whereas proliferation of 
AGS (Figure 5.3.15D) and MKN45 cells (Figure 5.3.15E) was not significantly 
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Figure 5.3.15 EdU incorporation in proliferating gastric myofibroblasts is 
induced by Wnt-3a and Wnt-5a. (A) Representative immunofluorescence 
images of proliferating cells that incorporated with EdU (green) after 
incubation with 1 µg/ml Wnt-3a or Wnt-5a for 24 h. IGF-II (100 ng/ml) was a 
positive control. Scale bars 50 µm. (B) Percentage of EdU positive cells in 
CAMs when incubated with Wnt-3a or Wnt-5a for 24 h. (C) Percentage of 
EdU positive cells in ATMs when incubated with Wnt-3a or Wnt-5a for 24 h. 
(D, E) No significant change in the proliferation rate of AGS and MKN45 
cells after Wnt-3a or Wnt-5a incubation. Each experiment was performed in 


















































































































































In the previous chapter, validated targets of significantly different miRNAs in 
gastric CAMs compared to their corresponding ATMs were enriched for cell cycle 
regulation and Wnt signalling. Furthermore, the Wnt signalling was significantly 
enriched with validated targets of miRNAs that were different in abundance in the 
comparison between each gastric CAM and its corresponding ATM from 12 
patients. These findings indicate alterations of Wnt signalling pathways in gastric 
CAMs that could be attributable to miRNA regulation. Nevertheless, this analysis 
does not provide an indication of whether the Wnt signalling is up or down-
regulated in CAMs or of which specific targets are affected.  
In this chapter, it was shown that Wnt-5a expression is increased in gastric CAMs 
and that Wnt-5a induces migration and proliferation of gastric CAMs. The 
mechanisms are thought to involve the non-canonical Wnt signalling pathway 
because it was found that Wnt-5a did not induce nuclear localisation of β-catenin 
or increase the TCF/LEF transcriptional activity that are markers for stimulation 
of the canonical Wnt pathway.             
To validate the bioinformatic data of miRNAs and Wnt signalling, the abundance 
of 20 transcripts, which were associated with Wnt signalling, was analysed in each 
of the 12 paired samples of gastric CAMs compared to their ATMs. Of all the 20 
transcripts, the mRNA abundance of WNT5A and TGFB2 were significantly up-
regulated in CAMs compared to ATMs. The link between Wnt-5a and TGFβ2 is 
not necessarily unexpected because the expression of Wnt-5a has been shown to 
be up-regulated by TGF-β signalling [269]. Additionally, gene analysis revealed 
that AGS and MKN45 cells did not express WNT5A mRNA. As a result, Wnt-5a 
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was selected for an investigation of its role in gastric CAMs and stromal-tumour 
interactions. Higher abundance of Wnt-5a in CAMs compared to ATMs was 
validated by Western blotting and quantitative PCR analyses. These analyses 
suggest increased abundance or activity of extracellular Wnt-5a, but future studies 
using conditioned medium from gastric myofibroblasts are needed to confirm this.   
Wnt-5a activates mainly the non-canonical Wnt signalling pathway [120] and this 
was confirmed in gastric myofibroblasts by the failure of Wnt-5a to induce 
nuclear localisation of β-catenin and to stimulate TCF/LEF activity. The activity 
of canonical Wnt/β-catenin signalling pathway was also verified in gastric 
myofibroblasts by using immunocytochemistry of β-catenin and luciferase 
expression of TCF/LEF activity. The data suggest that increased activity of 
canonical Wnt pathway in gastric CAMs compared to ATMs, and this was 
increased further by Wnt-3a, but not Wnt-5a. Future studies should include 
nuclear extraction of gastric myofibroblasts so that the abundance of β-catenin in 
cell nuclei could be determined by Western blot analysis. In the future, the 
observation worth exploring in more detail is increased WNT5A mRNA 
abundance in a sample of gastric CAMs by Wnt-3a; it is known that Wnt-3a 
increases the transcription of TGFβ2 [270] which activates the TGF-β signalling 
pathway, leading to up-regulation of Wnt-5a expression [269], suggesting a 
possible mechanism for the present observations.    
The functional roles of canonical and non-canonical Wnt signalling pathways in 
gastric myofibroblasts by Wnt-3a and Wnt-5a, respectively, were determined 
using migration and proliferation assays. Both Wnt-3a and Wnt-5a were shown to 
stimulate the migration and proliferation of gastric CAMs. Additionally, both 
Wnt-3a and Wnt-5a stimulated the proliferation of ATMs. Moreover, Wnt-5a but 
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not Wnt-3a stimulated the migration of ATMs. The data, therefore, suggest that 
Wnt-5a expression in gastric CAMs and ATMs could act in an autocrine manner 
and that increased abundance of Wnt-5a could play a role in regulating migration 
and proliferation of CAMs. Previous work using these cells has shown that CAMs 
exhibit a higher rate of migration and proliferation compared to corresponding 
ATMs [179], and it is possible that Wnt-5a is a mediator of the phenotype of 
CAMs.  
Both Wnt-5a and Wnt-3a were found to induce the migration of AGS cancer cells. 
The mechanisms that might be involved include altered expression of MMPs [271, 
272] and EMT [273]. Compatible with this, other studies have demonstrated that 
Wnt proteins from stromal cells activate Wnt signalling pathways in cancer cells, 
thus implicating interactions between cancer cells and the tumour 
microenvironment [274]. For example, Wnt-5a expression is induced in 
macrophages when they are co-cultured with breast cancer cells, and in turn Wnt-
5a induces the invasiveness of cancer cells [275].   
In conclusion, the findings suggest that Wnt-5a released from gastric CAMs 
influences migration and proliferation of CAMs and also contributes to cancer cell 
migration. Moreover, Wnt-5a expression might be regulated by β-catenin-
dependent TCF/LEF activity through TGF-β signalling pathway (Figure 5.4.1). It 
would be useful to identify cancer cell-derived cytokines such as Wnt-3a that may 
act in a paracrine manner, to regulate Wnt-5a expression in CAMs. In the 
following chapter, the relationship between Wnt-5a and miRNAs in gastric CAMs 
were investigated.   
 













Figure 5.4.1 A schematic representation of Wnt-5a in stromal-tumour 
interactions. The release of Wnt-5a from CAMs stimulates the migration 
of cancer cells through paracrine signalling. Wnt-5a also acts in an 
autocrine manner to induce the migration and proliferation of CAMs. 
Increased Wnt-5a expression may be regulated by TCF/LEF activity in 
CAMs but the actual mechanism is not yet explored.  
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 6.1 Introduction 
In previous chapters, the results showed that the abundance of hsa-miR-181d and 
Wnt-5a was increased in gastric CAMs compared to corresponding ATMs. Wnt-
5a was also found to induce migration and proliferation of gastric CAMs, and 
migration of AGS cells. Although increased abundance of miR-181b has been 
identified in cancer-associated fibroblasts from endometrial cancer [11], the 
functional role of hsa-miR-181d in gastric myofibroblasts is not understood. In 
chapter 3, paired individual sample analysis of CAMs and ATMs indicated that 
the mRNA and protein levels of TIMP-3 were related to hsa-miR-181d 
abundance. In addition, predicted targets of hsa-miR-181d that encode 
extracellular proteins were involved in the regulation of chemotaxis and 
proteolysis.      
The canonical Wnt/β-catenin signalling has been shown to regulate expression of 
miR-181 family members in other cell types [254, 276]. Additionally, an increase 
in miR-181 expression has been shown to induce the motility and invasion of 
hepatocellular stem cells [277] and breast cancer cells [278]. Furthermore, miR-
181 expression correlates with the metastatic potential of breast cancer cells [278] 
and is also associated with lymph-node metastasis in oral squamous cell 
carcinoma [279]. A study using miRNA expression profiling has identified 
increased expression of hsa-miR-181b and hsa-miR-181d in gastric cancer 
compared to normal gastric epithelium, and suggested that hsa-miR-181b 
associates with sensitivity to chemotherapy [280]. On the other hand, hsa-miR-
181a and hsa-miR-181b could function as tumour suppressors, notably in glioma 
and chronic lymphocytic leukaemia [281, 282]. In view of the previously 
validated data that hsa-miR-181d abundance was increased and that TIMP3 
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transcript abundance was decreased in paired samples of gastric CAMs compared 
to corresponding ATMs, the hypothesis for this chapter was that hsa-miR-181d 
expression was regulated by Wnt signalling in CAMs and in turn, influenced cell 
migration by regulating ECM proteins (e.g. TIMP-3). 
The specific aims for the work described in this chapter were: 
6.1.1 To determine the relationship between hsa-miR-181d and Wnt-5a in gastric 
     CAMs. 
6.1.2 To investigate the functional role of hsa-miR-181d in gastric CAMs and   
     ATMs, and its involvement in stromal-epithelial interactions. 
 
 




Using quantitative RT-PCR, the relative abundance of hsa-miR-181d was 
determined  in gastric CAMs after incubation with 1 µg/ml recombinant Wnt-3a 
or Wnt-5a for 24 h. Nucleofection protocol was carried out for knockdown and 
overexpression of hsa-miR-181d in gastric CAMs and ATMs, respectively 
(Chapter 2.11). After 24, 48 and 72 h post-transfection, the abundance of hsa-
miR-181d and TIMP3 mRNA was determined in gastric myofibroblasts. After 48 
h post-transfection, migration and EdU incorporation assays were performed in 
myofibroblasts in the presence or absence of 1 µg/ml recombinant Wnt-5a. 
Conditioned medium (CM) from transfected samples of myofibroblasts was 
collected to perform migration and EdU incorporation assays using AGS cells. 
Recombinant TIMP-3 (100 ng/ml) was used in AGS cell migration assay in the 














6.3.1 An increase in hsa-miR-181d abundance in gastric CAMs by Wnt-5a   
To determine whether hsa-miR-181d was regulated by Wnt signalling pathways, 
the abundance of hsa-miR-181d was determined in gastric CAMs after incubation 
with Wnt-3a or Wnt-5a. RT-PCR analysis showed that the abundance of hsa-miR-
181d was significantly increased (2-fold) after incubation with Wnt-5a while no 
significant change was obtained after incubation with Wnt-3a (Figure 6.3.1).      
 
6.3.2 An inverse correlation between TIMP3 mRNA and hsa-miR-181d  
To investigate the role of hsa-miR-181d in gastric myofibroblasts, a strategy was 
adopted for hsa-miR-181d knockdown in CAMs and overexpression in ATMs, 
and these were carried out using nucleofection with hsa-miR-181d inhibitor and 
precursor plasmids, respectively. The nucleofection efficiency at 48 h post-
transfection was approximately 50%, and this was obtained by determining the 
proportion of green fluorescent protein (GFP) positive myofibroblasts in 10 
different fields and the mean was expressed as a percentage.  
Since the post-transfection period that showed maximum change in hsa-miR-181d  
abundance was unknown, total RNA was extracted from gastric myofibroblasts 
after 24, 48 and 72 h post-transfection followed by the determination of hsa-miR-
181d relative abundance. In hsa-miR-181d knockdown CAMs, the abundance of 
hsa-miR-181d was significantly decreased by approximately 30% after 48h post-  






































Figure 6.3.1 Abundance of hsa-miR-181d is increased in gastric 
CAMs by Wnt-5a. The relative abundance of hsa-miR-181d was 
increased significantly after gastric CAMs were incubated with 1 µg/ml 
Wnt-5a, but not Wnt-3a. Each experiment was performed in triplicate. 
(*p < 0.05) 
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Figure 6.3.2 Abundance of TIMP3 mRNA is inversely correlated with hsa-
miR-181d after hsa-miR-181d knockdown in CAMs and overexpression in 
ATMs. (A) The relative abundance of hsa-miR-181d in CAMs after 24, 48 
and 72 h post-transfection with hsa-miR-181d inhibitor plasmid. (B) The 
relative abundance of hsa-miR-181d in ATMs after 24 and 48 h post-
transfection with hsa-miR-181d precursor plasmid. (C) The relative mRNA 
abundance of TIMP3 in CAMs and ATMs after hsa-miR-181d knockdown 
and overexpression, respectively. Each experiment was performed in 
triplicate. (*p < 0.05) 
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transfection while a non-significant decrease by approximately 10% was found 
after 24 and 72 h post-transfection (Figure 6.3.2A). When hsa-miR-181d was 
overexpressed in ATMs, its abundance was significantly increased by 
approximately 20% after 48 h post-transfection, but no significant change was 
found after 24 h post-transfection (Figure 6.3.2B). The significance of hsa-miR-
181d abundance difference in CAMs and ATMs was followed by analysis of 
TIMP3 mRNA, which is a known target of the miR-181 family. After 48 h post-
transfection, the mRNA abundance of TIMP3 was significantly increased by 
approximately 30% in hsa-miR-181d knockdown CAMs and decreased by 
approximately 20% in hsa-miR-181d overexpressed ATMs (Figure 6.3.2C), 
indicating the abundance of TIMP3 is inversely correlated with hsa-miR-181d 
abundance.  
 
6.3.3 Decreased migration and proliferation of gastric CAMs after               
hsa-miR-181d knockdown  
Here, the role of hsa-miR-181d in the regulation of migration and proliferation in 
gastric CAMs was determined. After 48 h post-transfection, migration and EdU 
incorporation assays were carried out using hsa-miR-181d knockdown CAMs and 
in the presence or absence of 1 µg/ml recombinant Wnt-5a. The basal migration of 
gastric CAMs was significantly decreased after hsa-miR-181d knockdown (Figure 
6.3.3A). In the presence of Wnt-5a, the migration of CAMs was significantly 
increased, and knockdown of hsa-miR-181d reduced the response. The results of 
EdU incorporation assays showed that the rate of proliferation was significantly  
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A             B     
                 
 
                   
 
Figure 6.3.3 Decreased migration and proliferation of gastric CAMs after hsa-
miR-181d knockdown. (A) The migration of hsa-miR-181d knockdown CAMs 
was significantly decreased when compared to control cells. Incubation with 
Wnt-5a (1 µg/ml, 16 h) significantly increased the migration of CAMs and hsa-
miR-181d knockdown CAMs although a lower response was found in hsa-miR-
181d knockdown CAMs. (B) Percentage of EdU positive cells was significantly 
decreased in hsa-miR-181d knockdown CAMs compared to control cells. 
Incubation with Wnt-5a (1 µg/ml, 24 h) significantly increased the percentage 
of EdU positive cells in CAMs but not after hsa-miR-181d knockdown. Each 
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decreased in hsa-miR-181d knockdown CAMs (Figure 6.6.3B). While Wnt-5a 
was able to increase the proliferation rate in gastric CAMs, there was no 
significant change in the proliferation rate of hsa-miR-181d knockdown CAMs 
after incubation with Wnt-5a.                                          .    
 
6.3.4 Effects of AGS cell migration and proliferation when incubated in 
conditioned medium from CAMs and ATMs following hsa-miR-181d 
knockdown and overexpression, respectively 
To determine whether the different hsa-miR-181d abundance in myofibroblasts 
regulates cancer cell migration, migration assays were performed by incubating 
AGS cells in CM from gastric myofibroblasts. After 48 h post-transfection, CM 
from hsa-miR-181d knockdown CAMs or hsa-miR-181d overexpressed ATMs 
was used for Boyden chamber chemotactic experiments. A significant decrease 
(approximately 30%) in AGS cell migration was found after incubation in CM 
from hsa-miR-181d knockdown CAMs compared to CM from control cells 
(Figure 6.3.4). On the other hand, there was no significant change in the migration 
of AGS cells after incubation in CM from hsa-miR-181d overexpressed ATMs 
and CM from control cells. Additionally, the proliferation rate of AGS cells was 
determined after incubation in CM from transfected samples, and the results 
showed there was no significant change compared to the basal control after 
incubation in CM from CAMs or ATMs (Figure 6.3.5).  
 
 




    















Figure 6.3.4 AGS cell migration is inhibited when incubated in CM from 
hsa-miR-181d knockdown CAMs. No significant change in AGS cell 
migration when incubated in CM from hsa-miR-181d overexpressed 
ATMs compared to control cells. Serum-free medium was the basal 
control. Each experiment was performed in triplicate. CAM-CM and 
ATM-CM indicate conditioned medium from CAMs and ATMs, 
respectively. (*p < 0.05) 
Figure 6.3.5 Proliferation rate of AGS cells was not significantly affected 
after incubation in CM from hsa-miR-181d knockdown CAMs and hsa-
miR-181d overexpressed ATMs. Serum-free medium was the basal 
control. Each experiment was performed in triplicate. CAM-CM and ATM-
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6.3.5 Inhibition of Wnt-5a-induced AGS cell migration by TIMP-3  
Since TIMP3 mRNA abundance was found to be regulated by hsa-miR-181d in 
gastric myofibroblasts, and studies has shown that TIMP-3 inhibits the activity of 
MMPs, a migration assay was carried out to determine the role of TIMP-3 on 
migration of AGS cells. The results showed that the migration of AGS cells was 
unresponsive to TIMP-3 alone, but in the presence of Wnt-5a stimulation, the 
migration of AGS cells was significantly decreased by TIMP-3 (Figure 6.3.6). 







Figure 6.3.6 Wnt-5a-induced migration of AGS cells is inhibited by 
recombinant TIMP-3. No significant different in basal migration of AGS 
cells when 100 ng/ml recombinant TIMP-3 was added. 1 µg/ml Wnt-5a 
significantly increased the migration of AGS cells and the response was 
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6.4 Discussion  
This is the first study that has identified a role of hsa-miR-181d in regulating 
gastric CAMs and influencing cancer cell migration. The results suggest that 
activation of the Wnt signalling pathway by Wnt-5a regulates the abundance of 
hsa-miR-181d in gastric CAMs, and that hsa-miR-181d plays a role in regulating 
the migration and proliferation of gastric CAMs. Additionally, knockdown of hsa-
miR-181d increases the expression of TIMP-3 in CAMs, and extracellular TIMP-
3 could inhibit the migration of AGS cells through Wnt-5a regulatory pathway 
(Figure 6.4.1).  
To determine the function of hsa-miR-181d in gastric myofibroblasts, 
nucleofection experiments with inhibitor and precursor plasmids of hsa-miR-181d 
were carried out using a paired sample of CAMs and ATMs. In chapter 3, RT-
PCR analysis had validated an increased abundance of hsa-miR-181d in CAMs 
compared to corresponding ATMs. As a result, the strategy for studying hsa-miR-
181d was to reduce its abundance in CAMs, termed knockdown, and to increase 
its abundance in ATMs, termed overexpression.  
The greatest significant difference in hsa-miR-181d abundance was a decrease of 
30% and was found in CAMs after 48 h post-transfection. This effect was 
transient as the abundance of hsa-miR-181d returned to control level after 72 h 
post-transfection. The nucleofection experiment demonstrated the targeting effect 
of TIMP3 mRNA by hsa-miR-181d following hsa-miR-181d knockdown in 
CAMs and hsa-miR-181d overexpression in ATMs. The transfection efficiency at 
48 h post-transfection was 50% and it is considered marginally low. It might be 
because these myofibroblasts were primary cell lines which are hard to transfect. 
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To increase the transfection efficiency, non-transfected myofibroblasts should be 
separated from those transfected ones by using flow cytometry so that there would 
be a homogenous population of transfected myofibroblasts. Alternatively, 
myofibroblasts could be transformed into a cell line that permanently 
overexpresses hsa-miR-181d without losing expression when cells divide. 
Previous findings in chapter 5 suggest that Wnt-5a is increased in gastric CAMs, 
and it may activate the non-canonical Wnt signalling pathway in gastric 
myofibroblasts. In this chapter, it was found that Wnt-5a stimulates the abundance 
of hsa-miR-181d in gastric CAMs. It would be useful to perform Wnt-5a 
knockdown in CAMs and then determine whether the abundance of hsa-miR-181d 
is down-regulated to confirm this finding. In addition, a previous study has 
indicated the induction of miR-181 expression in hepatocellular cancer cells by 
the canonical Wnt/β-catenin signalling pathway [254]. These suggest that hsa-
miR-181d could be regulated by both canonical and non-canonical Wnt signalling 
pathways, depending on the cellular context. Since the abundance of hsa-miR-
181d was previously found to be increased in CAMs compared to NTMs, it would 
be beneficial to investigate the regulation of hsa-miR-181d in NTMs and to 
determine whether this miRNA is differentially regulated in CAMs.   
Functional studies of hsa-miR-181d were performed in CAMs so that the 
contribution of hsa-miR-181d in the tumour microenvironment could be 
identified. Compatible with other studies focusing on miR-181s, the results 
showed that the rates of migration and proliferation in gastric CAMs were 
inhibited when hsa-miR-181d was knockdown. Furthermore, RT-PCR analysis 
indicated WNT5A mRNA abundance was not significantly changed after 
knockdown of hsa-miR-181d in CAMs. In the presence of Wnt-5a stimulation, the 
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migration of hsa-miR-181d knockdown CAMs was significantly reduced when 
compared to control cells, indicating hsa-miR-181d is a downstream target of 
Wnt-5a. In contrast, the proliferation rate of hsa-miR-181d knockdown CAMs 
was not significantly changed after stimulation from Wnt-5a. These preliminary 
results suggest that Wnt-5a is a potent regulator of migrating CAMs through hsa-
miR-181d while other mechanisms are involved in the regulation of cell cycle 
progression in CAMs.  
Targets of hsa-miR-181d that encode extracellular proteins such as TIMP-3 could 
be involved in the regulation of AGS cell migration. The hypothesis was that Wnt-
5a from CAMs induces hsa-miR-181d abundance and in turn, down-regulates the 
expression of ECM proteins to promote cell migration. Results obtained showed 
that the migration of AGS cells was partially inhibited after incubation in CM 
from hsa-miR-181d knockdown CAMs compared to control cells. In contrast, 
there was no significant difference in AGS cell migration after incubation in CM 
from hsa-miR-181d overexpressed ATMs and control cells. Therefore, the data 
suggest that targets of hsa-miR-181d in CAMs include secretory factors, which 
contribute to cancer cell migration. Future studies could use mass spectrometry to 
examine the protein abundance in CM from hsa-miR-181d knockdown CAMs so 
that direct and downstream targets of hsa-miR-181d could be identified. A similar 
approach has been used in determining the secretome of gastric myofibroblasts 
[179]. Moreover, migration assays have specifically indicated TIMP-3 as a 
putative regulator of AGS cell migration because the results showed that Wnt-5a-
induced AGS cell migration was inhibited by TIMP-3, thus suggesting a common 
regulatory function of TIMP-3 that opposes the stimulatory effect of Wnt-5a.  
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In conclusion, the present study suggests that increased Wnt-5a expression in 
gastric CAMs may regulate the abundance of hsa-miR-181d, whose targets are 
associated with cell cycle and ECM proteins, thus leading to increased migration 
and proliferation of myofibroblast. In gastric CAMs, TIMP-3 expression is shown 
to be regulated by hsa-miR-181d and is involved in inhibiting Wnt-5a-stimulated 
migration of AGS cells, thus implicating the role of Wnt-5a and hsa-miR-181d in 







Figure 6.4.1 A schematic representation showing regulatory roles of hsa-
miR-181d and Wnt-5a in CAMs and the significance for cancer cell 
migration. Hsa-miR-181d plays a role in the migration and proliferation of 
gastric CAMs. Wnt-5a stimulates the expression of hsa-miR-181d which 
down-regulates TIMP-3 expression, leading to an increase in cell migration.  

























The present thesis has characterised the miRNA expression profiles of stromal 
myofibroblasts from tumours, pre-neoplastic and normal stromal tissues, and has 
investigated the role of miRNAs in regulatory processes that might affect 
myofibroblast role in cancer initiation and progression. Global miRNA expression 
profiles of NTMs from the stomach and oesophageal tissues were clearly distinct 
from each other, suggesting the contribution of miRNAs in myofibroblasts that 
regulate the functions of different epithelia. Additionally, bone marrow derived 
MSCs, which are recognized as precursors of myofibroblasts, exhibited distinct 
global miRNA expression profiles compared to gastric and oesophageal 
myofibroblasts.  
Network enrichment analysis was performed using validated targets of miRNAs 
that were different in abundance between two myofibroblast populations. The 
results showed that affected processes were related to the regulation of cell cycle 
progression and signalling pathways. Wnt signalling, in particular, was 
significantly influenced and was linked to different hsa-miR-181d abundance in 
gastric CAMs compared to ATMs.  
Microarray gene expression analysis showed that WNT5A mRNA was 
significantly up-regulated in CAMs compared to ATMs, and the expression of 
Wnt-5a in paired samples of gastric myofibroblasts was validated by Western blot 
and RT-PCR analyses. The results from functional studies showed that Wnt-5a 
stimulates the migration and proliferation of gastric myofibroblasts probably by 
activating the non-canonical Wnt signalling pathway. In addition, the abundance 
of hsa-miR-181d in gastric CAMs was induced by Wnt-5a, and knockdown of 
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hsa-miR-181 significantly decreased the migration and proliferation of CAMs. 
The migration of CAMs after hsa-miR-181d knockdown, was significantly 
increased by Wnt-5a but a lower response was found when compared to CAMs 
before hsa-miR-181d knockdown. However, the proliferation rate of CAMs after 
hsa-miR-181d knockdown was not significantly increased in response to Wnt-5a. 
TIMP-3, whose expression inversely correlated with hsa-miR-181d abundance, 
inhibited the migration of AGS cells in the presence of Wnt-5a stimulation. These 
findings, therefore, suggest that Wnt-5a regulates the migration of CAMs through 
modulation of hsa-miR-181d, and that both Wnt-5a and hsa-miR-181d play a role 
in cancer cell migration through stromal-tumour interactions.       
 
7.2 Implications of miRNA profiling 
The study of miRNA expression profiles in chapter 3 showed that CAMs 
originated from stomach and oesophageal cancers were distinguished by their 
global miRNA expression. This is the first data analysis to compare miRNA 
expression in gastric and oesophageal CAMs. Nonetheless, the miRNA profiles 
could not classify gastric CAMs into their origins from different tumour subtypes 
such as diffuse-type and intestinal-type gastric carcinomas, suggesting gastric 
CAMs of different cancer subtypes exhibit a common pattern of miRNA 
abundance. On the other hand, the miRNA profiles of SC-CAMs and AC-CAMs 
might be distinct from each other. Further studies using larger sample sizes of 
oesophageal CAMs may help to resolve the issue of whether there are differences 
between oesophageal cancer subtypes. Many studies have used cancer samples for 
miRNA profiling, and one of the initial studies highlighted the potential of 
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miRNA expression for cancer-type classification [159]. This suggests miRNAs 
might play a role in tissue specificity and also, there might be a possibility that 
miRNA profiles in CAMs could determine their tumour origins in the 
gastrointestinal tract.  
Analysis of global miRNA expression profiles showed distinct profiles of MSCs 
in comparison to NTMs of gastric and oesophageal origins. Studies have shown 
that bone marrow MSCs transform into myofibroblast phenotype during wound 
healing [67], but the mechanism involving miRNAs is unknown. Several miRNAs 
such as hsa-miR-29b and hsa-miR-34a that were significantly different in 
abundance have been shown to regulate differentiation of MSCs [78, 225]. Other 
than cells differentiation, differential miRNA abundance might play a role in 
phenotypic differences between MSCs and NTMs. Moreover, MSCs may 
contribute to myofibroblast population in the tumour stroma [193]. Therefore, to 
inhibit the role of MSCs in tumour growth and progression, it would be crucial to 
determine whether these differentially abundant miRNAs could regulate the 
expression of myofibroblast markers (e.g. α-SMA) or influence myofibroblast 
differentiation.  
Using hierarchical clustering analysis of differential miRNA abundance, there 
were distinct clusters between CAMs and ATMs, CAMs and NTMs, and between 
ATMs and NTMs. Thus, mRNA abundance and protein expression that are 
significantly different between two different myofibroblast populations could 
potentially be regulated by these differentially abundant miRNAs. Furthermore, 
novel miRNA targets may be identified by using proteomic and gene expression 
data of myofibroblasts through correlation analysis and complementary binding 
site on 3’UTR of mRNA.   
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7.3 Limitations of enriched network analysis 
MicroRNA research has largely focused on determining the true targets of 
individual miRNAs because predicted targets from computational algorithm 
programs show more than 30% false positives [283]. Recently, there is an 
increased interest in the role of co-expressed miRNAs in regulating biological 
processes.  
In chapter 4, validated targets of differentially abundant miRNAs were used for 
the identification of affected processes. These processes are predictive regulation 
only, and the selection of processes related to myofibroblast function is needed for 
validation work. In addition, bioinformatic analysis does not allow the discovery 
of novel protein interactions or miRNA targets. Moreover, epigenetic alterations 
such as DNA methylation might play a prominent role in the regulation of gene 
expression, so that mechanisms of miRNA regulation are not responsible for 
specific alteration in gene expression. This was not taken into consideration in the 
present study, but it is highly recommended in the future. Furthermore, a recent 
study suggests that single-nucleotide polymorphisms (SNPs) in miRNA genes 
might affect their functional role, contributing to increased risk of cancer [284]. 
This is a research topic that needs to be explored in myofibroblast studies.  
Nonetheless, bioinformatic analysis does have its advantages: a) miRNA targets 
that are being used are already validated so they relate to a function of a miRNA 
better compared to predicted targets; b) analysis of large sample sizes and 
comparison among different populations are efficient using the same platform and 
c) a better understanding of myofibroblast biology. For the latter, miRNAs that 
were difference in abundance in gastric CAMs compared to ATMs were involved 
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in the regulation of cell cycle progression. Therefore, this might result in an 
increased rate of proliferation in CAMs compared to ATMs, indicating the 
regulation of miRNAs in myofibroblast proliferation, but validation work is 
needed to confirm. 
 
7.4 Implications of Wnt-5a and hsa-miR-181d  
The tumour microenvironment has been implicated in malignant progression 
[127]. Gene expression analysis identified up-regulation of WNT5A mRNA in 
gastric CAMs compared to ATMs, and this occurred in 10 of the 12 pairs (83%) 
of gastric myofibroblasts. Since increased expression of Wnt-5a has been 
identified in a subset of gastric carcinoma, and has been associated with poor 
prognosis [264], it is suggested that increased Wnt-5a in gastric CAMs contributes 
to cancer progression, and that this protein might be predominantly expressed in 
the tumour stroma. Thus, targeting Wnt-5a signalling from stromal cells as a 
therapeutic strategy could inhibit tumour growth and progression. Since studies 
have shown that genetic alterations in stromal cells are rare, these cells, in 
particularly CAMs, are thought to exhibit greater genetic stability than cancer 
cells and less likely to acquire resistant to chemotherapy [178]. Preliminary data 
suggest that Wnt-3a induces Wnt-5a abundance in gastric CAMs by activating the 
canonical Wnt/β-catenin signalling pathway. Additionally, a recent study indicates 
the role of LRP6, a coreceptor of the canonical pathway, in mediating Wnt 
transduction, and promoting myofibroblast activation and proliferation [285]. This 
provides further evidence that targeting Wnt signalling is crucial to inhibit 
myofibroblast function in diseases.  
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Besides gastric cancer, Wnt-5a is implicated in malignant progression of other 
cancers [286], and also shown to exhibit tumour suppressive role in colorectal 
[287] and oesophageal squamous cell carcinomas [288]. The abnormal Wnt-5a 
expression in cancer might be a consequence of altered miRNA regulation even 
though WNT5A gene regulated by DNA methylation has been reported [287]. 
Unlike Wnt-3a, Wnt-5a was found to be a potent inducer of migration in gastric 
myofibroblasts. On the other hand, AGS cell migration, but not proliferation, was 
moderately increased by Wnt-5a. It would be interesting to determine changes in 
gene expression that are induced by Wnt-5a in CAMs, and to investigate whether 
these altered genes affect cancer cell behaviour through paracrine signalling or 
ECM remodelling. One such phenomenon is suggested in chapter 6 when it was 
found that Wnt-5a stimulates the abundance of hsa-miR-181d in gastric CAMs 
and that hsa-miR-181d down-regulates TIMP-3 expression to induce cell 
migration. Further studies using in vivo studies will be able to verify whether 
decreased TIMP-3 expression induce gastric cancer cell invasiveness and 
metastatic potential. Proteomic techniques using mass spectrometry will be useful 
to determine TIMP-3 activity in the ECM, and to identify novel targets of hsa-
miR-181d. 
Increase in hsa-miR-181d abundance was found in 5 of the 12 pairs (42%) of 
gastric CAMs and corresponding ATMs. This might suggest that increased Wnt-
5a does not necessarily induce hsa-miR-181d abundance in CAMs. Besides Wnt 
signalling, regulation of miR-181c expression has been linked to DNA 
methylation in gastric carcinoma [245]. Since gastric CAMs have already been 
studied to exhibit global DNA hypomethylation [149], the association of hsa-miR-
181d with epigenetics in CAMs is suggested. Furthermore, up-regulation of hsa-
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miR-181d has been found in gastric carcinoma [280]. Therefore, the development 
of strategy targeting hsa-miR-181d in stromal and cancer cells will be important in 
the inhibition of cancer progression.  
Currently, the first clinical trial for treating hepatitis using miRNA therapeutic 
approach is being carried out [289], thus raising the possibility of cancer treatment 
in the near future. With increasing knowledge from miRNA research and 
advances in miRNA treatment technique, miRNA gene therapy that regulates a 
number of proteins associated with the development of specific tumours is 
promising. Additionally, therapeutic targeting of epigenetic regulation in the 
tumour stroma may provide an alternative for inhibiting cancer progression, and 
may be more effective compared to cancer cell therapy. On the whole, the present 
study has identified the contribution of miRNAs in regulating cellular processes in 
myofibroblasts that could influence cancer progression, suggesting stromal cells 
as a suitable therapeutic drug target to achieve better treatment outcomes for 
patients with gastric and oesophageal cancers, which remain intractable to most 
therapies.  
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Real-time quantitative RT-PCR analysis 
All cDNAs were prepared using 2 µg of RNA which was reverse transcribed with 
AMV reverse transcriptase (Promega, Southampton, UK) and oligoDT (Promega). 
Real-time PCR was carried out in an ABI7500 thermocycler (Applied Biosystems, 
Warrington, UK) using Precision 2x real time PCR master mix (Primer Design, 
Southampton, UK) and either 5’-FAM, 3’-TAMRA double dye probes 
(Eurogentec, Southampton, UK) or SYBR green chemistry. Primers used for PCR 
analyses were GAPDH, TIMP3 and WNT5A (Appendix Table 2.1). Standard 
curves were developed using serial dilutions of cDNA template corresponding to 
the relevant gene amplicon ligated into pGEM-T Easy (Promega). This work was 
done by Dr Islay Steele.  
Primer/Probe Sequence 
hGAPDH probe CGT CGC CAG CCG AGC CAC A 
hGAPDH forward GCT CCT CCT GTT CGA CAG TCA 
hGAPDH reverse ACC TTC CCC ATG GTG TCT GA 
hTIMP 3 forward CCA GGA CGC CTT CTG CAA 
hTIMP 3 reverse CCC CTC CTT TAC CAG CTT CTT C 
hWnt5A probe TTT CTT TTC TGC CTC ACC CCT TTG TCT CCA 
hWnt5A forward GAA ATG CGT GTT GGG TTG AAG 






Appendix Table 2.1 PCR primer and probe sequences of GAPDH, 
TIMP3 and WNT5A. 
 




Gene expression arrays 
Myofibroblasts were cultured at 80% confluency and RNA was extracted using 
the RNeasy kit (Qiagen, Crawley, UK) according to the manufacturer’s 
instructions. Samples were analysed using GeneChip©Human Genome U133 Plus 
2.0 arrays (Affymetrix, Santa Clara, CA, USA) according to the manufacturer’s 
instructions at the Liverpool Genome Facility and using a GeneChip® Scanner 
3000 (Affymetrix) to generate images. Further analysis was performed to identify 
the corresponding gene products by using MetaCore™, a data-mining tool 
developed by GeneGo (www.genego.com); and to annotate the gene products by 
cellular component using Gene Ontology database (www.geneontology.org). 
Quality control was performed using Microarray Suite 5.0 QC Metrics 
(Affymetrix) to ensure the uniformity of the arrays. Gene array data was analysed 
using GeneSpring GX v.10 (Agilent Technologies, Wokingham, UK). 
Experiments were normalised by using the MAS5 algorithm and filtered using the 
present (P), marginal (M) and absent (A) calls generated by MAS5.  In each 
comparison being performed, the gene must be flagged as P at least 1 of the 
experimental groups. Statistical analysis was performed using unpaired t-tests 



























1 Sz173/4 7 AV203 1.97 1.24 0.292 0.78 9.9 
 
2 Sz282/4 6 AV204 2 2.05 0.867 1.78 10 
 
3 Sz198/4 7 AV205 2.03 1.04 0.472 1.92 10 
4 Sz294/4 6 AV206 2 1.78 0.674 0.75 10 
5 Sz308/4 11 AV207 1.99 1.51 0.683 1 10 
6 Sz389/4 5 AV208 1.99 1.63 0.724 1 10 
7 Sz305/4 10 AV209 2.01 0.85 0.152 0.28 9.7 
8 L429/2 (replicate 1) 8 AV210 2.02 1.74 0.819 1.58 - 
9 L429/2 (replicate 2) 8 AV211 2.04 1.54 0.661 1.78 - 
10 L429/2 (replicate 3) 8 AV212 2.03 1.94 0.728 1.4 - 
11 L429/2 (replicate 4) 8 AV213 2.04 2.08 1.01 1.85 - 
12 L429/2 (replicate 5) 8 AV214 2.05 1.82 0.809 1.85 - 
13 L429/2 (replicate 6) 8 AV215 2.03 1.56 0.673 2.25 - 
14 L395/2 10 AV218 2.05 1.46 0.716 1.23 9.7 
15 L7641/22 5 AV219 2.05 1.78 1.36 3.63 9.7 
16 L7642/9 4 AV220 2.03 1.55 0.52 1.03 9.8 
17 Sz190/1 7 AV221 2.02 1.67 0.613 1.73 9.8 
18 Sz190/2 7 AV222 2.01 1.95 0.577 1.43 9.9 
19 Sz192/1 8 AV223 2.03 1.97 1.34 1.45 10 
20 Sz192/2 6 AV224 2.02 1.51 0.952 1.85 9.8 
21 Sz294/1 6 AV225 2.04 1.71 0.979 1.6 9.9 
22 Sz294/2 6 AV226 2.04 2.04 0.836 1.85 9.7 
23 Sz305/1 6 AV227 2.02 0.81 0.564 1.6 10 
24 Sz305/22 5 AV228 2.04 1.95 0.929 1.78 9.7 
25 Sz271/1 7 AV229 2.01 1.23 0.745 1.45 9.9 
26 Sz271/2 8 AV230 2.02 1.44 0.919 1.28 9.8 
27 HMSC7F3914 5 AV232 2.03 2 0.96 1.5 9.7 
28 Sz42/9 5 AV233 2.03 1.73 0.955 0.95 9.4 
29 Sz173/9 6 AV234 2.01 1.79 0.747 1.48 9.9 
30 Sz45/1 6 AV235 2.04 1.82 0.935 2.88 9.8 
31 Sz45/9 6 AV236 2.03 1.25 0.306 1.08 9.6 
32 HMSC7F3674 5 AV237 2.01 1.69 0.63 1.5 9.7 
33 HMSC7F3753 5 AV238 2.02 1.53 0.591 1.5 9.7 
34 Sz268/2 9 AV239 2.01 1.64 0.81 0.68 9.7 
35 Sz306/2 10 AV240 2.04 1.66 0.378 0.83 9.5 
36 Sz194/2 6 AV241 2.06 0.91 0.36 0.73 9.6 
37 Sz279/6 6 AV242 2.05 1.9 0.908 2.3 9.6 
38 Sz306/1 7 AV243 2.05 1.4 0.588 1.25 9.6 
39 Sz467/2 8 AV244 2.05 1.99 1.02 3.7 9.7 
40 Sz173/1 9 AV245 2.05 1.38 0.435 1.05 9.5 
41 Sz173/2 8 AV246 2.01 1.79 0.81 2.13 9.5 
42 Sz282/2 7 AV247 2.03 1.63 1.03 1.28 9.6 
43 Sz373/2 8 AV248 2.03 1.87 1.2 2.6 9.7 
44 HMSCGF4393 7 AV249 2.04 1.42 0.702 1.5 9.7 
45 HMSC7F3458 5 AV250 2.02 1.82 0.541 1.5 9.2 
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46 HMSC PromoCell 5 AV251 2.03 1.99 0.9362 1.5 9.5 
47 Sz194/1 6 AV252 2.03 1.54 0.977 1.03 9.6 
48 Sz268/22 7 AV253 2.05 2.1 1.21 1.1 9.7 
49 Sz282/1 7 AV254 2.04 1.96 1.15 1.83 9.7 
50 Sz308/1 7 AV255 2.02 2.05 0.884 1 9.3 
51 Sz308/22 7 AV256 2.03 1.54 0.585 1 9.8 
52 Sz45/2 6 AV257 2.04 1.34 0.624 1.85 9.8 
53 Sz45/22 8 AV258 2.01 1.49 0.809 1.18 9.7 
54 Sz187/1 8 AV259 2.04 1.97 1.23 2.58 9.6 
55 Sz193/2 6 AV260 2.03 1.77 0.818 1.18 9.5 
56 Sz193/1 6 AV261 2.03 1.9 1.05 2.7 9.7 
57 Sz198/1 7 AV262 2.04 1.74 1.35 3.08 9.9 
58 Sz198/2 7 AV263 2.01 1.9 0.914 1.15 9.8 
59 Sz197/1 6 AV264 2.02 1.54 0.758 2.75 9.7 
60 Sz173/22 9 AV265 2.04 1.83 0.695 1.5 9.6 
61 Sz268/1 7 AV266 2.03 1.94 0.963 1.78 9.7 
62 Sz241/6 7 AV267 2.03 1.74 0.608 1.25 9.6 
63 Sz261/6 5 AV268 2.02 1.99 0.735 1.58 9.6 
64 Sz360/1 6 AV269 2.05 1.04 0.506 1.6 9.3 
65 Sz389/1 6 AV270 2.04 1.89 0.714 1.6 9.8 
66 Sz389/2 6 AV271 2.04 1.89 0.906 1.3 9.6 
67 L1212/22 4 AV272 2.07 1.12 1.19 4 9.5 
68 Sz246/22 6 AV273 2.06 2.01 1.08 1.9 9.9 
69 Sz279/22 4 AV274 2.04 1.8 1.04 4 9.9 
70 Sz334/2 5 AV275 2.05 1.77 0.592 2.1 9.9 
71 Sz360/2 6 AV276 2.07 0.88 0.384 0.9 9.6 
72 Sz246/2 6 AV277 2.03 1.56 0.582 1.1 9.3 
73 Sz246/6 5 AV278 2.03 1.49 0.879 1.5 9.4 
74 Sz261/2 6 AV279 2.05 1.76 0.669 2.6 9.7 
75 Sz334/22 5 AV280 2.06 1.12 0.374 2.2 9.6 
76 Sz241/2 6 AV281 1.99 1.26 0.485 1.8 9.1 
77 Sz261/22 6 AV282 2 1.99 0.71 1.9 9.7 
78 Sz351/2 5 AV283 2.01 1.83 0.865 1.9 9.6 
79 Sz351/6 5 AV284 2.02 1.05 0.733 1.6 9.6 
80 Sz42/2 7 AV285 2.02 1.58 0.968 2 9.3 
81 Sz196/2 5 AV286 2.03 1.95 0.489 1.9 9.7 
82 Sz334/6 5 AV287 2.02 1.93 1.15 2.3 10 
83 L355/22 5 AV288 2.03 1.56 1.05 2.1 9.3 
84 Sz241/22 6 AV289 2.04 1.47 0.56 1.8 9.7 
85 Sz351/22 5 AV290 2.04 1.63 0.441 1.3 9.2 
86 Sz373/1 7 AV291 2.04 2.05 0.802 1.48 9.4 
87 Sz467/1 7 AV292 2.05 0.61 0.239 1.03 9.6 
88 Sz42/1 5 AV293 2.02 1.38 1.07 6 8.4 
89 Sz294/22 5 AV294 2.04 1.52 1.01 1.93 9.7 
90 L429/2 6 AV295 2.02 1.61 0.613 1.6 9.7 


























Appendix 3.2.1 RNA purity, RNA concentration and RIN were 
determined in human myofibroblasts and MSCs. Myofibroblast sample 
is represented by Sz or L, followed by patient number and tissue origin. 
Legend: HMSC; human mesenchymal stromal cells, Sz; patient tissue 
from Szeged, L; patient tissue from Liverpool. Tissue origins: 1 (cancer 
tissue), 2 (adjacent non-tumour tissue or gastric corpus), 4 (lymph 















Appendix 3.2.2 Good RNA quality and no DNA contamination in total 
RNA sample of myofibroblasts of lymph node origin. (A) Each 
electropherogram showed two resolving peaks at approximately 4000 
and 2000 nt representing rRNA 28S and 18S respectively. RIN of more 
than 9.5 was obtained. (B) Electrophoresis assay showed two distinct 
bands, namely, rRNA 28S and 18S, at 4000 and 2000 nt respectively. 
nt represents nucleotides.  
 






(Input: 100ng/µl Total RNA) 
Proportion of 
miRNAs in 






small RNA (%) 
Sz282/4 341.5 0.342 13150 2.57 
Sz294/4 153.8 0.154 12849 1.20 
Sz308/4 378.0 0.378 12008 3.15 














Appendix 3.2.3 Concentration of miRNAs (10 to 40 nt) and 
small RNAs (<200 nt) in total RNA samples from lymph node 
derived myofibroblasts. The proportion of miRNAs in total RNA 
sample and small RNA fraction were determined.                 
 
Appendix 3.2.4 Small RNA assay using total RNA samples of lymph 
node derived myofibroblasts. Three resolving peaks between 4 and 
150 nt indicates the integrity of small RNAs.  
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Sample  ID 
number 
miRNA                
concentration (pg/µl) 
Small RNA 
concentration (pg/µl)  
Proportion of miRNAs 
in 100ng total RNA (%)  
Proportion of 
miRNAs in 
small RNAs (%) 
Sz294/1 
AV142* 392.5 4232 0.393 9 
AV225 414.6 11007 0.415 4 
Sz294/2 
AV143* 358.5 1927 0.359 19 
AV226 352.5 12576 0.353 3 
Sz190/1 
AV152* 868.5 4131 0.869 21 
AV221 216.2 10654 0.216 2 
Sz190/2 
AV153* 299.2 2918 0.299 10 





A         B 




Appendix 3.2.5 Small RNA concentration increased after six months storage at -
80oC whereas miRNA concentration was not greatly affected. Asterisk indicates 

















































Appendix 3.2.6 Concentration of miRNAs increases six-fold in enriched 
small RNA sample compared to total RNA sample. (A) The percentage 
of miRNAs increased from 0.5% to 3% after enrichment procedure. 
0.1% miRNAs was detected in large RNA fraction. (B) Electrophoresis 
assay showed bands intensity in total RNA, large RNA fraction and 
enriched small RNA fraction. 
 





















Appendix 3.2.7 Correlation between spike-in controls for (A) Hy3 and 
(B) Hy5 channels on different array slides of MSCs (n = 6). Pearson 
correlation coefficient of about 1 was obtained. 
 


















Appendix 3.2.8 Correlation between spike-in controls for (A) Hy3 and 
(B) Hy5 channels on different array slides of gastric myofibroblasts (n = 
49). Pearson correlation coefficient of about 1 was obtained. 
 









Appendix 3.2.9 Correlation between spike-in controls for (A) Hy3 and (B) 
Hy5 channels on different array slides of oesophageal myofibroblasts (n = 
22). Pearson correlation coefficient of about 1 was obtained. 
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No.  Probe Id Annotation Number of samples  
1 146011 hsa-let-7a 6 
2 42530 hsa-let-7a-2* 6 
3 17749 hsa-let-7b 6 
4 42769 hsa-let-7b* 6 
5 145820 hsa-let-7c 6 
6 145968 hsa-let-7d 6 
7 145846 hsa-let-7e 6 
8 17752 hsa-let-7f 6 
9 145840 hsa-let-7f-1* 6 
10 46438 hsa-let-7g 6 
11 9938 hsa-let-7i 6 
12 145746 hsa-let-7i* 6 
13 145943 hsa-miR-100 6 
14 31026 hsa-miR-101 6 
15 10919 hsa-miR-103 6 
16 46801 hsa-miR-106a 6 
17 19582 hsa-miR-106b 6 
18 10923 hsa-miR-107 6 
19 13485 hsa-miR-10a 6 
20 10925 hsa-miR-10b 6 
21 46258 hsa-miR-1184 6 
22 46712 hsa-miR-1201 6 
23 46345 hsa-miR-1207-3p 6 
24 46806 hsa-miR-1227 6 
25 46514 hsa-miR-1246 6 
26 145977 hsa-miR-1247 6 
27 46427 hsa-miR-1248 6 
28 46210 hsa-miR-1249 6 
29 46380 hsa-miR-1255a 6 
30 46923 hsa-miR-1259 6 
31 10928 hsa-miR-125a-5p 6 
32 30787 hsa-miR-125b 6 
33 145838 hsa-miR-125b-1* 6 
34 145975 hsa-miR-1260 6 
35 46248 hsa-miR-1261 6 
36 46732 hsa-miR-1264 6 
37 46737 hsa-miR-1265 6 
38 42829 hsa-miR-127-3p 6 
39 46292 hsa-miR-1274a 6 
40 46328 hsa-miR-1274b 6 
41 46620 hsa-miR-1275 6 
42 42692 hsa-miR-127-5p 6 
43 46698 hsa-miR-1280 6 
44 46634 hsa-miR-1281 6 
45 145981 hsa-miR-1285 6 
46 46921 hsa-miR-1290 6 
47 42467 hsa-miR-129-5p 6 
48 46944 hsa-miR-1297 6 
49 46739 hsa-miR-1308 6 
50 10138 hsa-miR-130a 6 
51 10936 hsa-miR-130b 6 
52 145760 hsa-miR-136 6 
53 42512 hsa-miR-136* 6 
54 145749 hsa-miR-137 6 
55 13140 hsa-miR-138 6 
56 42872 hsa-miR-138-1* 6 
57 42630 hsa-miR-140-3p 6 
58 4700 hsa-miR-140-5p 6 
59 46467 hsa-miR-143* 6 
60 42641 hsa-miR-145 6 
61 31867 hsa-miR-145* 6 
62 146072 hsa-miR-1469 6 
63 10306 hsa-miR-146b-5p 6 
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64 10955 hsa-miR-148a 6 
65 19585 hsa-miR-148b 6 
66 42486 hsa-miR-149* 6 
67 145678 hsa-miR-150 6 
68 17463 hsa-miR-151-3p 6 
69 11260 hsa-miR-151-5p 6 
70 17676 hsa-miR-152 6 
71 145857 hsa-miR-154 6 
72 10964 hsa-miR-155 6 
73 27720 hsa-miR-15a 6 
74 17280 hsa-miR-15b 6 
75 10967 hsa-miR-16 6 
76 42650 hsa-miR-17 6 
77 42865 hsa-miR-181a 6 
78 10972 hsa-miR-181b 6 
79 145636 hsa-miR-181d 6 
80 46810 hsa-miR-1827 6 
81 10977 hsa-miR-183 6 
82 17953 hsa-miR-183* 6 
83 145801 hsa-miR-184 6 
84 42902 hsa-miR-185 6 
85 17904 hsa-miR-185* 6 
86 18739 hsa-miR-186 6 
87 42588 hsa-miR-18a 6 
88 27536 hsa-miR-190 6 
89 28431 hsa-miR-1908 6 
90 10985 hsa-miR-191 6 
91 146103 hsa-miR-1913 6 
92 146091 hsa-miR-1914 6 
93 10986 hsa-miR-193a-3p 6 
94 46443 hsa-miR-193a-5p 6 
95 10987 hsa-miR-193b 6 
96 13148 hsa-miR-195 6 
97 10990 hsa-miR-196a 6 
98 145889 hsa-miR-196b 6 
99 146165 hsa-miR-1973 6 
100 146200 hsa-miR-1974 6 
101 146140 hsa-miR-1976 6 
102 146001 hsa-miR-1977 6 
103 146016 hsa-miR-1978 6 
104 146167 hsa-miR-1979 6 
105 10995 hsa-miR-199a-3p/hsa-miR-199b-3p 6 
106 29562 hsa-miR-199a-5p 6 
107 19591 hsa-miR-199b-5p 6 
108 10997 hsa-miR-19a 6 
109 10998 hsa-miR-19b 6 
110 42968 hsa-miR-202 6 
111 145996 hsa-miR-205* 6 
112 145845 hsa-miR-20a 6 
113 5740 hsa-miR-21 6 
114 42524 hsa-miR-21* 6 
115 145852 hsa-miR-210 6 
116 146161 hsa-miR-2115* 6 
117 146010 hsa-miR-2116 6 
118 11014 hsa-miR-214 6 
119 145822 hsa-miR-214* 6 
120 11020 hsa-miR-22 6 
121 42532 hsa-miR-22* 6 
122 11022 hsa-miR-221 6 
123 42475 hsa-miR-221* 6 
124 11023 hsa-miR-222 6 
125 17918 hsa-miR-222* 6 
126 11024 hsa-miR-223 6 
127 42566 hsa-miR-224 6 
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128 146163 hsa-miR-224* 6 
129 42744 hsa-miR-23a 6 
130 145841 hsa-miR-23b 6 
131 17506 hsa-miR-24 6 
132 146043 hsa-miR-24-1* 6 
133 42950 hsa-miR-24-2* 6 
134 42682 hsa-miR-25 6 
135 42929 hsa-miR-25* 6 
136 11030 hsa-miR-26a 6 
137 146008 hsa-miR-26b 6 
138 46483 hsa-miR-27a 6 
139 145944 hsa-miR-27b 6 
140 146100 hsa-miR-296-5p 6 
141 11038 hsa-miR-299-5p 6 
142 11039 hsa-miR-29a 6 
143 145638 hsa-miR-29a* 6 
144 11040 hsa-miR-29b 6 
145 17810 hsa-miR-29b-1* 6 
146 11041 hsa-miR-29c 6 
147 42513 hsa-miR-300 6 
148 13143 hsa-miR-301a 6 
149 146086 hsa-miR-30a 6 
150 146112 hsa-miR-30b 6 
151 42923 hsa-miR-30c 6 
152 19596 hsa-miR-30d 6 
153 28191 hsa-miR-30e 6 
154 145676 hsa-miR-30e* 6 
155 11052 hsa-miR-31 6 
156 46320 hsa-miR-31* 6 
157 11053 hsa-miR-32 6 
158 29575 hsa-miR-32* 6 
159 27533 hsa-miR-320a 6 
160 46324 hsa-miR-320b 6 
161 46228 hsa-miR-320c 6 
162 46870 hsa-miR-320d 6 
163 42887 hsa-miR-331-3p 6 
164 11065 hsa-miR-335 6 
165 145745 hsa-miR-335* 6 
166 42673 hsa-miR-337-3p 6 
167 17944 hsa-miR-337-5p 6 
168 42739 hsa-miR-339-5p 6 
169 29872 hsa-miR-340 6 
170 32884 hsa-miR-342-3p 6 
171 27217 hsa-miR-34a 6 
172 42724 hsa-miR-34b 6 
173 11074 hsa-miR-34c-5p 6 
174 145865 hsa-miR-361-3p 6 
175 14301 hsa-miR-361-5p 6 
176 27544 hsa-miR-363* 6 
177 11078 hsa-miR-365 6 
178 29529 hsa-miR-369-3p 6 
179 145844 hsa-miR-374a 6 
180 14302 hsa-miR-374b 6 
181 146009 hsa-miR-376a 6 
182 42885 hsa-miR-376a* 6 
183 145642 hsa-miR-376b 6 
184 42629 hsa-miR-376c 6 
185 11091 hsa-miR-377 6 
186 11093 hsa-miR-379 6 
187 145832 hsa-miR-381 6 
188 145643 hsa-miR-382 6 
189 145644 hsa-miR-409-3p 6 
190 11102 hsa-miR-410 6 
191 17482 hsa-miR-411 6 
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192 42784 hsa-miR-411* 6 
193 42730 hsa-miR-423-3p 6 
194 27565 hsa-miR-423-5p 6 
195 42965 hsa-miR-424 6 
196 17608 hsa-miR-425 6 
197 18847 hsa-miR-450a 6 
198 29379 hsa-miR-452 6 
199 146076 hsa-miR-483-3p 6 
200 145753 hsa-miR-484 6 
201 42694 hsa-miR-485-3p 6 
202 14285 hsa-miR-487b 6 
203 17927 hsa-miR-491-3p 6 
204 42661 hsa-miR-492 6 
205 11125 hsa-miR-493* 6 
206 145901 hsa-miR-494 6 
207 42676 hsa-miR-495 6 
208 42442 hsa-miR-498 6 
209 42581 hsa-miR-513a-5p 6 
210 42550 hsa-miR-516a-5p 6 





213 46221 hsa-miR-519d 6 
214 13132 hsa-miR-519e* 6 
215 11175 hsa-miR-525-5p 6 
216 14272 hsa-miR-542-3p 6 
217 42917 hsa-miR-551b 6 
218 28966 hsa-miR-574-3p 6 
219 27740 hsa-miR-574-5p 6 
220 17295 hsa-miR-583 6 
221 145647 hsa-miR-584 6 
222 42531 hsa-miR-602 6 
223 27672 hsa-miR-615-3p 6 
224 32825 hsa-miR-620 6 
225 145740 hsa-miR-625* 6 
226 42958 hsa-miR-628-3p 6 
227 17566 hsa-miR-629* 6 
228 17354 hsa-miR-637 6 
229 42832 hsa-miR-638 6 
230 42679 hsa-miR-642 6 
231 21498 hsa-miR-654-3p 6 
232 29736 hsa-miR-656 6 
233 145973 hsa-miR-664 6 
234 145768 hsa-miR-665 6 
235 29490 hsa-miR-7 6 
236 29190 hsa-miR-708 6 
237 146196 hsa-miR-711 6 
238 146064 hsa-miR-718 6 
239 42751 hsa-miR-720 6 
240 27568 hsa-miR-744 6 
241 145805 hsa-miR-765 6 
242 42808 hsa-miR-874 6 
243 46259 hsa-miR-885-5p 6 
244 42806 hsa-miR-886-3p 6 
245 17885 hsa-miR-886-5p 6 
246 42825 hsa-miR-888* 6 
247 145693 hsa-miR-92a 6 
248 30687 hsa-miR-93 6 
249 42539 hsa-miR-933 6 
250 42776 hsa-miR-938 6 
251 42608 hsa-miR-942 6 
252 11182 hsa-miR-98 6 
253 42708 hsa-miR-99a 6 
254 11184 hsa-miR-99b 6 
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255 28302 hsa-miRPlus-A1015 6 
256 42780 hsa-miRPlus-A1065 6 
257 42793 hsa-miRPlus-A1072 6 
258 17858 hsa-miRPlus-A1073 6 
259 17848 hsa-miRPlus-A1087 6 
260 28534 hsa-miRPlus-D1058 6 
261 46649 hsa-miRPlus-E1012 6 
262 46466 hsa-miRPlus-E1016 6 
263 21526 hsa-miRPlus-E1031 6 
264 46749 hsa-miRPlus-E1033 6 
265 46537 hsa-miRPlus-E1038 6 
266 46352 hsa-miRPlus-E1082 6 
267 46512 hsa-miRPlus-E1088 6 
268 46330 hsa-miRPlus-E1097 6 
269 46861 hsa-miRPlus-E1098 6 
270 46382 hsa-miRPlus-E1104 6 
271 145983 hsa-miRPlus-E1114 6 
272 46733 hsa-miRPlus-E1117 6 
273 46662 hsa-miRPlus-E1146 6 
274 145938 hsa-miRPlus-E1151 6 
275 46555 hsa-miRPlus-E1153 6 
276 46561 hsa-miRPlus-E1168 6 
277 46817 hsa-miRPlus-E1172 6 
278 46506 hsa-miRPlus-E1186 6 
279 45587 hsa-miRPlus-E1200 6 
280 46883 hsa-miRPlus-E1209 6 
281 46343 hsa-miRPlus-E1212 6 
282 46885 hsa-miRPlus-E1225 6 
283 145935 hsa-miRPlus-E1232 6 
284 46557 hsa-miRPlus-E1233 6 
285 46247 hsa-miRPlus-E1234 6 
286 46256 hsa-miRPlus-E1238 6 
287 46711 hsa-miRPlus-E1245 6 
288 46445 hsa-miRPlus-E1247 6 
289 145978 hsa-miRPlus-E1258 6 
290 45891 hsa-miRPlus-E1285 6 
291 46756 hsa-miRPlus-F1001 6 
292 46635 hsa-miRPlus-F1004 6 
293 46731 hsa-miRPlus-F1017 6 
294 46933 hsa-miRPlus-F1026 6 
295 46297 hsa-miRPlus-F1041 6 
296 46519 hsa-miRPlus-F1042 6 
297 46417 hsa-miRPlus-F1058 6 
298 46334 hsa-miRPlus-F1059 6 
299 46630 hsa-miRPlus-F1064 6 
300 46871 hsa-miRPlus-F1066 6 
301 46386 hsa-miRPlus-F1074 6 
302 46498 hsa-miRPlus-F1099 6 
303 46241 hsa-miRPlus-F1130 6 
304 46353 hsa-miRPlus-F1147 6 
305 46590 hsa-miRPlus-F1154 6 
306 45614 hsa-miRPlus-F1155 6 
307 46474 hsa-miRPlus-F1158 6 
308 46601 hsa-miRPlus-F1163 6 
309 46298 hsa-miRPlus-F1180 6 
310 46602 hsa-miRPlus-F1194 6 
311 46882 hsa-miRPlus-F1195 6 
312 46655 hsa-miRPlus-F1215 6 
313 46632 hsa-miRPlus-F1222 6 
314 46599 hsa-miRPlus-F1225 6 
315 46359 hsa-miRPlus-F1231 6 
316 146113 hsa-miRPlus-G1246-3p 6 
317 146158 hsa-miRPlus-G1316-5p 6 
318 17854 hsa-miR-106b* 5 
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319 46624 hsa-miR-1236 5 
320 42571 hsa-miR-129* 5 
321 42783 hsa-miR-197 5 
322 5730 hsa-miR-208a 5 
323 11037 hsa-miR-299-3p 5 
324 11045 hsa-miR-302c* 5 
325 17893 hsa-miR-362-3p 5 
326 14270 hsa-miR-493 5 
327 11164 hsa-miR-519e 5 
328 17546 hsa-miR-585 5 
329 42818 hsa-miR-597 5 
330 42749 hsa-miR-659 5 
331 145701 hsa-miR-668 5 
332 30033 hsa-miR-877 5 
333 42771 hsa-miR-877* 5 
334 17718 hsa-miR-92b 5 
335 46580 hsa-miRPlus-E1077 5 
336 46379 hsa-miRPlus-E1093 5 
337 145940 hsa-miRPlus-E1110 5 
338 46473 hsa-miRPlus-E1112 5 
339 46529 hsa-miRPlus-F1023 5 
340 46570 hsa-miRPlus-F1080 5 
341 46273 hsa-miRPlus-F1166 5 














Appendix 3.3.1 MicroRNAs that were expressed in at least 80% of 
MSCs (n = 6). 
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No. Probe Id Annotation Number of samples 
1 146011 hsa-let-7a 6 
2 42530 hsa-let-7a-2* 6 
3 17749 hsa-let-7b 6 
4 145820 hsa-let-7c 6 
5 145968 hsa-let-7d 6 
6 145846 hsa-let-7e 6 
7 17752 hsa-let-7f 6 
8 46438 hsa-let-7g 6 
9 9938 hsa-let-7i 6 
10 145943 hsa-miR-100 6 
11 31026 hsa-miR-101 6 
12 10919 hsa-miR-103 6 
13 46801 hsa-miR-106a 6 
14 19582 hsa-miR-106b 6 
15 10923 hsa-miR-107 6 
16 13485 hsa-miR-10a 6 
17 46258 hsa-miR-1184 6 
18 46712 hsa-miR-1201 6 
19 46345 hsa-miR-1207-3p 6 
20 46514 hsa-miR-1246 6 
21 145977 hsa-miR-1247 6 
22 46210 hsa-miR-1249 6 
23 46380 hsa-miR-1255a 6 
24 46923 hsa-miR-1259 6 
25 10928 hsa-miR-125a-5p 6 
26 30787 hsa-miR-125b 6 
27 145975 hsa-miR-1260 6 
28 46248 hsa-miR-1261 6 
29 46732 hsa-miR-1264 6 
30 46737 hsa-miR-1265 6 
31 42829 hsa-miR-127-3p 6 
32 46292 hsa-miR-1274a 6 
33 46328 hsa-miR-1274b 6 
34 46620 hsa-miR-1275 6 
35 46698 hsa-miR-1280 6 
36 145981 hsa-miR-1285 6 
37 42571 hsa-miR-129* 6 
38 46921 hsa-miR-1290 6 
39 42467 hsa-miR-129-5p 6 
40 46944 hsa-miR-1297 6 
41 46739 hsa-miR-1308 6 
42 10138 hsa-miR-130a 6 
43 10936 hsa-miR-130b 6 
44 145760 hsa-miR-136 6 
45 42512 hsa-miR-136* 6 
46 13140 hsa-miR-138 6 
47 42872 hsa-miR-138-1* 6 
48 42630 hsa-miR-140-3p 6 
49 42641 hsa-miR-145 6 
50 146072 hsa-miR-1469 6 
51 19585 hsa-miR-148b 6 
52 42486 hsa-miR-149* 6 
53 145678 hsa-miR-150 6 
54 17463 hsa-miR-151-3p 6 
55 11260 hsa-miR-151-5p 6 
56 17676 hsa-miR-152 6 
57 27720 hsa-miR-15a 6 
58 17280 hsa-miR-15b 6 
59 10967 hsa-miR-16 6 
60 42650 hsa-miR-17 6 
61 42865 hsa-miR-181a 6 
62 145636 hsa-miR-181d 6 
63 46810 hsa-miR-1827 6 
 Appendices  
226 
 
64 10977 hsa-miR-183 6 
65 17953 hsa-miR-183* 6 
66 145801 hsa-miR-184 6 
67 42902 hsa-miR-185 6 
68 17904 hsa-miR-185* 6 
69 18739 hsa-miR-186 6 
70 27536 hsa-miR-190 6 
71 28431 hsa-miR-1908 6 
72 10985 hsa-miR-191 6 
73 146091 hsa-miR-1914 6 
74 10986 hsa-miR-193a-3p 6 
75 46443 hsa-miR-193a-5p 6 
76 10987 hsa-miR-193b 6 
77 13148 hsa-miR-195 6 
78 42538 hsa-miR-196a* 6 
79 42783 hsa-miR-197 6 
80 146165 hsa-miR-1973 6 
81 146200 hsa-miR-1974 6 
82 146001 hsa-miR-1977 6 
83 146016 hsa-miR-1978 6 
84 146167 hsa-miR-1979 6 
85 10995 hsa-miR-199a-3p/hsa-miR-199b-3p 6 
86 29562 hsa-miR-199a-5p 6 
87 19591 hsa-miR-199b-5p 6 
88 10997 hsa-miR-19a 6 
89 10998 hsa-miR-19b 6 
90 42968 hsa-miR-202 6 
91 145996 hsa-miR-205* 6 
92 145845 hsa-miR-20a 6 
93 5740 hsa-miR-21 6 
94 42524 hsa-miR-21* 6 
95 145852 hsa-miR-210 6 
96 146161 hsa-miR-2115* 6 
97 146010 hsa-miR-2116 6 
98 11014 hsa-miR-214 6 
99 11020 hsa-miR-22 6 
100 42532 hsa-miR-22* 6 
101 11022 hsa-miR-221 6 
102 42475 hsa-miR-221* 6 
103 11023 hsa-miR-222 6 
104 42566 hsa-miR-224 6 
105 146163 hsa-miR-224* 6 
106 42744 hsa-miR-23a 6 
107 145841 hsa-miR-23b 6 
108 17506 hsa-miR-24 6 
109 146043 hsa-miR-24-1* 6 
110 42950 hsa-miR-24-2* 6 
111 42682 hsa-miR-25 6 
112 42929 hsa-miR-25* 6 
113 11030 hsa-miR-26a 6 
114 146008 hsa-miR-26b 6 
115 46483 hsa-miR-27a 6 
116 145944 hsa-miR-27b 6 
117 11038 hsa-miR-299-5p 6 
118 11039 hsa-miR-29a 6 
119 145638 hsa-miR-29a* 6 
120 11040 hsa-miR-29b 6 
121 11041 hsa-miR-29c 6 
122 42513 hsa-miR-300 6 
123 13143 hsa-miR-301a 6 
124 146086 hsa-miR-30a 6 
125 146112 hsa-miR-30b 6 
126 42923 hsa-miR-30c 6 
127 19596 hsa-miR-30d 6 
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128 28191 hsa-miR-30e 6 
129 145676 hsa-miR-30e* 6 
130 11052 hsa-miR-31 6 
131 46320 hsa-miR-31* 6 
132 11053 hsa-miR-32 6 
133 29575 hsa-miR-32* 6 
134 27533 hsa-miR-320a 6 
135 46324 hsa-miR-320b 6 
136 46228 hsa-miR-320c 6 
137 46870 hsa-miR-320d 6 
138 42957 hsa-miR-323-3p 6 
139 42887 hsa-miR-331-3p 6 
140 11065 hsa-miR-335 6 
141 145745 hsa-miR-335* 6 
142 42673 hsa-miR-337-3p 6 
143 17944 hsa-miR-337-5p 6 
144 42739 hsa-miR-339-5p 6 
145 145859 hsa-miR-33a 6 
146 145950 hsa-miR-33b 6 
147 29872 hsa-miR-340 6 
148 27217 hsa-miR-34a 6 
149 42724 hsa-miR-34b 6 
150 145865 hsa-miR-361-3p 6 
151 14301 hsa-miR-361-5p 6 
152 11078 hsa-miR-365 6 
153 29529 hsa-miR-369-3p 6 
154 145844 hsa-miR-374a 6 
155 14302 hsa-miR-374b 6 
156 146009 hsa-miR-376a 6 
157 42885 hsa-miR-376a* 6 
158 145642 hsa-miR-376b 6 
159 42629 hsa-miR-376c 6 
160 11091 hsa-miR-377 6 
161 11093 hsa-miR-379 6 
162 145832 hsa-miR-381 6 
163 145644 hsa-miR-409-3p 6 
164 17482 hsa-miR-411 6 
165 42784 hsa-miR-411* 6 
166 42730 hsa-miR-423-3p 6 
167 27565 hsa-miR-423-5p 6 
168 42965 hsa-miR-424 6 
169 18847 hsa-miR-450a 6 
170 29379 hsa-miR-452 6 
171 146076 hsa-miR-483-3p 6 
172 42480 hsa-miR-485-5p 6 
173 14285 hsa-miR-487b 6 
174 42703 hsa-miR-490-3p 6 
175 17822 hsa-miR-490-5p 6 
176 17927 hsa-miR-491-3p 6 
177 42661 hsa-miR-492 6 
178 11125 hsa-miR-493* 6 
179 145901 hsa-miR-494 6 
180 42442 hsa-miR-498 6 
181 42581 hsa-miR-513a-5p 6 
182 42550 hsa-miR-516a-5p 6 





185 46221 hsa-miR-519d 6 
186 13132 hsa-miR-519e* 6 
187 11175 hsa-miR-525-5p 6 
188 14272 hsa-miR-542-3p 6 
189 42917 hsa-miR-551b 6 
190 28966 hsa-miR-574-3p 6 
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191 27740 hsa-miR-574-5p 6 
192 17295 hsa-miR-583 6 
193 145647 hsa-miR-584 6 
194 42531 hsa-miR-602 6 
195 27672 hsa-miR-615-3p 6 
196 32825 hsa-miR-620 6 
197 145740 hsa-miR-625* 6 
198 42958 hsa-miR-628-3p 6 
199 17566 hsa-miR-629* 6 
200 17354 hsa-miR-637 6 
201 42832 hsa-miR-638 6 
202 42679 hsa-miR-642 6 
203 21498 hsa-miR-654-3p 6 
204 145973 hsa-miR-664 6 
205 145768 hsa-miR-665 6 
206 29490 hsa-miR-7 6 
207 146196 hsa-miR-711 6 
208 42751 hsa-miR-720 6 
209 27568 hsa-miR-744 6 
210 145805 hsa-miR-765 6 
211 42808 hsa-miR-874 6 
212 46259 hsa-miR-885-5p 6 
213 42806 hsa-miR-886-3p 6 
214 17885 hsa-miR-886-5p 6 
215 42825 hsa-miR-888* 6 
216 145693 hsa-miR-92a 6 
217 30687 hsa-miR-93 6 
218 42539 hsa-miR-933 6 
219 11182 hsa-miR-98 6 
220 42708 hsa-miR-99a 6 
221 11184 hsa-miR-99b 6 
222 28302 hsa-miRPlus-A1015 6 
223 42780 hsa-miRPlus-A1065 6 
224 42793 hsa-miRPlus-A1072 6 
225 17858 hsa-miRPlus-A1073 6 
226 17848 hsa-miRPlus-A1087 6 
227 28534 hsa-miRPlus-D1058 6 
228 46649 hsa-miRPlus-E1012 6 
229 46466 hsa-miRPlus-E1016 6 
230 21526 hsa-miRPlus-E1031 6 
231 46749 hsa-miRPlus-E1033 6 
232 46537 hsa-miRPlus-E1038 6 
233 46580 hsa-miRPlus-E1077 6 
234 46352 hsa-miRPlus-E1082 6 
235 46512 hsa-miRPlus-E1088 6 
236 46330 hsa-miRPlus-E1097 6 
237 46861 hsa-miRPlus-E1098 6 
238 46382 hsa-miRPlus-E1104 6 
239 145983 hsa-miRPlus-E1114 6 
240 46733 hsa-miRPlus-E1117 6 
241 46662 hsa-miRPlus-E1146 6 
242 145938 hsa-miRPlus-E1151 6 
243 46555 hsa-miRPlus-E1153 6 
244 46561 hsa-miRPlus-E1168 6 
245 46817 hsa-miRPlus-E1172 6 
246 46506 hsa-miRPlus-E1186 6 
247 46883 hsa-miRPlus-E1209 6 
248 46343 hsa-miRPlus-E1212 6 
249 46885 hsa-miRPlus-E1225 6 
250 145935 hsa-miRPlus-E1232 6 
251 46247 hsa-miRPlus-E1234 6 
252 46256 hsa-miRPlus-E1238 6 
253 46445 hsa-miRPlus-E1247 6 
254 145978 hsa-miRPlus-E1258 6 
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255 45891 hsa-miRPlus-E1285 6 
256 46731 hsa-miRPlus-F1017 6 
257 46933 hsa-miRPlus-F1026 6 
258 46519 hsa-miRPlus-F1042 6 
259 46334 hsa-miRPlus-F1059 6 
260 46630 hsa-miRPlus-F1064 6 
261 46871 hsa-miRPlus-F1066 6 
262 46386 hsa-miRPlus-F1074 6 
263 46498 hsa-miRPlus-F1099 6 
264 46241 hsa-miRPlus-F1130 6 
265 46353 hsa-miRPlus-F1147 6 
266 46590 hsa-miRPlus-F1154 6 
267 45614 hsa-miRPlus-F1155 6 
268 46273 hsa-miRPlus-F1166 6 
269 46298 hsa-miRPlus-F1180 6 
270 46786 hsa-miRPlus-F1193 6 
271 46602 hsa-miRPlus-F1194 6 
272 46882 hsa-miRPlus-F1195 6 
273 46655 hsa-miRPlus-F1215 6 
274 46632 hsa-miRPlus-F1222 6 
275 46599 hsa-miRPlus-F1225 6 
276 46359 hsa-miRPlus-F1231 6 
277 146113 hsa-miRPlus-G1246-3p 6 
278 146158 hsa-miRPlus-G1316-5p 6 
279 145840 hsa-let-7f-1* 5 
280 46624 hsa-miR-1236 5 
281 46634 hsa-miR-1281 5 
282 10306 hsa-miR-146b-5p 5 
283 10964 hsa-miR-155 5 
284 10972 hsa-miR-181b 5 
285 146103 hsa-miR-1913 5 
286 32884 hsa-miR-342-3p 5 
287 145643 hsa-miR-382 5 
288 17608 hsa-miR-425 5 
289 42676 hsa-miR-495 5 
290 46829 hsa-miR-664* 5 
291 42761 hsa-miR-675 5 
292 29190 hsa-miR-708 5 
293 42776 hsa-miR-938 5 
294 145940 hsa-miRPlus-E1110 5 
295 46711 hsa-miRPlus-E1245 5 
296 46756 hsa-miRPlus-F1001 5 
297 46570 hsa-miRPlus-F1080 5 
298 46474 hsa-miRPlus-F1158 5 
 
 
Appendix 3.3.2a MicroRNAs that were expressed in at least 80% 
of gastric NTMs (n = 6) from corpus. 
 
 Appendices  
230 
 
No. Probe Id Annotation Number of samples 
1 146011 hsa-let-7a 6 
2 42530 hsa-let-7a-2* 6 
3 17749 hsa-let-7b 6 
4 145820 hsa-let-7c 6 
5 145968 hsa-let-7d 6 
6 145846 hsa-let-7e 6 
7 17752 hsa-let-7f 6 
8 145840 hsa-let-7f-1* 6 
9 46438 hsa-let-7g 6 
10 9938 hsa-let-7i 6 
11 145943 hsa-miR-100 6 
12 31026 hsa-miR-101 6 
13 10919 hsa-miR-103 6 
14 46801 hsa-miR-106a 6 
15 19582 hsa-miR-106b 6 
16 10923 hsa-miR-107 6 
17 13485 hsa-miR-10a 6 
18 46258 hsa-miR-1184 6 
19 46712 hsa-miR-1201 6 
20 46514 hsa-miR-1246 6 
21 145977 hsa-miR-1247 6 
22 46210 hsa-miR-1249 6 
23 46380 hsa-miR-1255a 6 
24 46923 hsa-miR-1259 6 
25 10928 hsa-miR-125a-5p 6 
26 30787 hsa-miR-125b 6 
27 145975 hsa-miR-1260 6 
28 46248 hsa-miR-1261 6 
29 46732 hsa-miR-1264 6 
30 46737 hsa-miR-1265 6 
31 42829 hsa-miR-127-3p 6 
32 46292 hsa-miR-1274a 6 
33 46328 hsa-miR-1274b 6 
34 46620 hsa-miR-1275 6 
35 46698 hsa-miR-1280 6 
36 145981 hsa-miR-1285 6 
37 42571 hsa-miR-129* 6 
38 46921 hsa-miR-1290 6 
39 42467 hsa-miR-129-5p 6 
40 46944 hsa-miR-1297 6 
41 46739 hsa-miR-1308 6 
42 10138 hsa-miR-130a 6 
43 10936 hsa-miR-130b 6 
44 145760 hsa-miR-136 6 
45 42512 hsa-miR-136* 6 
46 13140 hsa-miR-138 6 
47 42872 hsa-miR-138-1* 6 
48 42630 hsa-miR-140-3p 6 
49 42641 hsa-miR-145 6 
50 146072 hsa-miR-1469 6 
51 19585 hsa-miR-148b 6 
52 42486 hsa-miR-149* 6 
53 145678 hsa-miR-150 6 
54 17463 hsa-miR-151-3p 6 
55 11260 hsa-miR-151-5p 6 
56 17676 hsa-miR-152 6 
57 10964 hsa-miR-155 6 
58 27720 hsa-miR-15a 6 
59 17280 hsa-miR-15b 6 
60 10967 hsa-miR-16 6 
61 42650 hsa-miR-17 6 
62 42865 hsa-miR-181a 6 
63 10972 hsa-miR-181b 6 
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64 145636 hsa-miR-181d 6 
65 46810 hsa-miR-1827 6 
66 10977 hsa-miR-183 6 
67 17953 hsa-miR-183* 6 
68 145801 hsa-miR-184 6 
69 42902 hsa-miR-185 6 
70 17904 hsa-miR-185* 6 
71 18739 hsa-miR-186 6 
72 42588 hsa-miR-18a 6 
73 27536 hsa-miR-190 6 
74 28431 hsa-miR-1908 6 
75 10985 hsa-miR-191 6 
76 146103 hsa-miR-1913 6 
77 146091 hsa-miR-1914 6 
78 10986 hsa-miR-193a-3p 6 
79 46443 hsa-miR-193a-5p 6 
80 10987 hsa-miR-193b 6 
81 13148 hsa-miR-195 6 
82 42538 hsa-miR-196a* 6 
83 42783 hsa-miR-197 6 
84 146165 hsa-miR-1973 6 
85 146200 hsa-miR-1974 6 
86 146001 hsa-miR-1977 6 
87 146016 hsa-miR-1978 6 
88 146167 hsa-miR-1979 6 
89 10995 hsa-miR-199a-3p/hsa-miR-199b-3p 6 
90 29562 hsa-miR-199a-5p 6 
91 19591 hsa-miR-199b-5p 6 
92 10997 hsa-miR-19a 6 
93 10998 hsa-miR-19b 6 
94 42968 hsa-miR-202 6 
95 145996 hsa-miR-205* 6 
96 145845 hsa-miR-20a 6 
97 5740 hsa-miR-21 6 
98 42524 hsa-miR-21* 6 
99 145852 hsa-miR-210 6 
100 146161 hsa-miR-2115* 6 
101 146010 hsa-miR-2116 6 
102 11014 hsa-miR-214 6 
103 11020 hsa-miR-22 6 
104 42532 hsa-miR-22* 6 
105 11022 hsa-miR-221 6 
106 42475 hsa-miR-221* 6 
107 11023 hsa-miR-222 6 
108 42566 hsa-miR-224 6 
109 146163 hsa-miR-224* 6 
110 42744 hsa-miR-23a 6 
111 145841 hsa-miR-23b 6 
112 17506 hsa-miR-24 6 
113 146043 hsa-miR-24-1* 6 
114 42950 hsa-miR-24-2* 6 
115 42682 hsa-miR-25 6 
116 42929 hsa-miR-25* 6 
117 11030 hsa-miR-26a 6 
118 146008 hsa-miR-26b 6 
119 46483 hsa-miR-27a 6 
120 145944 hsa-miR-27b 6 
121 146049 hsa-miR-28-5p 6 
122 11038 hsa-miR-299-5p 6 
123 11039 hsa-miR-29a 6 
124 145638 hsa-miR-29a* 6 
125 11040 hsa-miR-29b 6 
126 11041 hsa-miR-29c 6 
127 42513 hsa-miR-300 6 
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128 13143 hsa-miR-301a 6 
129 146086 hsa-miR-30a 6 
130 146112 hsa-miR-30b 6 
131 42923 hsa-miR-30c 6 
132 19596 hsa-miR-30d 6 
133 28191 hsa-miR-30e 6 
134 145676 hsa-miR-30e* 6 
135 11052 hsa-miR-31 6 
136 46320 hsa-miR-31* 6 
137 11053 hsa-miR-32 6 
138 29575 hsa-miR-32* 6 
139 27533 hsa-miR-320a 6 
140 46324 hsa-miR-320b 6 
141 46228 hsa-miR-320c 6 
142 46870 hsa-miR-320d 6 
143 42957 hsa-miR-323-3p 6 
144 42887 hsa-miR-331-3p 6 
145 11065 hsa-miR-335 6 
146 145745 hsa-miR-335* 6 
147 42673 hsa-miR-337-3p 6 
148 17944 hsa-miR-337-5p 6 
149 42739 hsa-miR-339-5p 6 
150 145859 hsa-miR-33a 6 
151 145950 hsa-miR-33b 6 
152 29872 hsa-miR-340 6 
153 32884 hsa-miR-342-3p 6 
154 27217 hsa-miR-34a 6 
155 42724 hsa-miR-34b 6 
156 145865 hsa-miR-361-3p 6 
157 14301 hsa-miR-361-5p 6 
158 11078 hsa-miR-365 6 
159 29529 hsa-miR-369-3p 6 
160 145844 hsa-miR-374a 6 
161 14302 hsa-miR-374b 6 
162 146009 hsa-miR-376a 6 
163 42885 hsa-miR-376a* 6 
164 145642 hsa-miR-376b 6 
165 42629 hsa-miR-376c 6 
166 11091 hsa-miR-377 6 
167 11093 hsa-miR-379 6 
168 145832 hsa-miR-381 6 
169 145643 hsa-miR-382 6 
170 145644 hsa-miR-409-3p 6 
171 17482 hsa-miR-411 6 
172 42784 hsa-miR-411* 6 
173 42730 hsa-miR-423-3p 6 
174 27565 hsa-miR-423-5p 6 
175 42965 hsa-miR-424 6 
176 17608 hsa-miR-425 6 
177 18847 hsa-miR-450a 6 
178 29379 hsa-miR-452 6 
179 146076 hsa-miR-483-3p 6 
180 42480 hsa-miR-485-5p 6 
181 14285 hsa-miR-487b 6 
182 42703 hsa-miR-490-3p 6 
183 17822 hsa-miR-490-5p 6 
184 17927 hsa-miR-491-3p 6 
185 42661 hsa-miR-492 6 
186 11125 hsa-miR-493* 6 
187 145901 hsa-miR-494 6 
188 42676 hsa-miR-495 6 
189 42442 hsa-miR-498 6 
190 42581 hsa-miR-513a-5p 6 
191 42550 hsa-miR-516a-5p 6 
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194 46221 hsa-miR-519d 6 
195 13132 hsa-miR-519e* 6 
196 11175 hsa-miR-525-5p 6 
197 14272 hsa-miR-542-3p 6 
198 42917 hsa-miR-551b 6 
199 28966 hsa-miR-574-3p 6 
200 27740 hsa-miR-574-5p 6 
201 17295 hsa-miR-583 6 
202 145647 hsa-miR-584 6 
203 42531 hsa-miR-602 6 
204 27672 hsa-miR-615-3p 6 
205 32825 hsa-miR-620 6 
206 145740 hsa-miR-625* 6 
207 42958 hsa-miR-628-3p 6 
208 17566 hsa-miR-629* 6 
209 17354 hsa-miR-637 6 
210 42832 hsa-miR-638 6 
211 42679 hsa-miR-642 6 
212 21498 hsa-miR-654-3p 6 
213 145973 hsa-miR-664 6 
214 145768 hsa-miR-665 6 
215 145701 hsa-miR-668 6 
216 42761 hsa-miR-675 6 
217 29490 hsa-miR-7 6 
218 146196 hsa-miR-711 6 
219 42751 hsa-miR-720 6 
220 27568 hsa-miR-744 6 
221 145805 hsa-miR-765 6 
222 42808 hsa-miR-874 6 
223 30033 hsa-miR-877 6 
224 46259 hsa-miR-885-5p 6 
225 42806 hsa-miR-886-3p 6 
226 17885 hsa-miR-886-5p 6 
227 42825 hsa-miR-888* 6 
228 145693 hsa-miR-92a 6 
229 30687 hsa-miR-93 6 
230 42539 hsa-miR-933 6 
231 11182 hsa-miR-98 6 
232 42708 hsa-miR-99a 6 
233 11184 hsa-miR-99b 6 
234 28302 hsa-miRPlus-A1015 6 
235 42780 hsa-miRPlus-A1065 6 
236 42793 hsa-miRPlus-A1072 6 
237 17858 hsa-miRPlus-A1073 6 
238 17848 hsa-miRPlus-A1087 6 
239 28534 hsa-miRPlus-D1058 6 
240 46649 hsa-miRPlus-E1012 6 
241 46466 hsa-miRPlus-E1016 6 
242 21526 hsa-miRPlus-E1031 6 
243 46749 hsa-miRPlus-E1033 6 
244 46537 hsa-miRPlus-E1038 6 
245 46580 hsa-miRPlus-E1077 6 
246 46352 hsa-miRPlus-E1082 6 
247 46512 hsa-miRPlus-E1088 6 
248 46330 hsa-miRPlus-E1097 6 
249 46861 hsa-miRPlus-E1098 6 
250 46382 hsa-miRPlus-E1104 6 
251 145940 hsa-miRPlus-E1110 6 
252 145983 hsa-miRPlus-E1114 6 
253 46733 hsa-miRPlus-E1117 6 
254 46662 hsa-miRPlus-E1146 6 
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255 145938 hsa-miRPlus-E1151 6 
256 46555 hsa-miRPlus-E1153 6 
257 46561 hsa-miRPlus-E1168 6 
258 46817 hsa-miRPlus-E1172 6 
259 46506 hsa-miRPlus-E1186 6 
260 46883 hsa-miRPlus-E1209 6 
261 46343 hsa-miRPlus-E1212 6 
262 46885 hsa-miRPlus-E1225 6 
263 145935 hsa-miRPlus-E1232 6 
264 46247 hsa-miRPlus-E1234 6 
265 46256 hsa-miRPlus-E1238 6 
266 46711 hsa-miRPlus-E1245 6 
267 46445 hsa-miRPlus-E1247 6 
268 145978 hsa-miRPlus-E1258 6 
269 45891 hsa-miRPlus-E1285 6 
270 46731 hsa-miRPlus-F1017 6 
271 46933 hsa-miRPlus-F1026 6 
272 46519 hsa-miRPlus-F1042 6 
273 46334 hsa-miRPlus-F1059 6 
274 46630 hsa-miRPlus-F1064 6 
275 46871 hsa-miRPlus-F1066 6 
276 46386 hsa-miRPlus-F1074 6 
277 46498 hsa-miRPlus-F1099 6 
278 46241 hsa-miRPlus-F1130 6 
279 46353 hsa-miRPlus-F1147 6 
280 46590 hsa-miRPlus-F1154 6 
281 45614 hsa-miRPlus-F1155 6 
282 46273 hsa-miRPlus-F1166 6 
283 46786 hsa-miRPlus-F1193 6 
284 46602 hsa-miRPlus-F1194 6 
285 46882 hsa-miRPlus-F1195 6 
286 46655 hsa-miRPlus-F1215 6 
287 46632 hsa-miRPlus-F1222 6 
288 46599 hsa-miRPlus-F1225 6 
289 46359 hsa-miRPlus-F1231 6 
290 146113 hsa-miRPlus-G1246-3p 6 
291 146158 hsa-miRPlus-G1316-5p 6 
292 46345 hsa-miR-1207-3p 5 
293 46427 hsa-miR-1248 5 
294 46634 hsa-miR-1281 5 
295 10306 hsa-miR-146b-5p 5 
296 27544 hsa-miR-363* 5 
297 42694 hsa-miR-485-3p 5 
298 42818 hsa-miR-597 5 
299 146064 hsa-miR-718 5 
300 46297 hsa-miRPlus-F1041 5 




Appendix 3.3.2b MicroRNAs that were expressed in at least 80% 
of gastric NTMs (n = 6) from antrum. 
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No. Probe Id Annotation Number of samples 
1 146011 hsa-let-7a 6 
2 42530 hsa-let-7a-2* 6 
3 17749 hsa-let-7b 6 
4 42769 hsa-let-7b* 6 
5 145820 hsa-let-7c 6 
6 145968 hsa-let-7d 6 
7 145846 hsa-let-7e 6 
8 17752 hsa-let-7f 6 
9 145840 hsa-let-7f-1* 6 
10 46438 hsa-let-7g 6 
11 9938 hsa-let-7i 6 
12 145943 hsa-miR-100 6 
13 31026 hsa-miR-101 6 
14 10919 hsa-miR-103 6 
15 46801 hsa-miR-106a 6 
16 19582 hsa-miR-106b 6 
17 10923 hsa-miR-107 6 
18 13485 hsa-miR-10a 6 
19 46258 hsa-miR-1184 6 
20 46712 hsa-miR-1201 6 
21 46345 hsa-miR-1207-3p 6 
22 46806 hsa-miR-1227 6 
23 46624 hsa-miR-1236 6 
24 46514 hsa-miR-1246 6 
25 145977 hsa-miR-1247 6 
26 46427 hsa-miR-1248 6 
27 46210 hsa-miR-1249 6 
28 46380 hsa-miR-1255a 6 
29 46923 hsa-miR-1259 6 
30 10928 hsa-miR-125a-5p 6 
31 30787 hsa-miR-125b 6 
32 145975 hsa-miR-1260 6 
33 46248 hsa-miR-1261 6 
34 46732 hsa-miR-1264 6 
35 46737 hsa-miR-1265 6 
36 42829 hsa-miR-127-3p 6 
37 46292 hsa-miR-1274a 6 
38 46328 hsa-miR-1274b 6 
39 46620 hsa-miR-1275 6 
40 46698 hsa-miR-1280 6 
41 46634 hsa-miR-1281 6 
42 145981 hsa-miR-1285 6 
43 42571 hsa-miR-129* 6 
44 46921 hsa-miR-1290 6 
45 42467 hsa-miR-129-5p 6 
46 46944 hsa-miR-1297 6 
47 46739 hsa-miR-1308 6 
48 10138 hsa-miR-130a 6 
49 10936 hsa-miR-130b 6 
50 145760 hsa-miR-136 6 
51 42512 hsa-miR-136* 6 
52 13140 hsa-miR-138 6 
53 42872 hsa-miR-138-1* 6 
54 42630 hsa-miR-140-3p 6 
55 42641 hsa-miR-145 6 
56 31867 hsa-miR-145* 6 
57 146072 hsa-miR-1469 6 
58 10306 hsa-miR-146b-5p 6 
59 19585 hsa-miR-148b 6 
60 42486 hsa-miR-149* 6 
61 145678 hsa-miR-150 6 
62 17463 hsa-miR-151-3p 6 
63 11260 hsa-miR-151-5p 6 
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64 17676 hsa-miR-152 6 
65 10964 hsa-miR-155 6 
66 27720 hsa-miR-15a 6 
67 17280 hsa-miR-15b 6 
68 10967 hsa-miR-16 6 
69 42650 hsa-miR-17 6 
70 42865 hsa-miR-181a 6 
71 10972 hsa-miR-181b 6 
72 145636 hsa-miR-181d 6 
73 46810 hsa-miR-1827 6 
74 10977 hsa-miR-183 6 
75 17953 hsa-miR-183* 6 
76 145801 hsa-miR-184 6 
77 42902 hsa-miR-185 6 
78 17904 hsa-miR-185* 6 
79 18739 hsa-miR-186 6 
80 42588 hsa-miR-18a 6 
81 27536 hsa-miR-190 6 
82 28431 hsa-miR-1908 6 
83 10985 hsa-miR-191 6 
84 146103 hsa-miR-1913 6 
85 146091 hsa-miR-1914 6 
86 10986 hsa-miR-193a-3p 6 
87 46443 hsa-miR-193a-5p 6 
88 10987 hsa-miR-193b 6 
89 13148 hsa-miR-195 6 
90 42783 hsa-miR-197 6 
91 146165 hsa-miR-1973 6 
92 146200 hsa-miR-1974 6 
93 146001 hsa-miR-1977 6 
94 146016 hsa-miR-1978 6 
95 146167 hsa-miR-1979 6 
96 10995 hsa-miR-199a-3p/hsa-miR-199b-3p 6 
97 29562 hsa-miR-199a-5p 6 
98 19591 hsa-miR-199b-5p 6 
99 10997 hsa-miR-19a 6 
100 10998 hsa-miR-19b 6 
101 42968 hsa-miR-202 6 
102 145996 hsa-miR-205* 6 
103 145845 hsa-miR-20a 6 
104 5740 hsa-miR-21 6 
105 42524 hsa-miR-21* 6 
106 145852 hsa-miR-210 6 
107 146161 hsa-miR-2115* 6 
108 146010 hsa-miR-2116 6 
109 11014 hsa-miR-214 6 
110 11020 hsa-miR-22 6 
111 42532 hsa-miR-22* 6 
112 11022 hsa-miR-221 6 
113 42475 hsa-miR-221* 6 
114 11023 hsa-miR-222 6 
115 42566 hsa-miR-224 6 
116 146163 hsa-miR-224* 6 
117 42744 hsa-miR-23a 6 
118 145841 hsa-miR-23b 6 
119 17506 hsa-miR-24 6 
120 146043 hsa-miR-24-1* 6 
121 42950 hsa-miR-24-2* 6 
122 42682 hsa-miR-25 6 
123 42929 hsa-miR-25* 6 
124 11030 hsa-miR-26a 6 
125 146008 hsa-miR-26b 6 
126 46483 hsa-miR-27a 6 
127 145944 hsa-miR-27b 6 
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128 11037 hsa-miR-299-3p 6 
129 11038 hsa-miR-299-5p 6 
130 11039 hsa-miR-29a 6 
131 145638 hsa-miR-29a* 6 
132 11040 hsa-miR-29b 6 
133 17810 hsa-miR-29b-1* 6 
134 11041 hsa-miR-29c 6 
135 42513 hsa-miR-300 6 
136 13143 hsa-miR-301a 6 
137 146086 hsa-miR-30a 6 
138 146112 hsa-miR-30b 6 
139 42923 hsa-miR-30c 6 
140 19596 hsa-miR-30d 6 
141 28191 hsa-miR-30e 6 
142 145676 hsa-miR-30e* 6 
143 11052 hsa-miR-31 6 
144 46320 hsa-miR-31* 6 
145 11053 hsa-miR-32 6 
146 29575 hsa-miR-32* 6 
147 27533 hsa-miR-320a 6 
148 46324 hsa-miR-320b 6 
149 46228 hsa-miR-320c 6 
150 46870 hsa-miR-320d 6 
151 42887 hsa-miR-331-3p 6 
152 11065 hsa-miR-335 6 
153 145745 hsa-miR-335* 6 
154 42673 hsa-miR-337-3p 6 
155 17944 hsa-miR-337-5p 6 
156 42739 hsa-miR-339-5p 6 
157 29872 hsa-miR-340 6 
158 32884 hsa-miR-342-3p 6 
159 27217 hsa-miR-34a 6 
160 42724 hsa-miR-34b 6 
161 145865 hsa-miR-361-3p 6 
162 14301 hsa-miR-361-5p 6 
163 11078 hsa-miR-365 6 
164 29529 hsa-miR-369-3p 6 
165 145844 hsa-miR-374a 6 
166 14302 hsa-miR-374b 6 
167 146009 hsa-miR-376a 6 
168 42885 hsa-miR-376a* 6 
169 145642 hsa-miR-376b 6 
170 42629 hsa-miR-376c 6 
171 11091 hsa-miR-377 6 
172 11093 hsa-miR-379 6 
173 145832 hsa-miR-381 6 
174 145643 hsa-miR-382 6 
175 145644 hsa-miR-409-3p 6 
176 11102 hsa-miR-410 6 
177 17482 hsa-miR-411 6 
178 42784 hsa-miR-411* 6 
179 42730 hsa-miR-423-3p 6 
180 27565 hsa-miR-423-5p 6 
181 42965 hsa-miR-424 6 
182 17608 hsa-miR-425 6 
183 18847 hsa-miR-450a 6 
184 29379 hsa-miR-452 6 
185 146076 hsa-miR-483-3p 6 
186 145753 hsa-miR-484 6 
187 14285 hsa-miR-487b 6 
188 42703 hsa-miR-490-3p 6 
189 17822 hsa-miR-490-5p 6 
190 17927 hsa-miR-491-3p 6 
191 42661 hsa-miR-492 6 
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192 11125 hsa-miR-493* 6 
193 145901 hsa-miR-494 6 
194 42676 hsa-miR-495 6 
195 42442 hsa-miR-498 6 
196 42581 hsa-miR-513a-5p 6 
197 42550 hsa-miR-516a-5p 6 





200 46221 hsa-miR-519d 6 
201 13132 hsa-miR-519e* 6 
202 11175 hsa-miR-525-5p 6 
203 14272 hsa-miR-542-3p 6 
204 42917 hsa-miR-551b 6 
205 28966 hsa-miR-574-3p 6 
206 27740 hsa-miR-574-5p 6 
207 17295 hsa-miR-583 6 
208 145647 hsa-miR-584 6 
209 17546 hsa-miR-585 6 
210 42531 hsa-miR-602 6 
211 27672 hsa-miR-615-3p 6 
212 32825 hsa-miR-620 6 
213 145740 hsa-miR-625* 6 
214 42958 hsa-miR-628-3p 6 
215 17566 hsa-miR-629* 6 
216 17354 hsa-miR-637 6 
217 42832 hsa-miR-638 6 
218 42679 hsa-miR-642 6 
219 21498 hsa-miR-654-3p 6 
220 29736 hsa-miR-656 6 
221 145973 hsa-miR-664 6 
222 145768 hsa-miR-665 6 
223 29490 hsa-miR-7 6 
224 146196 hsa-miR-711 6 
225 146064 hsa-miR-718 6 
226 42751 hsa-miR-720 6 
227 27568 hsa-miR-744 6 
228 145805 hsa-miR-765 6 
229 42808 hsa-miR-874 6 
230 30033 hsa-miR-877 6 
231 46259 hsa-miR-885-5p 6 
232 42806 hsa-miR-886-3p 6 
233 17885 hsa-miR-886-5p 6 
234 42825 hsa-miR-888* 6 
235 145693 hsa-miR-92a 6 
236 30687 hsa-miR-93 6 
237 42539 hsa-miR-933 6 
238 11182 hsa-miR-98 6 
239 42708 hsa-miR-99a 6 
240 11184 hsa-miR-99b 6 
241 28302 hsa-miRPlus-A1015 6 
242 42780 hsa-miRPlus-A1065 6 
243 42793 hsa-miRPlus-A1072 6 
244 17858 hsa-miRPlus-A1073 6 
245 17848 hsa-miRPlus-A1087 6 
246 28534 hsa-miRPlus-D1058 6 
247 46649 hsa-miRPlus-E1012 6 
248 46466 hsa-miRPlus-E1016 6 
249 21526 hsa-miRPlus-E1031 6 
250 46749 hsa-miRPlus-E1033 6 
251 46537 hsa-miRPlus-E1038 6 
252 46580 hsa-miRPlus-E1077 6 
253 46512 hsa-miRPlus-E1088 6 
254 46330 hsa-miRPlus-E1097 6 
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255 46861 hsa-miRPlus-E1098 6 
256 46382 hsa-miRPlus-E1104 6 
257 145940 hsa-miRPlus-E1110 6 
258 145983 hsa-miRPlus-E1114 6 
259 46733 hsa-miRPlus-E1117 6 
260 46662 hsa-miRPlus-E1146 6 
261 145938 hsa-miRPlus-E1151 6 
262 46555 hsa-miRPlus-E1153 6 
263 46561 hsa-miRPlus-E1168 6 
264 46817 hsa-miRPlus-E1172 6 
265 46506 hsa-miRPlus-E1186 6 
266 46883 hsa-miRPlus-E1209 6 
267 46343 hsa-miRPlus-E1212 6 
268 46885 hsa-miRPlus-E1225 6 
269 145935 hsa-miRPlus-E1232 6 
270 46557 hsa-miRPlus-E1233 6 
271 46256 hsa-miRPlus-E1238 6 
272 46445 hsa-miRPlus-E1247 6 
273 145978 hsa-miRPlus-E1258 6 
274 45891 hsa-miRPlus-E1285 6 
275 46756 hsa-miRPlus-F1001 6 
276 46635 hsa-miRPlus-F1004 6 
277 46731 hsa-miRPlus-F1017 6 
278 46933 hsa-miRPlus-F1026 6 
279 46297 hsa-miRPlus-F1041 6 
280 46519 hsa-miRPlus-F1042 6 
281 46334 hsa-miRPlus-F1059 6 
282 46630 hsa-miRPlus-F1064 6 
283 46871 hsa-miRPlus-F1066 6 
284 46386 hsa-miRPlus-F1074 6 
285 46498 hsa-miRPlus-F1099 6 
286 46241 hsa-miRPlus-F1130 6 
287 46353 hsa-miRPlus-F1147 6 
288 46590 hsa-miRPlus-F1154 6 
289 45614 hsa-miRPlus-F1155 6 
290 46601 hsa-miRPlus-F1163 6 
291 46273 hsa-miRPlus-F1166 6 
292 46298 hsa-miRPlus-F1180 6 
293 46602 hsa-miRPlus-F1194 6 
294 46882 hsa-miRPlus-F1195 6 
295 46655 hsa-miRPlus-F1215 6 
296 46632 hsa-miRPlus-F1222 6 
297 46599 hsa-miRPlus-F1225 6 
298 46359 hsa-miRPlus-F1231 6 
299 146113 hsa-miRPlus-G1246-3p 6 
300 146158 hsa-miRPlus-G1316-5p 6 
301 145746 hsa-let-7i* 5 
302 145857 hsa-miR-154 5 
303 42538 hsa-miR-196a* 5 
304 146140 hsa-miR-1976 5 
305 146049 hsa-miR-28-5p 5 
306 11061 hsa-miR-329 5 
307 145859 hsa-miR-33a 5 
308 145950 hsa-miR-33b 5 
309 27544 hsa-miR-363* 5 
310 145705 hsa-miR-431 5 
311 11111 hsa-miR-432 5 
312 42694 hsa-miR-485-3p 5 
313 145701 hsa-miR-668 5 
314 29190 hsa-miR-708 5 
315 46742 hsa-miRPlus-E1067 5 
316 46352 hsa-miRPlus-E1082 5 
317 46296 hsa-miRPlus-F1036 5 
318 46570 hsa-miRPlus-F1080 5 
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319 46503 hsa-miRPlus-F1104 5 






No. Probe Id Annotation Relative abundance p-value 
1 145975 hsa-miR-1260 -1.46 8.95E-04 
2 42751 hsa-miR-720 -1.46 2.98E-04 
3 46512 hsa-miRPlus-E1088 -1.43 4.17E-05 
4 46382 hsa-miRPlus-E1104 1.35 4.50E-05 
5 46324 hsa-miR-320b 1.36 5.68E-04 
6 145805 hsa-miR-765 1.37 1.17E-04 
7 42829 hsa-miR-127-3p 1.37 1.63E-04 
8 28966 hsa-miR-574-3p 1.38 4.43E-07 
9 46712 hsa-miR-1201 1.38 2.04E-06 
10 17295 hsa-miR-583 1.38 6.68E-06 
11 146086 hsa-miR-30a 1.39 3.63E-04 
12 46228 hsa-miR-320c 1.42 1.60E-04 
13 17749 hsa-let-7b 1.44 6.18E-04 
14 27533 hsa-miR-320a 1.46 1.33E-04 
15 19596 hsa-miR-30d 1.46 1.83E-06 
16 31026 hsa-miR-101 1.57 5.50E-04 
17 13143 hsa-miR-301a 1.59 9.77E-05 
18 46870 hsa-miR-320d 1.59 1.34E-06 




Appendix 3.3.3 MicroRNAs that were expressed in at least 80% 
of oesophageal NTMs (n = 6). 
 
Appendix 3.3.4 Relative abundance of significantly 
different miRNAs in gastric NTMs compared to 
oesophageal NTMs, at p < 0.001. 
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No. Probe Id Annotation Relative abundance p-value 
1 46749 hsa-miRPlus-E1033 -2.78 7.98E-07 
2 11041 hsa-miR-29c -2.5 2.43E-07 
3 146076 hsa-miR-483-3p -2.44 2.65E-05 
4 42965 hsa-miR-424 -2.44 9.12E-06 
5 42679 hsa-miR-642 -2.43 4.87E-06 
6 31026 hsa-miR-101 -2.31 2.16E-06 
7 13143 hsa-miR-301a -2.26 2.43E-08 
8 28302 hsa-miRPlus-A1015 -2.14 4.50E-06 
9 11040 hsa-miR-29b -1.91 3.94E-04 
10 146112 hsa-miR-30b -1.82 5.64E-06 
11 19596 hsa-miR-30d -1.8 2.65E-09 
12 46630 hsa-miRPlus-F1064 -1.8 1.73E-05 
13 145844 hsa-miR-374a -1.78 9.70E-08 
14 46882 hsa-miRPlus-F1195 -1.76 7.70E-06 
15 46555 hsa-miRPlus-E1153 -1.76 3.81E-05 
16 27217 hsa-miR-34a -1.74 2.19E-04 
17 42887 hsa-miR-331-3p -1.73 1.80E-06 
18 46382 hsa-miRPlus-E1104 -1.71 1.29E-08 
19 27568 hsa-miR-744 -1.69 3.21E-11 
20 145678 hsa-miR-150 -1.67 5.63E-05 
21 10919 hsa-miR-103 -1.62 1.12E-06 
22 145805 hsa-miR-765 -1.59 1.37E-06 
23 10138 hsa-miR-130a -1.58 7.62E-06 
24 42513 hsa-miR-300 -1.57 8.19E-04 
25 42872 hsa-miR-138-1* -1.57 7.22E-04 
26 10923 hsa-miR-107 -1.57 4.99E-08 
27 42917 hsa-miR-551b -1.56 1.52E-06 
28 17904 hsa-miR-185* -1.54 5.42E-05 
29 42885 hsa-miR-376a* -1.5 7.07E-07 
30 28966 hsa-miR-574-3p -1.49 5.58E-08 
31 46870 hsa-miR-320d -1.46 4.81E-05 
32 17295 hsa-miR-583 -1.45 9.12E-07 
33 11260 hsa-miR-151-5p -1.43 3.23E-05 
34 14272 hsa-miR-542-3p -1.41 2.43E-04 
35 145935 hsa-miRPlus-E1232 -1.4 4.05E-04 
36 19585 hsa-miR-148b -1.39 6.14E-05 
37 146113 hsa-miRPlus-G1246-3p -1.39 2.53E-04 
38 145938 hsa-miRPlus-E1151 -1.39 1.83E-06 
39 45614 hsa-miRPlus-F1155 -1.38 3.48E-04 
40 10985 hsa-miR-191 -1.37 6.73E-05 
41 46228 hsa-miR-320c -1.36 4.25E-04 
42 27565 hsa-miR-423-5p -1.35 4.42E-04 
43 11039 hsa-miR-29a -1.35 9.24E-04 
44 42475 hsa-miR-221* 1.43 1.59E-05 
45 42630 hsa-miR-140-3p 1.49 3.78E-05 
46 27720 hsa-miR-15a 1.71 1.10E-05 
47 42751 hsa-miR-720 1.76 9.83E-05 




Appendix 3.3.5 Relative abundance of significantly different 
miRNAs in MSCs compared to gastric NTMs, at p < 0.001. 
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No. Probe Id Annotation Relative abundance p-value 
1 46749 hsa-miRPlus-E1033 -2.43 1.23E-04 
2 11041 hsa-miR-29c -1.88 5.43E-05 
3 27217 hsa-miR-34a -1.79 4.92E-05 
4 11014 hsa-miR-214 1.39 3.80E-04 
5 11022 hsa-miR-221 1.6 5.44E-05 
6 11023 hsa-miR-222 1.77 8.99E-04 
7 42630 hsa-miR-140-3p 1.85 1.23E-06 
8 27720 hsa-miR-15a 1.91 5.02E-05 




No. Probe Id Annotation Relative abundance p-value 
1 46871 hsa-miRPlus-F1066 1.23 1.30E-04 
2 46933 hsa-miRPlus-F1026 1.33 3.42E-05 
3 45614 hsa-miRPlus-F1155 1.35 2.49E-04 
4 145745 hsa-miR-335* 1.36 1.39E-04 
5 42730 hsa-miR-423-3p 1.36 9.61E-05 
6 46221 hsa-miR-519d 1.38 2.38E-05 
7 10985 hsa-miR-191 1.40 1.39E-04 
8 145935 hsa-miRPlus-E1232 1.42 5.17E-04 
9 11184 hsa-miR-99b 1.43 5.28E-06 
10 146167 hsa-miR-1979 1.44 2.98E-04 
11 145938 hsa-miRPlus-E1151 1.45 1.01E-07 
12 145805 hsa-miR-765 1.50 3.38E-06 
13 46662 hsa-miRPlus-E1146 1.54 3.25E-05 
14 19596 hsa-miR-30d 1.55 2.98E-04 
15 14285 hsa-miR-487b 1.56 3.09E-04 
16 46801 hsa-miR-106a 1.58 6.95E-04 
17 146008 hsa-miR-26b 1.59 3.67E-05 
18 46353 hsa-miRPlus-F1147 1.60 6.96E-04 
19 42917 hsa-miR-551b 1.61 2.41E-04 
20 42524 hsa-miR-21* 1.61 4.01E-04 
21 145693 hsa-miR-92a 1.62 1.83E-04 
22 145844 hsa-miR-374a 1.68 3.05E-06 
23 10997 hsa-miR-19a 1.70 4.58E-05 
24 42486 hsa-miR-149* 1.72 1.96E-04 
25 42825 hsa-miR-888* 1.73 3.32E-06 
26 42929 hsa-miR-25* 1.73 7.57E-04 
27 46731 hsa-miRPlus-F1017 1.74 1.49E-04 
28 46698 hsa-miR-1280 1.81 6.94E-07 
29 145820 hsa-let-7c 1.83 5.86E-04 
30 145996 hsa-miR-205* 1.83 1.27E-05 
31 46328 hsa-miR-1274b 1.86 2.23E-06 
32 42724 hsa-miR-34b 1.86 2.53E-06 
33 31026 hsa-miR-101 1.93 6.21E-06 
34 145801 hsa-miR-184 1.95 9.35E-04 
35 42539 hsa-miR-933 1.98 8.53E-07 
36 28302 hsa-miRPlus-A1015 1.98 2.41E-05 
37 10998 hsa-miR-19b 2.03 9.05E-06 
38 17927 hsa-miR-491-3p 2.28 1.71E-08 
 
 
Appendix 3.3.6 Relative abundance of significantly 
different miRNAs in MSCs compared to oesophageal 
NTMs, at p < 0.001. 
 
Appendix 3.3.7 Relative abundance of significantly 
different miRNAs in gastric CAMs compared to SC- 
CAMs, at p < 0.001.  
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No. Probe Id Annotation Relative abundance p-value  
1 46861 hsa-miRPlus-E1098 1.25 7.67E-04 
2 145938 hsa-miRPlus-E1151 1.32 3.56E-06 
3 10985 hsa-miR-191 1.37 3.86E-04 
4 145844 hsa-miR-374a 1.40 8.18E-04 
5 145805 hsa-miR-765 1.47 2.67E-05 
6 145983 hsa-miRPlus-E1114 1.49 3.62E-05 
7 42539 hsa-miR-933 1.53 2.51E-04 
8 17927 hsa-miR-491-3p 1.54 8.79E-04 
9 42917 hsa-miR-551b 1.56 9.01E-04 
10 46882 hsa-miRPlus-F1195 1.56 8.41E-04 
11 19596 hsa-miR-30d 1.60 4.22E-04 
12 28302 hsa-miRPlus-A1015 1.66 7.78E-04 









Appendix 3.3.8 Relative abundance of significantly 
different miRNAs in gastric CAMs compared to AC- 
CAMs, at p < 0.001.  
 





Patient hsa-miR-483-3p  Patient hsa-miR-181d 
Sz192 -1.72 Sz192 -1.8 Sz190 2.47 
Sz190 -1.5 Sz268 -1.58 Sz389 1.62 
Sz294 -1.29 Sz389 -1.37 Sz192 1.5 
Sz268 -1.29 Sz194 -1.2 Sz198 1.36 
Sz308 -1.22 Sz305 -1.19 Sz45 1.31 
Sz305 -1.2 Sz308 -1.11 Sz271 1.17 
Sz194 -1.15 Sz45 -1.09 Sz194 1.15 
Sz389 -1.14 Sz190 -1.07 Sz268 1.09 
Sz42 -1.1 Sz294 -1.03 Sz305 1.03 
Sz198 1.03 Sz42 -1.01 Sz294 -1.02 
Sz45 1.15 Sz198 1.09 Sz42 -1.05 
Sz271 1.2 Sz271 1.11 Sz308 -1.17 
Patient hsa-miR-106b Patient hsa-miR-93 Patient hsa-miR-15b 
Sz268 1.69 Sz268 1.71 Sz268 2.19 
Sz192 1.51 Sz192 1.54 Sz305 1.58 
Sz190 1.4 Sz190 1.54 Sz192 1.57 
Sz305 1.38 Sz305 1.45 Sz194 1.49 
Sz194 1.35 Sz194 1.23 Sz190 1.15 
Sz271 1.19 Sz271 1.18 Sz45 1.14 
Sz42 1.1 Sz389 1.05 Sz198 1.11 
Sz308 1 Sz308 1.04 Sz308 1.11 
Sz198 -1.03 Sz294 -1.01 Sz271 1.1 
Sz294 -1.06 Sz42 -1.03 Sz42 -1.01 
Sz389 -1.08 Sz198 -1.08 Sz294 -1.01 
Sz45 -1.1 Sz45 -1.18 Sz389 -1.2 
Patient hsa-miR-130b Patient hsa-miR-32   
Sz190 1.94 Sz190 1.96   
Sz192 1.93 Sz268 1.43   
Sz305 1.34 Sz192 1.41   
Sz268 1.28 Sz45 1.19   
Sz389 1.22 Sz389 1.17   
Sz198 1.1 Sz305 1.16   
Sz308 1.08 Sz198 1.14   
Sz294 1.04 Sz271 1.14   
Sz271 1.02 Sz194 1.04   
Sz194 -1.03 Sz42 1.03   
Sz45 -1.07 Sz294 1.03   
Sz42 -1.11 Sz308 1   
Patient hsa-miR-301a Patient hsa-miR-15a   
Sz190 2.35 Sz268 2.26   
Sz192 1.61 Sz194 1.58   
Sz305 1.41 Sz271 1.41   
Sz268 1.31 Sz190 1.38   
Sz389 1.27 Sz192 1.37   
Sz42 1.08 Sz198 1.11   
Sz308 1.08 Sz305 1.09   
Sz194 1.03 Sz42 -1.01   
Sz198 -1.03 Sz45 -1.01   
Sz271 -1.06 Sz308 -1.03   
Sz45 -1.1 Sz389 -1.07   





Appendix 3.3.9 Relative abundance of 10 miRNAs in paired individual 
samples of gastric CAMs compared to corresponding ATMs from 12 patients. 
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No. Probe Id Annotation Relative abundance p-value 
1 146016 hsa-miR-1978 -1.96 7.78E-04 
2 42965 hsa-miR-424 -1.67 6.02E-04 
3 42641 hsa-miR-145 -1.59 1.48E-02 
4 11014 hsa-miR-214 -1.47 5.82E-04 
5 145725 hsa-miR-518b -1.47 3.98E-03 
6 11030 hsa-miR-26a -1.37 1.03E-03 
7 42679 hsa-miR-642 -1.37 3.38E-03 
8 46883 hsa-miRPlus-E1209 -1.37 3.52E-04 
9 42513 hsa-miR-300 -1.35 5.46E-04 
10 21526 hsa-miRPlus-E1031 1.36 2.64E-02 
11 46506 hsa-miRPlus-E1186 1.37 2.00E-03 
12 46732 hsa-miR-1264 1.38 6.95E-05 
13 46698 hsa-miR-1280 1.40 2.38E-05 
14 42825 hsa-miR-888* 1.42 2.79E-05 
15 145978 hsa-miRPlus-E1258 1.42 4.95E-04 





No. Probe Id Annotation Relative abundance p-value 
1 46258 hsa-miR-1184 -1.45 2.37E-02 
2 46883 hsa-miRPlus-E1209 -1.33 1.27E-02 
3 145801 hsa-miR-184 -1.20 3.20E-02 
4 17482 hsa-miR-411 1.16 1.66E-02 
5 11038 hsa-miR-299-5p 1.19 2.24E-02 
6 42532 hsa-miR-22* 1.20 1.56E-02 
7 11182 hsa-miR-98 1.22 8.20E-03 
8 145820 hsa-let-7c 1.27 3.45E-02 
9 146011 hsa-let-7a 1.29 8.99E-04 
10 17944 hsa-miR-337-5p 1.30 2.68E-02 
11 10987 hsa-miR-193b 1.37 5.92E-03 
12 42744 hsa-miR-23a 1.40 2.56E-02 
13 46483 hsa-miR-27a 1.40 2.38E-02 
14 145944 hsa-miR-27b 1.42 4.81E-02 
15 11052 hsa-miR-31 1.62 4.48E-03 






Appendix 3.3.10 Relative abundance of significantly 
different miRNAs in gastric ATMs compared to NTMs, 
at p < 0.05. 
 
Appendix 3.3.11 Relative abundance of significantly 
different miRNAs in pairwise analysis of SC-CAMs 
compared to SC-ATMs, at p < 0.05 (paired t-test). 
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Patient hsa-miR-1184  Patient hsa-miR-184  Patient hsa-miR-411 
Sz360 -1.78  Sz373 -1.35  Sz306 1.23 
Sz467 -1.58  Sz360 -1.23  Sz373 1.21 
Sz306 -1.29  Sz306 -1.17  Sz467 1.15 
Sz373 -1.23  Sz467 -1.07  Sz360 1.07 
 
Patient hsa-miR-299-5p  Patient hsa-miR-98  Patient hsa-let-7c 
Sz467 1.25  Sz373 1.32  Sz360 1.54 
Sz360 1.25  Sz467 1.22  Sz467 1.24 
Sz373 1.23  Sz306 1.17  Sz306 1.19 
Sz306 1.06  Sz360 1.15  Sz373 1.15 
 
Patient hsa-let-7a  Patient hsa-miR-337-5p  Patient hsa-miR-193b 
Sz373 1.33  Sz373 1.46  Sz467 1.52 
Sz467 1.31  Sz467 1.41  Sz373 1.43 
Sz360 1.29  Sz306 1.29  Sz360 1.31 
Sz306 1.22  Sz360 1.09  Sz306 1.24 
        
Patient hsa-miR-27a  Patient hsa-miR-23a  Patient hsa-miR-27b 
Sz467 1.7  Sz467 1.72  Sz467 1.87 
Sz373 1.5  Sz373 1.49  Sz373 1.5 
Sz360 1.28  Sz360 1.28  Sz306 1.21 
Sz306 1.19  Sz306 1.19  Sz360 1.18 
        
Patient hsa-miR-31  Patient hsa-miR-335    
Sz306 1.9  Sz373 3.87    
Sz360 1.68  Sz306 3.18    
Sz467 1.55  Sz360 2.53    











Appendix 3.3.12 Relative abundance of 14 miRNAs in paired 
individual samples of SC-CAMs compared to corresponding SC-ATMs 
from 4 patients.  
 















No. Probe Id Annotation Relative abundance p-value  
1 42965 hsa-miR-424 -1.72 2.18E-02 
2 42708 hsa-miR-99a -1.67 2.98E-02 
3 145820 hsa-let-7c -1.64 2.32E-03 
4 10306 hsa-miR-146b-5p -1.61 1.55E-02 
5 31026 hsa-miR-101 -1.59 2.54E-02 
6 10987 hsa-miR-193b -1.54 5.03E-04 
7 11052 hsa-miR-31 -1.52 1.82E-02 
8 46320 hsa-miR-31* -1.52 1.54E-02 
9 11030 hsa-miR-26a -1.49 3.46E-02 
10 17749 hsa-let-7b -1.47 7.93E-03 
11 46561 hsa-miRPlus-E1168 -1.47 4.16E-02 
12 5740 hsa-miR-21 -1.43 3.52E-02 
13 30787 hsa-miR-125b -1.41 2.24E-02 
14 10998 hsa-miR-19b -1.41 3.23E-02 
15 145647 hsa-miR-584 -1.39 2.76E-02 
16 146011 hsa-let-7a -1.37 5.91E-03 
17 145832 hsa-miR-381 -1.35 5.69E-03 
18 29379 hsa-miR-452 -1.35 3.75E-02 
19 146001 hsa-miR-1977 1.36 2.17E-02 
20 11039 hsa-miR-29a 1.36 2.68E-03 
21 11022 hsa-miR-221 1.41 7.99E-04 
22 11041 hsa-miR-29c 1.44 3.16E-02 
23 11023 hsa-miR-222 1.50 3.09E-03 
24 146165 hsa-miR-1973 1.65 7.62E-03 
25 46620 hsa-miR-1275 1.70 3.15E-03 
26 11040 hsa-miR-29b 1.87 1.30E-03 
 
No. Probe Id Annotation Relative abundance p-value 
1 10998 hsa-miR-19b -1.61 2.25E-04 
2 31026 hsa-miR-101 -1.59 8.03E-03 
3 145693 hsa-miR-92a -1.56 3.60E-04 
4 10997 hsa-miR-19a -1.49 3.28E-04 
5 42703 hsa-miR-490-3p -1.45 1.02E-02 
6 42708 hsa-miR-99a -1.45 3.97E-02 
7 145845 hsa-miR-20a -1.41 3.74E-03 
8 46801 hsa-miR-106a -1.39 1.31E-02 
9 17927 hsa-miR-491-3p -1.39 8.91E-04 
10 32884 hsa-miR-342-3p -1.35 5.75E-03 
11 17566 hsa-miR-629* -1.35 3.46E-03 
12 11023 hsa-miR-222 1.46 4.01E-03 
13 17506 hsa-miR-24 1.47 4.53E-03 
14 146086 hsa-miR-30a 1.51 4.72E-02 
15 11022 hsa-miR-221 1.54 9.86E-04 
16 145852 hsa-miR-210 1.60 2.67E-02 
17 13140 hsa-miR-138 1.62 1.88E-02 
18 145981 hsa-miR-1285 1.93 5.40E-03 
Appendix 3.3.13 Relative abundance of significantly 
different miRNAs in oesophageal SC-CAMs compared 
to oesophageal NTMs, at p < 0.05. 
 
Appendix 3.3.14 Relative abundance of significantly 
different miRNAs in oesophageal SC-ATMs compared 
to oesophageal NTMs, at p < 0.05. 
 





Annotation Relative abundance p-value 
1 27533 hsa-miR-320a 1.15 2.29E-02 
2 46324 hsa-miR-320b 1.16 2.73E-02 
3 10967 hsa-miR-16 1.19 7.88E-03 
4 31867 hsa-miR-145* 1.34 3.59E-02 




 Sz173 Sz193 Sz282 
hsa-miR-16 1.21 1.16 1.22 
hsa-miR-145 2.04 1.91 1.54 
hsa-miR-320a 1.18 1.10 1.16 












No. Probe Id Annotation Relative abundance p-value 
1 10306 hsa-miR-146b-5p -1.85 8.18E-03 
2 29379 hsa-miR-452 -1.39 2.39E-02 
3 146113 hsa-miRPlus-G1246-3p -1.33 4.41E-04 
4 46923 hsa-miR-1259 -1.32 3.46E-03 
5 46466 hsa-miRPlus-E1016 -1.32 7.02E-03 
6 17944 hsa-miR-337-5p -1.15 3.95E-02 
7 11175 hsa-miR-525-5p 1.16 3.62E-02 
8 45891 hsa-miRPlus-E1285 1.19 3.16E-02 
9 145981 hsa-miR-1285 1.44 2.31E-02 
No. Probe Id Annotation Relative abundance p-value 
1 42965 hsa-miR-424 -1.69 2.18E-02 
2 11030 hsa-miR-26a -1.52 8.78E-03 
3 31026 hsa-miR-101 -1.47 7.17E-03 
4 42708 hsa-miR-99a -1.47 4.44E-02 
5 10306 hsa-miR-146b-5p -1.45 2.87E-02 
6 30787 hsa-miR-125b -1.43 6.62E-03 
7 27217 hsa-miR-34a -1.35 1.21E-02 
8 146200 hsa-miR-1974 1.35 2.14E-02 
9 11040 hsa-miR-29b 1.38 3.73E-02 
10 46292 hsa-miR-1274a 1.50 4.33E-02 
Appendix 3.3.15 Relative abundance of significantly 
different miRNAs in pairwise analysis of AC-CAMs 
compared to AC-ATMs, at p < 0.05 (paired t-test). 
 
Appendix 3.3.16 Relative abundance of 
miRNAs in paired individual samples of 
AC-CAMs compared to corresponding 
AC-ATMs from 3 patients.  
 
Appendix 3.3.17 Relative abundance of significantly 
different miRNAs in oesophageal AC-CAMs 
compared to oesophageal NTMs, at p < 0.05. 
 
Appendix 3.3.18 Relative abundance of significantly 
different miRNAs in oesophageal AC-ATMs 
compared to oesophageal NTMs, at p < 0.05. 
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No. Networks  p-value 
1 Cell cycle_G1-S Growth factor regulation 1.956E-14 
2 Cell cycle_G1-S Interleukin regulation 3.169E-14 
3 Signal transduction_WNT signalling 6.083E-11 
4 Development_Hemopoiesis, Erythropoietin pathway 3.348E-09 
5 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 5.769E-09 
6 Development_EMT_Regulation of epithelial-to-mesenchymal transition 6.642E-09 
7 Reproduction_Male sex differentiation 4.016E-08 
8 Cell cycle_G0-G1 1.475E-07 
9 Proliferation_Positive regulation cell proliferation 1.943E-07 
10 Signal Transduction_TGF-beta, GDF and Activin signalling 2.951E-07 
11 Cell cycle_Core 3.402E-07 
12 DNA damage_Checkpoint 1.483E-06 
13 Reproduction_Feeding and Neurohormone signalling 1.761E-06 
14 Development_Hedgehog signalling 3.903E-06 
15 Development_Regulation of telomere length 4.668E-06 
16 Cell cycle_G1-S 6.524E-06 
17 Inflammation_IL-2 signalling 1.400E-05 
18 Inflammation_IL-10 anti-inflammatory response 1.653E-05 
19 Signal transduction_Leptin signalling 2.653E-05 
20 Cardiac development_BMP_TGF_beta_signalling 2.711E-05 
21 Inflammation_MIF signalling 3.075E-05 
22 Reproduction_FSH-beta signalling pathway 4.991E-05 
23 Signal transduction_NOTCH signalling 5.538E-05 
24 Development_Regulation of angiogenesis 6.641E-05 
25 Immune response_TCR signalling 6.981E-05 
26 Reproduction_Progesterone signalling 7.596E-05 
27 Proliferation_Negative regulation of cell proliferation 9.736E-05 
28 Signal transduction_Androgen receptor nuclear signalling 1.168E-04 
29 Development_Ossification and bone remodelling 1.183E-04 
30 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and JAK/STAT 1.276E-04 
31 Cardiac development_Role of NADPH oxidase and ROS 1.443E-04 
32 Inflammation_IL-6 signalling 1.640E-04 
33 Signal transduction_ESR1-nuclear pathway 2.376E-04 
34 Development_Blood vessel morphogenesis 2.900E-04 
35 Inflammation_IFN-gamma signalling 5.347E-04 
36 Signal Transduction_BMP and GDF signalling 5.945E-04 
37 Signal transduction_Androgen receptor signalling cross-talk 6.191E-04 
38 Cell cycle_G2-M 7.777E-04 
39 Apoptosis_Apoptosis stimulation by external signals 8.402E-04 
40 Immune response_Th17-derived cytokines 1.006E-03 
41 Development_Keratinocyte differentiation 1.063E-03 
42 Signal Transduction_Cholecystokinin signalling 1.401E-03 
43 Reproduction_Spermatogenesis, motility and copulation 1.459E-03 
44 Proliferation_Lymphocyte proliferation 1.566E-03 
45 Apoptosis_Anti-apoptosis mediated by external signals via NF-kB 1.906E-03 
46 Inflammation_Jak-STAT Pathway 1.969E-03 
47 Signal transduction_ERBB-family signalling 2.353E-03 
48 Inflammation_IL-4 signalling 3.038E-03 
49 Inflammation_Kallikrein-kinin system 3.610E-03 
50 Inflammation_Interferon signalling 3.610E-03 
 
 
Appendix 4.3.1 Networks enriched by targets of differentially abundant 
miRNAs in pairwise analysis of gastric CAMs compared to ATMs. 
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No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 7.626E-11 
2 Development_EMT_Regulation of epithelial-to-mesenchymal transition 1.694E-09 
3 Cell cycle_G1-S Interleukin regulation 1.376E-07 
4 Reproduction_FSH-beta signalling pathway 2.353E-06 
5 Signal Transduction_TGF-beta, GDF and Activin signalling 3.952E-06 
6 Development_Hemopoiesis, Erythropoietin pathway 6.901E-06 
7 Inflammation_IL-10 anti-inflammatory response 1.572E-05 
8 DNA damage_Checkpoint 2.295E-05 
9 Signal transduction_Leptin signalling 2.394E-05 
10 Signal transduction_WNT signalling 3.577E-05 
11 Signal transduction_NOTCH signalling 4.388E-05 
12 Proliferation_Positive regulation cell proliferation 4.607E-05 
13 Reproduction_Male sex differentiation 3.119E-04 
14 Development_Regulation of angiogenesis 3.959E-04 
15 Development_Ossification and bone remodelling 4.260E-04 
16 Development_Hedgehog signalling 5.265E-04 
17 Development_Blood vessel morphogenesis 5.672E-04 
18 Proliferation_Negative regulation of cell proliferation 8.177E-04 
19 Signal transduction_Androgen receptor signalling cross-talk 9.207E-04 
20 Signal transduction_ESR1-nuclear pathway 1.039E-03 
21 Cell cycle_G1-S 1.216E-03 
22 Cell cycle_Core 2.515E-03 
23 Signal transduction_Nitric oxide signalling 4.472E-03 
24 Signal transduction_ERBB-family signalling 4.472E-03 
25 Cardiac development_BMP_TGF_beta_signalling 5.830E-03 
26 Cell adhesion_Cadherins 7.056E-03 
27 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and JAK/STAT 7.416E-03 
28 Cell adhesion_Glycoconjugates 9.577E-03 
29 Cell cycle_G0-G1 9.577E-03 





Appendix 4.3.2 Networks enriched by targets of differentially 
abundant miRNAs in gastric CAMs compared to NTMs. 
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No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 7.361E-13 
2 Cell cycle_G1-S Interleukin regulation 2.075E-10 
3 Development_EMT_Regulation of epithelial-to-mesenchymal transition 2.360E-08 
4 Signal Transduction_TGF-beta, GDF and Activin signalling 1.292E-07 
5 Signal transduction_WNT signalling 1.620E-07 
6 Development_Hemopoiesis, Erythropoietin pathway 2.342E-07 
7 DNA damage_Checkpoint 9.375E-07 
8 Reproduction_FSH-beta signalling pathway 7.032E-06 
9 Inflammation_IL-10 anti-inflammatory response 7.076E-06 
10 Signal transduction_NOTCH signalling 1.366E-05 
11 Signal transduction_Androgen receptor signalling cross-talk 4.972E-05 
12 Inflammation_MIF signalling 6.923E-05 
13 Cell cycle_G1-S 9.537E-05 
14 Proliferation_Positive regulation cell proliferation 1.018E-04 
15 Reproduction_Male sex differentiation 1.232E-04 
16 Cell cycle_Core 2.024E-04 
17 Reproduction_Feeding and Neurohormone signalling 2.485E-04 
18 Signal transduction_ERBB-family signalling 2.955E-04 
19 Proliferation_Negative regulation of cell proliferation 3.622E-04 
20 Signal transduction_ESR1-membrane pathway 4.770E-04 
21 Development_Hedgehog signalling 1.082E-03 
22 Development_Ossification and bone remodelling 1.360E-03 
23 Cardiac development_Role of NADPH oxidase and ROS 1.553E-03 
24 Inflammation_IL-4 signalling 2.115E-03 
25 Proliferation_Lymphocyte proliferation 2.687E-03 
26 Signal transduction_Nitric oxide signalling 2.912E-03 
27 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 3.541E-03 
28 Cell adhesion_Cadherins 3.933E-03 
29 Immune response_Innate immune response to RNA viral infection 4.211E-03 
30 Cell adhesion_Glycoconjugates 6.324E-03 
31 Cell cycle_G0-G1 6.324E-03 
32 Immune response_Th17-derived cytokines 6.324E-03 
33 Development_Blood vessel morphogenesis 6.697E-03 
34 Cell adhesion_Platelet-endothelium-leucocyte interactions 7.642E-03 
35 Reproduction_Progesterone signalling 7.650E-03 
36 Immune response_T helper cell differentiation 7.881E-03 
37 Signal transduction_Leptin signalling 7.881E-03 
38 Signal transduction_ESR1-nuclear pathway 7.995E-03 
39 Translation_Regulation of initiation 1.376E-02 
40 Development_Keratinocyte differentiation 1.391E-02 
41 Signal Transduction_BMP and GDF signalling 1.400E-02 





Appendix 4.3.3 Networks enriched by targets of differentially 
abundant miRNAs in gastric ATMs compared to NTMs. 
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No. Networks p-value 
1 Signal Transduction_TGF-beta, GDF and Activin signalling 2.429E-11 
2 Signal Transduction_BMP and GDF signalling 3.065E-07 
3 Cell cycle_G1-S Growth factor regulation 6.057E-07 
4 Development_Hedgehog signalling 6.216E-07 
5 Reproduction_Feeding and Neurohormone signalling 1.828E-06 
6 Signal transduction_ESR1-nuclear pathway 1.963E-06 
7 Cell cycle_G1-S Interleukin regulation 2.853E-06 
8 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 1.026E-05 
9 Development_Blood vessel morphogenesis 1.151E-05 
10 Signal transduction_NOTCH signalling 1.395E-05 
11 Development_Hemopoiesis, Erythropoietin pathway 1.594E-05 
12 Proliferation_Negative regulation of cell proliferation 2.550E-05 
13 Proliferation_Positive regulation cell proliferation 5.401E-05 
14 Cell cycle_G1-S 6.556E-05 
15 Signal transduction_ESR1-membrane pathway 1.145E-04 
16 Transcription_Nuclear receptors transcriptional regulation 2.216E-04 
17 Cardiac development_Role of NADPH oxidase and ROS 2.274E-04 
18 Reproduction_Progesterone signalling 2.376E-04 
19 Signal transduction_Androgen receptor signaling cross-talk 2.782E-04 
20 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 2.782E-04 
21 Reproduction_Male sex differentiation 3.343E-04 
22 Apoptosis_Apoptosis stimulation by external signals 3.441E-04 
23 Development_EMT_Regulation of epithelial-to-mesenchymal transition 4.244E-04 
24 Cell cycle_G0-G1 4.569E-04 
25 Inflammation_TREM1 signalling 4.606E-04 
26 Signal transduction_WNT signalling 5.121E-04 
27 Development_Regulation of telomere length 7.711E-04 
28 Development_Neurogenesis in general 7.826E-04 
29 Inflammation_IL-10 anti-inflammatory response 7.980E-04 
30 Immune response_Th17-derived cytokines 7.980E-04 
31 Development_Skeletal muscle development 8.164E-04 
32 Inflammation_Jak-STAT Pathway 9.515E-04 
33 Inflammation_IL-6 signalling 1.017E-03 
34 Cardiac development_Wnt_beta-catenin, Notch, VEGF, IP3 and integrin 
signalling 
1.026E-03 
35 Apoptosis_Anti-apoptosis mediated by external signals via NF-kB 1.315E-03 
36 Development_Ossification and bone remodelling 1.802E-03 
37 Reproduction_Spermatogenesis, motility and copulation 1.932E-03 
38 Reproduction_FSH-beta signalling pathway 2.056E-03 
39 Inflammation_MIF signalling 3.356E-03 
40 Response to hypoxia and oxidative stress 3.853E-03 
41 Development_Keratinocyte differentiation 3.919E-03 
42 Proteolysis_ECM remodelling 7.368E-03 
43 Cardiac development_BMP_TGF_beta_signalling 8.193E-03 
44 Development_Regulation of angiogenesis 8.401E-03 
45 Cell cycle_G2-M 1.083E-02 
46 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and 
JAK/STAT 
1.128E-02 
47 Cardiac development_FGF_ErbB signalling 1.165E-02 
48 Development_Cartilage development 1.200E-02 
49 Cell adhesion_Integrin-mediated cell-matrix adhesion 1.202E-02 




Appendix 4.3.4 Networks enriched by targets of differentially 
abundant miRNAs in pairwise analysis of oesophageal SC-CAMs 
compared to SC-ATMs.  
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No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 2.553E-12 
2 Cell cycle_G0-G1 7.493E-12 
3 Cell cycle_G1-S Interleukin regulation 1.352E-11 
4 Cell cycle_G1-S 5.318E-10 
5 Development_Hemopoiesis, Erythropoietin pathway 7.016E-10 
6 Development_Hedgehog signalling 3.328E-09 
7 Signal transduction_NOTCH signalling 3.772E-09 
8 Development_EMT_Regulation of epithelial-to-mesenchymal transition 5.174E-09 
9 Cell cycle_Core 9.081E-09 
10 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 9.133E-09 
11 Signal Transduction_TGF-beta, GDF and Activin signalling 2.708E-08 
12 Development_Regulation of telomere length 4.526E-08 
13 Proliferation_Positive regulation cell proliferation 1.399E-07 
14 Proliferation_Negative regulation of cell proliferation 1.939E-07 
15 Immune response_Th17-derived cytokines 2.851E-07 
16 Signal transduction_WNT signalling 4.613E-07 
17 Inflammation_MIF signalling 9.048E-07 
18 Cardiac development_Role of NADPH oxidase and ROS 1.028E-06 
19 DNA damage_Checkpoint 1.028E-06 
20 Reproduction_Progesterone signalling 1.362E-06 
21 Signal transduction_Androgen receptor signalling cross-talk 2.397E-06 
22 Development_Blood vessel morphogenesis 9.009E-06 
23 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 1.732E-05 
24 Cardiac development_Wnt_beta-catenin, Notch, VEGF, IP3 and integrin signalling 2.469E-05 
25 Signal transduction_ESR1-nuclear pathway 3.755E-05 
26 Inflammation_Interferon signalling 5.716E-05 
27 Reproduction_Feeding and Neurohormone signalling 6.527E-05 
28 Inflammation_IL-10 anti-inflammatory response 8.036E-05 
29 Cardiac development_BMP_TGF_beta_signalling 1.496E-04 
30 Cell adhesion_Amyloid proteins 1.503E-04 
31 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and JAK/STAT 1.668E-04 
32 Apoptosis_Apoptosis stimulation by external signals 1.799E-04 
33 Signal transduction_Androgen receptor nuclear signalling 1.987E-04 
34 Apoptosis_Apoptotic mitochondria 2.161E-04 
35 Inflammation_IL-2 signalling 4.203E-04 
36 Signal Transduction_BMP and GDF signalling 5.077E-04 
37 Inflammation_Amphoterin signalling 6.345E-04 
38 Apoptosis_Endoplasmic reticulum stress pathway 6.975E-04 
39 Apoptosis_Apoptotic nucleus 7.614E-04 
40 Immune response_TCR signalling 8.972E-04 
41 Signal transduction_ERBB-family signalling 1.063E-03 
42 Cardiac development_FGF_ErbB signalling 1.078E-03 
43 Autophagy_Autophagy 1.595E-03 
44 Signal transduction_ESR1-membrane pathway 1.729E-03 
45 DNA damage_Core 2.217E-03 
46 Inflammation_IL-4 signalling 2.514E-03 
47 Apoptosis_Anti-apoptosis mediated by external signals via NF-kB 3.304E-03 
48 Development_Regulation of angiogenesis 3.529E-03 
49 Signal Transduction_Cholecystokinin signalling 4.023E-03 




Appendix 4.3.5 Networks enriched by targets of differentially abundant 
miRNAs in oesophageal SC-CAMs compared to oesophageal NTMs.  
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No. Networks p-value 
1 Development_EMT_Regulation of epithelial-to-mesenchymal transition 3.251E-16 
2 Signal Transduction_TGF-beta, GDF and Activin signalling 3.434E-14 
3 Cell cycle_G1-S Growth factor regulation 6.050E-13 
4 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 1.050E-12 
5 Reproduction_Feeding and Neurohormone signalling 2.405E-11 
6 Signal Transduction_BMP and GDF signalling 1.799E-09 
7 Inflammation_MIF signalling 3.133E-09 
8 Signal transduction_Androgen receptor signalling cross-talk 3.463E-09 
9 Signal transduction_WNT signalling 3.948E-09 
10 Development_Cartilage development 9.792E-09 
11 Reproduction_FSH-beta signalling pathway 3.808E-08 
12 Immune response_Th17-derived cytokines 6.182E-08 
13 Proliferation_Negative regulation of cell proliferation 8.582E-08 
14 Cell cycle_G1-S Interleukin regulation 8.994E-08 
15 Cell adhesion_Cell-matrix interactions 1.686E-07 
16 Apoptosis_Apoptosis stimulation by external signals 3.012E-07 
17 Development_Hemopoiesis, Erythropoietin pathway 3.557E-07 
18 Development_Regulation of angiogenesis 4.285E-07 
19 Signal transduction_ESR1-nuclear pathway 8.043E-07 
20 Proliferation_Positive regulation cell proliferation 1.292E-06 
21 Signal transduction_NOTCH signalling 1.691E-06 
22 Development_Ossification and bone remodelling 2.110E-06 
23 Signal transduction_Nitric oxide signalling 3.657E-06 
24 Signal transduction_ERBB-family signalling 3.722E-06 
25 Reproduction_Progesterone signalling 4.083E-06 
26 Inflammation_TREM1 signalling 6.987E-06 
27 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 7.915E-06 
28 Cell adhesion_Platelet-endothelium-leucocyte interactions 9.622E-06 
29 Reproduction_Male sex differentiation 9.853E-06 
30 Apoptosis_Endoplasmic reticulum stress pathway 2.654E-05 
31 Apoptosis_Apoptotic nucleus 3.019E-05 
32 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and JAK/STAT 3.324E-05 
33 DNA damage_Checkpoint 3.378E-05 
34 Development_Hedgehog signalling 4.008E-05 
35 Signal transduction_ESR1-membrane pathway 4.619E-05 
36 Proteolysis_ECM remodelling 4.668E-05 
37 Apoptosis_Apoptotic mitochondria 4.668E-05 
38 Immune response_TCR signalling 5.122E-05 
39 Cell adhesion_Amyloid proteins 5.210E-05 
40 Inflammation_Amphoterin signalling 5.322E-05 
41 Cell cycle_G1-S 5.426E-05 
42 Inflammation_IL-10 anti-inflammatory response 5.616E-05 
43 Cell adhesion_Integrin-mediated cell-matrix adhesion 6.794E-05 
44 Cell cycle_G0-G1 9.793E-05 
45 Cardiac development_BMP_TGF_beta_signalling 1.038E-04 
46 Signal transduction_Leptin signalling 1.188E-04 
47 Cell cycle_Core 1.577E-04 
48 Cardiac development_FGF_ErbB signaling 2.345E-04 
49 Cardiac development_Role of NADPH oxidase and ROS 3.860E-04 




Appendix 4.3.6 Networks enriched by targets of differentially 
abundant miRNAs in oesophageal SC-ATMs compared to 
oesophageal NTMs.  
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No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 1.026E-14 
2 Cell cycle_G1-S Interleukin regulation 2.779E-10 
3 Development_EMT_Regulation of epithelial-to-mesenchymal transition 2.814E-09 
4 Inflammation_MIF signalling 4.128E-09 
5 Reproduction_Feeding and Neurohormone signalling 6.526E-09 
6 Signal Transduction_TGF-beta, GDF and Activin signalling 2.959E-08 
7 DNA damage_Checkpoint 1.363E-07 
8 Development_Hemopoiesis, Erythropoietin pathway 1.918E-07 
9 Inflammation_IL-2 signalling 2.769E-07 
10 Proliferation_Negative regulation of cell proliferation 8.930E-07 
11 Signal transduction_ESR1-nuclear pathway 1.597E-06 
12 Reproduction_FSH-beta signalling pathway 2.522E-06 
13 Proliferation_Positive regulation cell proliferation 2.639E-06 
14 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 3.358E-06 
15 Cell cycle_G0-G1 3.917E-06 
16 Cell cycle_G1-S 4.581E-06 
17 Reproduction_Male sex differentiation 4.976E-06 
18 Inflammation_IL-10 anti-inflammatory response 5.196E-06 
19 Signal transduction_ESR1-membrane pathway 5.957E-06 
20 Reproduction_Progesterone signalling 2.378E-05 
21 Cell cycle_Core 2.828E-05 
22 Signal transduction_WNT signalling 6.335E-05 
23 Signal transduction_Androgen receptor signaling cross-talk 2.294E-04 
24 Signal transduction_CREM pathway 2.856E-04 
25 Immune response_Th17-derived cytokines 3.898E-04 
26 Development_Regulation of angiogenesis 4.206E-04 
27 Cell adhesion_Platelet-endothelium-leucocyte interactions 8.719E-04 
28 Apoptosis_Anti-apoptosis mediated by external signals via NF-kB 8.872E-04 
29 Signal transduction_Nitric oxide signalling 1.243E-03 
30 Development_Blood vessel morphogenesis 1.336E-03 
31 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 1.372E-03 
32 Inflammation_IL-4 signalling 1.425E-03 
33 Inflammation_IFN-gamma signalling 1.773E-03 
34 Inflammation_Amphoterin signalling 1.902E-03 
35 Immune response_BCR pathway 2.039E-03 
36 Cell cycle_G2-M 2.277E-03 
37 Signal transduction_Leptin signalling 2.361E-03 
38 Development_Hedgehog signalling 2.914E-03 
39 Signal transduction_NOTCH signalling 3.976E-03 
40 Inflammation_Jak-STAT Pathway 6.634E-03 
41 Inflammation_IL-13 signalling pathway 7.474E-03 
42 Cytoskeleton_Macropinocytosis and its regulation 9.432E-03 
43 Inflammation_IL-6 signalling 1.047E-02 
44 Signal transduction_ERBB-family signalling 1.252E-02 
45 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and JAK/STAT 1.269E-02 
46 Reproduction_Spermatogenesis, motility and copulation 1.430E-02 
47 Inflammation_Interferon signalling 1.430E-02 




Appendix 4.3.7 Networks enriched by targets of differentially 
abundant miRNAs in pairwise analysis of oesophageal AC-CAMs 
compared to AC-ATMs. 
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No. Networks p-value 
1 Signal Transduction_TGF-beta, GDF and Activin signalling 3.320E-04 
2 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 4.523E-04 
3 Signal transduction_ESR1-membrane pathway 7.999E-04 
4 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 8.117E-04 
5 Proliferation_Negative regulation of cell proliferation 9.834E-04 
6 Development_Regulation of angiogenesis 1.471E-03 
7 Inflammation_MIF signalling 1.712E-03 
8 Signal transduction_ESR1-nuclear pathway 2.107E-03 
9 Signal transduction_NOTCH signalling 2.292E-03 
10 Inflammation_TREM1 signalling 2.552E-03 
11 Apoptosis_Apoptosis stimulation by external signals 4.286E-03 
12 Reproduction_FSH-beta signalling pathway 5.035E-03 
13 Cell adhesion_Platelet-endothelium-leucocyte interactions 5.859E-03 


















Appendix 4.3.8 Networks enriched by targets of differentially 
abundant miRNAs in oesophageal AC-CAMs compared to 
oesophageal NTMs.  
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No. Networks p-value 
1 Cell cycle_G1-S Growth factor regulation 1.147E-11 
2 Development_EMT_Regulation of epithelial-to-mesenchymal transition 1.465E-11 
3 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 2.528E-10 
4 Signal transduction_WNT signalling 2.860E-09 
5 Reproduction_Feeding and Neurohormone signalling 7.628E-09 
6 Proliferation_Negative regulation of cell proliferation 2.446E-08 
7 Reproduction_Progesterone signalling 7.273E-08 
8 Inflammation_MIF signalling 9.110E-08 
9 Signal transduction_ESR1-membrane pathway 2.318E-07 
10 Signal Transduction_TGF-beta, GDF and Activin signalling 2.858E-07 
11 Signal transduction_Androgen receptor signalling cross-talk 4.710E-07 
12 DNA damage_Checkpoint 7.495E-07 
13 Signal transduction_ESR1-nuclear pathway 7.712E-07 
14 Cell cycle_G1-S Interleukin regulation 9.904E-07 
15 Signal transduction_NOTCH signalling 4.617E-06 
16 Signal transduction_ERBB-family signalling 4.899E-06 
17 Development_Cartilage development 4.899E-06 
18 Immune response_Th17-derived cytokines 1.000E-05 
19 Reproduction_FSH-beta signalling pathway 1.049E-05 
20 Reproduction_Male sex differentiation 2.428E-05 
21 Apoptosis_Apoptosis stimulation by external signals 2.654E-05 
22 Cardiac development_FGF_ErbB signalling 3.890E-05 
23 Proliferation_Positive regulation cell proliferation 4.507E-05 
24 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and JAK/STAT 5.425E-05 
25 Cell cycle_G0-G1 5.833E-05 
26 Development_Hemopoiesis, Erythropoietin pathway 8.825E-05 
27 Signal Transduction_BMP and GDF signalling 1.127E-04 
28 Development_Hedgehog signalling 1.286E-04 
29 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 1.307E-04 
30 Development_Ossification and bone remodelling 1.763E-04 
31 Development_Regulation of angiogenesis 1.907E-04 
32 Muscle contraction_Relaxin signalling 2.474E-04 
33 Cell cycle_G2-M 2.891E-04 
34 Inflammation_IL-10 anti-inflammatory response 4.579E-04 
35 Cell adhesion_Cell-matrix interactions 5.161E-04 
36 Signal transduction_Nitric oxide signalling 7.083E-04 
37 Cell cycle_Core 7.858E-04 
38 Apoptosis_Endoplasmic reticulum stress pathway 9.205E-04 
39 DNA damage_Core 9.742E-04 
40 Apoptosis_Apoptotic mitochondria 1.025E-03 
41 Cell adhesion_Platelet-endothelium-leucocyte interactions 1.295E-03 
42 Apoptosis_Apoptotic nucleus 1.416E-03 
43 Immune response_IL-5 signalling 1.429E-03 
44 Inflammation_IL-2 signalling 1.679E-03 
45 Cell cycle_G1-S 1.947E-03 
46 Cardiac development_BMP_TGF_beta_signalling 2.035E-03 
47 Cell adhesion_Amyloid proteins 2.247E-03 
48 Reproduction_Gonadotropin regulation 2.584E-03 
49 Apoptosis_Anti-apoptosis mediated by external signals via NF-kB 4.987E-03 




Appendix 4.3.9 Networks enriched by targets of differentially 
abundant miRNAs in oesophageal AC-ATMs compared to 
oesophageal NTMs.  
 









(out of 12) 
1 Cell cycle_G1-S Growth factor regulation Patient 2 1.98E-04 1.42E-21 11 
   Patient 3 4.04E-13 
   Patient 4 4.39E-15 
   Patient 5 1.60E-17 
   Patient 6 1.15E-07 
   Patient 7 1.42E-21 
   Patient 8 1.14E-11 
   Patient 9 2.34E-02 
   Patient 10 1.37E-13 
   Patient 11 7.67E-04 
    Patient 12 4.38E-13 
2 Cell cycle_G1-S Interleukin regulation  Patient 2 1.79E-06 1.54E-21 
 
10 
  Patient 3 2.17E-09  
    Patient 4 9.23E-14  
    Patient 5 8.28E-17  
    Patient 6 1.51E-05  
    Patient 7 1.54E-21  
    Patient 8 3.39E-07  
    Patient 10 1.71E-13  
    Patient 11 1.01E-05  
    Patient 12 3.40E-11  
3 Signal Transduction_TGF-beta, GDF and Activin signaling Patient 3 3.84E-17 3.84E-17 10 
    Patient 4 2.36E-08  
    Patient 5 2.21E-07  
    Patient 6 6.55E-09  
    Patient 7 3.37E-09  
    Patient 8 3.85E-15  
    Patient 9 1.26E-02  
    Patient 10 1.15E-07  
    Patient 11 2.71E-03  
    Patient 12 2.43E-14  
4 Development_EMT_Regulation of epithelial-to- Patient 2 7.16E-04 6.72E-17 10 
 mesenchymal transition  Patient 3 6.72E-17  
    Patient 4 7.03E-11  
    Patient 5 2.22E-11  
    Patient 6 1.36E-06  
    Patient 7 9.45E-14  
    Patient 8 1.56E-13  
    Patient 9 4.01E-02  
    Patient 10 3.14E-08  
    Patient 12 5.84E-12  
5 Signal transduction_NOTCH signaling Patient 2 4.66E-03 1.24E-11 9 
    Patient 3 1.24E-11   
    Patient 4 9.78E-13   
    Patient 5 4.14E-08   
    Patient 6 5.53E-03   
    Patient 7 3.82E-14   
    Patient 8 6.87E-08   
    Patient 10 2.40E-11   
    Patient 12 1.22E-07   
6 Signal transduction_WNT signaling Patient 1 4.65E-03 2.25E-11 12 
    Patient 2 4.42E-04  
    Patient 3 2.25E-11  
    Patient 4 9.85E-10  
    Patient 5 1.27E-09  
    Patient 6 2.89E-04  
    Patient 7 2.19E-13  
    Patient 8 2.34E-06 
    Patient 9 1.33E-02 
    Patient 10 1.52E-07 
    Patient 11 2.26E-02  
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7 Apoptosis_Anti-Apoptosis mediated by external signals via  Patient 3 1.50E-10 1.50E-10 8 
  PI3K/AKT  Patient 4 9.42E-07  
    Patient 5 5.29E-08  
    Patient 7 5.04E-09  
    Patient 8 2.34E-06  
    Patient 9 1.39E-03  
    Patient 10 6.80E-06  
    Patient 12 3.37E-05  
8 Reproduction_FSH-beta signaling pathway Patient 3 1.74E-10 1.74E-10 9 
    Patient 4 2.78E-07  
    Patient 5 1.51E-05  
    Patient 6 3.14E-06  
    Patient 7 4.99E-08  
    Patient 8 1.38E-07  
    Patient 10 5.29E-04  
    Patient 11 2.20E-03  
     Patient 12 5.71E-08  
9 Inflammation_IL-10 anti-inflammatory response Patient 2 1.51E-03 3.85E-10 11 
    Patient 3 4.39E-03  
    Patient 4 1.88E-05  
    Patient 5 3.85E-10  
    Patient 6 1.06E-02  
    Patient 7 1.07E-07  
    Patient 8 3.97E-06  
    Patient 9 1.90E-03  
    Patient 10 1.58E-03  
    Patient 11 2.10E-04  
    Patient 12 1.47E-07  
10 Proliferation_Negative regulation of cell proliferation Patient 2 1.89E-05 1.05E-09 11 
    Patient 3 1.52E-04  
    Patient 4 3.19E-06  
    Patient 5 1.69E-07  
    Patient 6 1.82E-04  
    Patient 7 2.66E-06  
    Patient 8 5.73E-06  
    Patient 9 2.13E-02  
    Patient 10 1.40E-06  
    Patient 11 3.55E-02  
    Patient 12 1.05E-09  
11 Proliferation_Positive regulation cell proliferation Patient 2 1.69E-03 1.48E-09 9 
    Patient 3 1.48E-09  
    Patient 4 5.88E-09  
    Patient 5 1.17E-05  
    Patient 7 1.81E-08  
    Patient 8 1.66E-05  
    Patient 9 2.61E-02  
    Patient 10 1.89E-05  
     Patient 12 2.25E-05  
12 Inflammation_TREM1 signaling Patient 3 6.20E-03 3.56E-09 8 
    Patient 4 9.24E-04  
    Patient 5 3.56E-09  
   
  
 Patient 7 1.17E-08  
Patient 8 9.76E-04 
    Patient 9 6.15E-03  
    Patient 10 1.75E-05  
     Patient 12 7.00E-03  
13 Reproduction_Progesterone signaling Patient 3 1.21E-04 1.60E-08 9 
    Patient 4 1.39E-04   
    Patient 5 3.09E-06   
    Patient 7 1.60E-08   
    Patient 8 2.25E-02   
    Patient 9 2.03E-02   
    Patient 10 3.48E-05   
    Patient 11 3.39E-02   
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14 Cell cycle_G0-G1 Patient 1 4.76E-03 2.87E-08 10 
    Patient 2 8.46E-06   
    Patient 3 1.12E-06   
    Patient 4 1.88E-05   
    Patient 5 3.83E-07   
    Patient 6 1.06E-02   
    Patient 7 1.07E-07   
    Patient 8 2.74E-05   
    Patient 10 2.87E-08   
     Patient 12 1.45E-06   
15 Development_Hedgehog signaling Patient 3 3.20E-07 3.03E-08 8 
    Patient 4 4.01E-06  
    Patient 5 7.75E-07  
    Patient 6 3.78E-02  
    Patient 7 3.03E-08  
    Patient 8 1.19E-06  
    Patient 10 1.32E-05  
     Patient 12 3.03E-04  
16 Development_Regulation of angiogenesis Patient 2 1.27E-02 4.09E-08 10 
    Patient 3 4.09E-08  
    Patient 4 1.13E-04  
    Patient 5 2.09E-06  
    Patient 6 5.93E-04  
    Patient 7 1.64E-06  
    Patient 8 3.21E-08  
    Patient 9 5.20E-04  
    Patient 10 7.76E-04  
     Patient 12 1.27E-05  
17 Cell cycle_Core Patient 2 1.34E-06 6.51E-08 9 
    Patient 3 5.88E-06  
    Patient 4 4.07E-05  
    Patient 5 1.36E-07  
    Patient 6 5.56E-04  
    Patient 7 6.51E-08  
    Patient 8 2.24E-03  
    Patient 10 1.03E-06  
     Patient 12 8.28E-07  
18 Signal transduction_ERBB-family signaling Patient 3 1.06E-03 6.61E-08 9 
    Patient 4 5.86E-04  
    Patient 5 1.62E-04  
   
  
 Patient 6 4.99E-03  
Patient 7 6.61E-08 
    Patient 8 2.82E-05  
    Patient 10 5.96E-06  
    Patient 11 2.52E-02  
     Patient 12 1.13E-03  
19 Reproduction_Feeding and Neurohormone signaling Patient 3 8.44E-05 2.74E-07 8 
    Patient 4 1.56E-06  
    Patient 5 4.20E-07  
    Patient 6 4.72E-02  
    Patient 7 2.74E-07  
    Patient 8 7.06E-03  
    Patient 10 7.91E-07  
     Patient 12 2.67E-05  
20 Apoptosis_Apoptosis stimulation by external signals Patient 3 1.76E-06 2.83E-07 8 
    Patient 4 8.49E-03  
    Patient 5 3.18E-05  
    Patient 6 1.64E-02  
    Patient 7 7.15E-05  
    Patient 8 2.83E-07  
    Patient 10 3.09E-04  
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21 Cell adhesion_Platelet-endothelium-leucocyte interactions Patient 1 1.92E-02 7.10E-07 9 
    Patient 3 4.93E-06  
    Patient 4 2.04E-03  
    Patient 5 4.00E-06  
    Patient 7 9.88E-06  
    Patient 8 2.77E-05  
    Patient 9 2.18E-06  
    Patient 10 5.07E-03  
     Patient 12 7.10E-07  
22 Signal transduction_ESR1-nuclear pathway Patient 2 1.95E-02 1.43E-06 8 
    Patient 3 1.43E-06  
    Patient 4 4.00E-06  
    Patient 5 3.66E-03  
    Patient 7 1.11E-04  
    Patient 8 4.19E-06  
    Patient 10 1.76E-02  
     Patient 12 6.37E-03  
23 Immune response_Th17-derived cytokines Patient 2 1.38E-02 1.45E-06 11 
    Patient 3 4.37E-05  
    Patient 4 1.09E-04  
    Patient 5 3.07E-06  
    Patient 6 1.06E-02  
    Patient 7 6.50E-06  
    Patient 8 2.74E-05  
    Patient 9 1.90E-03  
    Patient 10 3.49E-06  
    Patient 11 3.34E-03  
     Patient 12 1.45E-06  
24 Cardiac development_BMP_TGF_beta_signaling Patient 2 3.25E-02 2.07E-06 9 
    Patient 3 2.07E-06  
    Patient 4 1.67E-03  
   
  
 Patient 5 2.07E-02  
Patient 6 6.64E-03 
    Patient 7 9.78E-03  
    Patient 8 1.96E-05  
    Patient 10 8.18E-03  
     Patient 12 9.47E-04  
25 Translation_Regulation of initiation Patient 3 4.43E-03 2.52E-06 8 
    Patient 4 6.41E-04  
    Patient 5 1.45E-02  
    Patient 6 2.48E-02  
    Patient 7 2.52E-06  
    Patient 8 1.70E-02  
    Patient 10 2.92E-03  
     Patient 12 7.49E-03  
26 Cell adhesion_Glycoconjugates Patient 1 4.68E-02 3.07E-06 10 
    Patient 3 4.39E-03  
    Patient 4 3.32E-02  
    Patient 5 3.07E-06  
    Patient 6 1.06E-02  
    Patient 7 4.25E-05  
    Patient 8 2.74E-05  
    Patient 9 2.61E-02  
    Patient 11 3.74E-02  
     Patient 12 9.54E-05  
27 Reproduction_Male sex differentiation Patient 2 1.99E-03 6.45E-06 9 
    Patient 3 1.75E-05  
    Patient 4 4.84E-03  
    Patient 5 1.82E-05  
    Patient 7 1.32E-05  
    Patient 8 6.45E-06  
    Patient 10 1.24E-04  
    Patient 11 8.12E-03  
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28 Inflammation_IL-4 signaling Patient 3 1.53E-03 6.42E-05 9 
    Patient 4 7.68E-04   
    Patient 5 1.69E-04  
    Patient 6 4.38E-03  
    Patient 7 6.42E-05  
    Patient 8 4.01E-03  
    Patient 9 3.98E-02  
    Patient 10 1.00E-03  
     Patient 12 8.41E-05  
29 Signal transduction_Nitric oxide signaling Patient 3 4.84E-03 1.95E-04 10 
    Patient 4 1.25E-02  
    Patient 5 2.23E-02  
    Patient 6 3.25E-02  
    Patient 7 2.76E-04  
    Patient 8 1.95E-04  
    Patient 9 1.75E-02  
    Patient 10 4.96E-04  
    Patient 11 2.52E-02  
     Patient 12 6.64E-03  
30 Proteolysis_ECM remodeling Patient 3 2.87E-03 2.42E-03 8 
   
  
 Patient 4 6.85E-03  
Patient 5 2.42E-03 
    Patient 6 8.44E-03  
    Patient 7 1.51E-02  
    Patient 8 2.81E-03  
    Patient 9 2.31E-02  
















Appendix 4.3.10 Networks significantly enriched by targets of miRNAs that 
exhibit at least 50% difference in abundance in each gastric CAM compared to 
corresponding ATM from 12 patients. 
 




No. Networks Patient p-value 
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  Sz467 2.21E-07 


































































































































Appendix 4.3.11 Networks significantly enriched by targets of miRNAs 
that exhibit at least 50% difference in abundance in each SC-CAM 
compared to corresponding SC-ATM from 4 patients. 
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No. Networks p-value 
Sz173 Sz193 Sz282 
1 Development_EMT_Regulation of epithelial-to-mesenchymal 
transition 
3.257e-26 1.503e-12 1.372e-10 
2 Signal Transduction_TGF-beta, GDF and Activin signaling 3.405e-21 2.281e-10 1.238e-6 
3 Signal transduction_WNT signaling 1.528e-20 3.601e-8 9.044e-7 
4 Cell cycle_G1-S Growth factor regulation 4.815e-20 1.217e-8 7.032e-11 
5 Signal transduction_NOTCH signaling 1.259e-19 1.572e-4 4.708e-13 
6 Cell cycle_G1-S Interleukin regulation 4.346e-15 4.167e-7 9.610e-12 
7 Apoptosis_Apoptosis stimulation by external signals 4.063e-13 2.376e-3 1.566e-3 
8 Development_Hedgehog signaling 1.134e-12 2.466e-4 1.996e-11 
9 Development_Blood vessel morphogenesis 1.833e-12  3.877e-5 
10 Development_Keratinocyte differentiation 1.101e-11  4.539e-4 
11 Apoptosis_Anti-Apoptosis mediated by external signals via PI3K/AKT 1.643e-11 2.821e-8 2.539e-2 
12 Apoptosis_Anti-Apoptosis mediated by external signals by Estrogen 6.969e-11 5.314e-3 1.215e-4 
13 Reproduction_FSH-beta signaling pathway 7.259e-11 1.095e-4 7.348e-5 
14 Development_Hemopoiesis, Erythropoietin pathway 7.330e-11 4.981e-6 9.597e-6 
15 Cell cycle_Core 1.034e-10  7.966e-4 
16 Signal transduction_ESR1-nuclear pathway 1.874e-10 2.388e-3 4.990e-6 
17 Signal transduction_Androgen receptor signaling cross-talk 2.155e-9 2.377e-7 1.444e-3 
18 Reproduction_Feeding and Neurohormone signaling 4.019e-9 1.910e-6 3.434e-4 
19 Proliferation_Negative regulation of cell proliferation 5.919e-9 2.016e-5 5.599e-4 
20 Reproduction_Male sex differentiation 7.352e-9 4.644e-6 2.741e-6 
21 Cardiac development_Role of NADPH oxidase and ROS 8.151e-9 5.293e-6 2.636e-5 
22 Reproduction_Progesterone signaling 8.877e-9 4.623e-4 8.326e-5 
23 Cell cycle_G0-G1 9.687e-9 1.446e-4 2.659e-4 
24 Signal Transduction_BMP and GDF signaling 1.304e-8 3.658e-6 7.141e-3 
25 Proliferation_Positive regulation cell proliferation 2.020e-8 2.401e-4 8.875e-6 
26 Signal transduction_ERBB-family signaling 2.272e-8 2.090e-3 1.930e-4 
27 DNA damage_Checkpoint 2.633e-8 1.640e-2 3.986e-5 
28 Apoptosis_Anti-Apoptosis mediated by external signals via MAPK and 
JAK/STAT 
4.301e-8 2.823e-2  
29 Immune response_Th17-derived cytokines 8.734e-8 5.271e-6 1.362e-2 
30 Apoptosis_Apoptotic nucleus 2.702e-7 1.085e-3 2.458e-2 
31 Signal transduction_Leptin signaling 2.804e-7 3.415e-2 2.396e-4 
32 Inflammation_IL-10 anti-inflammatory response 6.818e-7 1.983e-4 3.670e-5 
33 Cell cycle_G2-M 8.074e-7  1.489e-5 
34 Immune response_TCR signaling 8.345e-7 2.087e-2 1.696e-2 
35 Inflammation_MIF signaling 4.248e-5 9.264e-7 8.009e-3 
36 Development_Ossification and bone remodeling 1.472e-6 1.069e-3 3.320e-2 
37 Inflammation_TREM1 signaling 1.507e-6 5.405e-3 2.971e-3 
38 Cardiac development_BMP_TGF_beta_signaling 1.852e-6 1.327e-4 3.151e-3 
39 Development_Cartilage development 1.105e-4 2.248e-6  
40 Inflammation_Amphoterin signaling 2.581e-6 2.612e-5 2.230e-4 
41 Cell adhesion_Cell-matrix interactions 
 
3.084e-6  
42 Development_Regulation of angiogenesis 3.272e-6 8.141e-4 1.216e-3 
43 Translation_Regulation of initiation 1.427e-5 3.423e-2 4.193e-6 
44 Cardiac development_FGF_ErbB signaling 4.918e-6 2.890e-3 1.852e-2 
45 Cell adhesion_Platelet-endothelium-leucocyte interactions 5.783e-6 6.803e-4  
46 Signal transduction_Nitric oxide signaling 6.509e-6 4.703e-3 7.309e-3 
47 Signal transduction_ESR1-membrane pathway 3.676e-4 7.828e-6 4.127e-5 
48 Inflammation_IL-2 signaling 8.251e-6 2.687e-3 1.880e-3 
49 Development_Regulation of telomere length 8.464e-6 1.056e-2 3.163e-2 




Appendix 4.3.12 Networks significantly enriched by targets of miRNAs that 
exhibit at least 50% difference in abundance in each AC-CAM compared to 
corresponding AC-ATM from 3 patients. Networks with p > 0.05 were indicated by 
shading in grey. 
 
